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Abstract 
 
According to regulatory guidelines, routine genotoxicity tests are not appropriate for 
biotechnology derived pharmaceuticals, including oligonucleotide based therapeutics, as 
they are not expected to interact with genomic DNA. However, reports of oligonucleotides 
capable of binding duplex DNA in a sequence specific manner to form triple-helix (triplex) 
or displacement-loop (D-loop) structures that in turn cause mutation have raised concern. 
The European Medicines Agency (EMA) has questioned the capability of antisense 
oligonucleotide (ASO) therapeutics to form such structures at genomic DNA. 
Additionally, concern has been expressed regarding the fate of chemically modified 
ASO degradation products (nucleotide analogues). It is well established that non-canonical 
antiretroviral nucleoside analogues, employed in antiretroviral therapy, result in gross 
chromosome aberrations following incorporation into genomic DNA. 
 This study has addressed these concerns by evaluating the genotoxic potential of a 
triplex forming oligonucleotide (TFO) and a D-loop forming ASO targeting genomic DNA. 
Furthermore, the incorporation efficiency and genotoxicity of nucleotide analogues derived 
from ASO degradation was investigated.  
 Data presented here demonstrate a TFO targeting genomic DNA was not capable 
of inducing mutation above the detection limit of this assay. However, a biologically active 
ASO molecule induced sequence specific mutation ~4.4 fold above control in a system 
where RAD51 protein expression was induced. Additionally, DNA polymerase was capable 
of incorporating various ASO derived nucleotide analogues into a primed DNA template 
with reduced efficiency. Treatment with phosphorothioate nucleotide analogue, one of the 
most common chemical modifications used in ASO design, induced mutation ~100 fold 
above control. 
 To conclude, ASO and their putative degradation products appeared to be capable 
of off-target mutagenesis providing favourable conditions were met. However, as 
genotoxicity data has been presented for a single ASO and nucleotide analogue, it seems 
plausible to suggest this work can provide a foundation to test future ASO therapeutics 
and putative degradation products. 
  
 3 
 
Statement of originality 
 
I certify that the research presented within this thesis is a product of my own work and that 
ideas, quotations or work from other people are fully acknowledged. This thesis has not 
been submitted for any other award. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information 
derived from it may be published without the prior written consent of the author.  
 
  
 4 
 
Acknowledgements  
 
To begin, I want to thank both of my supervisors Prof. Nigel J. Gooderham and Dr. 
Catherine Priestley who tirelessly read abstracts, manuscripts and even my thesis. It 
seems only yesterday I sat across you both in Nigel’s office for my PhD interview. My 
passion and diligence towards my project is a testament to the brilliance of Nigel and 
Catherine as supervisors. Without you both, I would not be writing this thesis which has 
opened avenues of opportunities for me. It seems almost insufficient for me to simply say, 
thank you, from the bottom of my heart.   
 
I also want to acknowledge the help and guidance from Dr. Mike O’Donovan and Mick 
Fellows as well as the entire Gen.Tox team at AstraZeneca. 
 
I especially thank my mother, father, brothers, sisters, grandparents and friends for their 
limitless support, advice and comfort throughout my education. I also want to apologise for 
the occasions I have been unavailable, but I can assure you, I was working.  
 
A special acknowledgement goes to my girlfriend Tabitha Jones and her family. Without 
Tabitha’s love, support and friendship I could not have completed this PhD.  
 
Although I have gained so much throughout my PhD, one of the most valuable assets I 
have taken from Imperial are the friendships I have made. I hope that with time, our 
friendships grow even stronger and we stay in touch.  Corrinne, Costas, Mike, Cancy, 
Rhiannon, Nurul, Wayne and Abdullah, I thank you all for the “mini-symposia” we held by 
our desks. Those lively debates are priceless memories, and Costas, I look forward to 
opening a laboratory together in Cyprus. I await your call.  
 
My advice to future PhD students that read this thesis is regarding my times of low. To get 
me by, I remembered the following saying, “you either want a PhD or you don’t” (Nigel J. 
Gooderham). The way I interpreted this was to simply crack on because you only have 
one shot. Good luck.   
  
 5 
 
List of abbreviations 
Abbreviation Definition 
µg Microgram 
µL Microliters  
µM Micromolar 
µm micrometer 
2’-OMe 2’-O-methyl-ribose 
2’OMe-ATP 
ATP modified to replace 2’OH group on ribose moiety with                 
O-methyl 
4NQO 4-Nitroquinoline 1-oxide 
5Me-dCTP dCTP modified to contain a methyl group in position 5 of cytidine 
6FAM 6-carboxyfluorescein 
6-TG 6-thioguanine 
AD3-HPRTPM 
Antisense oligonucleotide with sequence homology to the 
ADAMTS3 and HPRT locus  
ADAMTS3 
A disintegrin and metalloproteinase with thrombospondin type 1, 
motif 3 
AIDS Acquired immunodeficiency syndrome 
ANOVA Analysis of variance 
ASO Antisense oligonucleotide 
ATP adenosine triphosphate 
AZT 3’-azido-2’, 3’-dideoxythymidine 
BCA Bicinchoninic acid 
bp Base pairs 
BSA Bovine serum albumin 
cDNA Complementary DNA 
CHO Chinese hamster ovary 
CMV Cytomegalovirus 
dAMP 2’-deoxyadenosine monophosphate 
dAMPαS 
dAMP modified to replace a non-bridging oxygen with sulphur on 
the α-phosphate group 
dATP 2’-deoxyadenosine triphosphate 
dATPαS 
dATP modified to replace a non-bridging oxygen with sulphur on 
the α-phosphate group 
dCTP 2’-deoxycytidine triphosphate  
dGTP 2’-deoxyguanosine triphosphate 
Didanosone 2’,3’-dideoxyinosine 
D-loop Displacement loop 
Dloop27 
D-loop oligonucleotide targeting the TFO27 HPRT target 
sequence 
DMD Duchenne muscular dystrophy 
DMSO Dimethylsulphoxide 
DNA Deoxyribonucleic acid 
 6 
 
dNTP Deoxyribonucleoside triphosphate 
DSBs Double strand breaks 
dTTP 2’-deoxythymidine triphosphate 
EBI European Bioinformatics Institute 
EDTA Ethylenediaminetetraacetic acid 
eGFP Enhanced green fluorescent protein 
EMA European Medicines Agency 
EMS Ethyl methanesulphonate 
EMSA Electrophoretic mobility shift assay 
FDA Food and Drug Administration 
GA motif  Purine motif  
Ganciclovir 9-[(1,3-dihydroxy-2-propoxy)-methyl]-guanine 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
gDNA Genomic DNA 
GFP Green fluorescent protein 
GT motif  Mixed motif  
h hour(s) 
HAART Highly active antiretroviral therapy 
HIFBS Heat inactivated foetal bovine serum 
HIHS Heat inactivated horse serum 
HIV-1 Human immunodeficiency virus type 1 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
HR Homologous recombination 
HRP Horse radish peroxidise  
ICH 
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human 
Use 
Kd Dissociation constant 
Lamivudine 2’, 3’-dideoxy-3’-thiacytidine 
LNA Locked nucleic acid 
MDM2 Murine double minute 2 
mins Minutes 
mL Millilitres  
MLA Mouse lymphoma assay 
MLH-1 Mut L homologue 1 
mM Millimolar 
MMR Mismatch repair 
MMS Methyl methanesulphonate 
mRNA messenger RNA 
MSH2 Mut S homologue 2 
NCBI-BLAST 
National Center for Biotechnology Information - Basic Local 
Alignment Search Tool 
NER Nucleotide excision repair 
ng Nanogram 
NHEJ Non homologous end joining 
 7 
 
nM Nanomolar 
nm Nanometer 
OECD Organisation for Economic Co-operation and Development  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PKC-α Protein kinase C-α 
PNA Peptide nucleic acid 
poly-rA Polyriboadenylic acid 
poly-rU Polyribouradylic acid 
Pso-SCR27-biot SCR27 conjugated 5’ to psoralen and 3’ biotin 
Pso-TFO27-biot TFO27 conjugated 5’ to psoralen and 3’ biotin 
PVDF Polyvinylidine fluoride 
R0 RPMI 1640 without serum (incomplete media) 
R10HIFBS RPMI 1640 media containing 10%w/v HIFBS (complete media) 
R10HIHS RPMI 1640 media containing 10%w/v HIHS (complete media) 
RFLP Restriction fragment length polymorphism 
RISC complex RNA-induced silencing (RISC) complex 
RNA Ribonucleic acid 
RNAi RNA interference 
RPD Relative population doubling 
RSG Relative suspension growth 
RTG Relative total growth 
SCE Sister chromatid exchange 
SCR27 Control oligonucleotide used in triplex studies 
SD Standard deviation 
SDS Sodium dodecyl sulphate 
siRNA Small interfering RNA 
SV40 Simian virus 40 
TA (Primer) annealing temperature 
TBE Tris, boric acid and EDTA 
TC motif  Pyrimidine motif  
TFO Triple-helix forming oligonucleotide 
TFO27 TFO targeting exon 3 of the HPRT locus 
TFT Trifluorothymidine 
TK Thymidine kinase 
TM (Primer) melting temperature 
TNE Targeted nucleotide exchange 
Triplex Triple-helix 
V Volts 
Vmax Maximum speed of incorporation 
 
 
 
 8 
 
Table of contents 
 
List of figures ................................................................................................................... 12 
List of tables ..................................................................................................................... 15 
Chapter 1. General introduction ..................................................................................... 16 
1.1. Introduction ............................................................................................................. 16 
1.2. Antisense oligonucleotides (ASO) ........................................................................... 17 
1.2.1. Chemical modifications ..................................................................................... 17 
1.2.2. Biological activity of ASO .................................................................................. 21 
1.2.3. ASO mechanism of action ................................................................................ 24 
1.2.4. ASO used in clinical trials ................................................................................. 26 
1.3. Concerns with oligonucleotide based pharmaceuticals ........................................... 29 
1.3.1. Triplex forming oligonucleotides (TFO) ............................................................. 30 
1.3.1.1. Mutagenicity of TFO ................................................................................... 33 
1.3.2. D-loop forming oligonucleotides........................................................................ 35 
1.3.2.1. Mutagenicity of D-loop forming oligonucleotides ........................................ 36 
1.3.3. Nucleotide analogues ....................................................................................... 44 
1.3.3.1. Mutagenicity of non-canonical nucleotide analogues ................................. 46 
1.3.3.2. Mutagenicity of canonical nucleotides ........................................................ 49 
1.4. Aims and objectives ................................................................................................ 52 
Chapter 2. Materials and Methods .................................................................................. 54 
2.1. Oligonucleotides ...................................................................................................... 54 
2.1.1. Triple-helix forming oligonucleotide design ....................................................... 54 
2.1.2. Displacement loop/ antisense oligonucleotide design ....................................... 55 
2.1.3. Serum stability of oligonucleotides .................................................................... 56 
2.1.4. Oligonucleotide third strand binding assay ....................................................... 58 
2.1.5. Detecting triplex formation at genomic DNA ..................................................... 58 
2.1.6. DNase I protection assay .................................................................................. 61 
2.1.7. Quadruplex forming ability of SupFG1 .............................................................. 62 
2.1.8. Primer extension assay .................................................................................... 66 
2.2. General cell culture ................................................................................................. 68 
2.2.1. Human lymphoblastoid TK6 cells ...................................................................... 68 
 9 
 
2.2.2. Human colon epithelial HCT116 cells ............................................................... 70 
2.2.3. Genomic DNA extraction from cultured cells .................................................... 70 
2.2.4. RNA extraction.................................................................................................. 71 
2.2.5. Protein extraction and quantification ................................................................. 72 
2.3. Cell treatments ........................................................................................................ 73 
2.3.1. MSH2 protein knockdown in TK6 cells using Silencer Select siRNA ................ 73 
2.3.2. Induction of RAD51 protein expression in TK6 cells ......................................... 74 
2.3.3 Oligonucleotide transfection efficiency using siPORT NeoFX and NTER in TK6 
cells ............................................................................................................................ 74 
2.3.4. Treatment of TK6 cells with oligonucleotide ..................................................... 75 
2.3.5. Treatment of TK6 cells with nucleosides and nucleotides ................................ 77 
2.4. HPRT and TK forward mutation assays .................................................................. 78 
2.4.1. Determining the TK mutant frequency (Day 3) ................................................. 78 
2.4.2. Determining the HPRT mutant frequency (Day 7) ............................................ 79 
2.4.3. The in vitro micronucleus assay ........................................................................ 80 
2.4.4. Treatment of HCT116 cells with oligonucleotide ............................................... 81 
2.4.5. Cytotoxicity following treatment of HCT116 cells .............................................. 81 
2.4.6. Determining the HPRT mutant frequency following treatment of HCT116 cells 81 
2.5. Polymerase Chain Reaction (PCR) ......................................................................... 82 
2.5.1. First strand cDNA synthesis from RNA extracts ............................................... 82 
2.5.2. PCR primer design ........................................................................................... 82 
2.5.3. PCR amplification of genomic DNA and cDNA ................................................. 83 
2.5.4. Agarose gel electrophoresis ............................................................................. 83 
2.5.5. Restriction enzyme digestion of PCR products ................................................. 84 
2.5.6. PCR product purification and DNA sequencing ................................................ 84 
2.6. Immunoblot ............................................................................................................. 86 
2.6.1. Preparation and electrophoresis of samples ..................................................... 86 
2.6.2. Transfer of protein ............................................................................................ 87 
2.6.3. Immunoblotting ................................................................................................. 87 
Chapter 3. The Genotoxicity of a triplex forming oligonucleotide targeting genomic 
DNA ................................................................................................................................... 90 
3.1. Introduction ............................................................................................................. 90 
3.2. Experimental outline ................................................................................................ 92 
3.3. Methods .................................................................................................................. 93 
 10 
 
3.4. Results .................................................................................................................... 94 
3.4.1. High affinity triplex formation............................................................................. 94 
3.4.2. Transfection efficiency ...................................................................................... 96 
3.4.3. Evaluating the genotoxic potential of a TFO at genomic DNA .......................... 98 
3.4.4. Serum stability of oligonucleotides .................................................................. 104 
3.4.5. Human TK6 cells contain the wild-type HPRT sequence ................................ 105 
3.4.6. Method development to detect triplex formation at genomic DNA .................. 107 
3.4.7. The previously employed SupFG1 triplex target sequence is capable of DNA 
quadruplex formation ................................................................................................ 112 
3.5. Discussion ............................................................................................................. 115 
Chapter 4. The Genotoxicity of an antisense oligonucleotide via targeted nucleotide 
exchange ........................................................................................................................ 120 
4.1. Introduction ........................................................................................................... 120 
4.2. Experimental outline .............................................................................................. 121 
4.3. Methods ................................................................................................................ 123 
4.4. Results .................................................................................................................. 124 
4.4.1. Genotoxicity of Dloop27 .................................................................................. 124 
4.4.2. Biological activity of AD3-hprtPM .................................................................... 126 
4.4.3. The of role of mismatch repair in antisense oligonucleotide genotoxicity ....... 128 
4.4.4. The of role of homologous recombination repair in antisense oligonucleotide 
genotoxicity ............................................................................................................... 137 
4.5. Discussion ............................................................................................................. 145 
Chapter 5. Incorporation and genotoxicity of oligonucleotide degradation products 
into the genome ............................................................................................................. 149 
5.1. Introduction ........................................................................................................... 149 
5.2. Experimental outline .............................................................................................. 151 
5.3. Methods ................................................................................................................ 152 
5.4. Results .................................................................................................................. 153 
5.4.1. In vitro incorporation efficiency of nucleotide analogues ................................. 153 
5.4.2. Genotoxic fate of canonical nucleotides ......................................................... 158 
5.4.3. Genotoxic fate of a phosphorothioate nucleotide analogue ............................ 162 
5.5. Discussion ............................................................................................................. 168 
Chapter 6. General discussion and conclusions ........................................................ 173 
 11 
 
6.1. Future work ........................................................................................................... 180 
References ..................................................................................................................... 183 
Appendix 1. Buffers and reagents ................................................................................ 205 
Publications ................................................................................................................... 206 
 
 
  
 12 
 
List of figures 
 
Figure 1.1. Chemical modifications used in ASO design................................................... 20 
Figure 1.2. Exon skipping by ASO targeting the DMD pre-mRNA. ................................... 24 
Figure 1.3. ASO mechanism of action............................................................................... 26 
Figure 1.4. DNA triplex formation. ..................................................................................... 31 
Figure 1.5. Hoogsteen hydrogen bonding between nucleotides of TFO and duplex DNA.32 
Figure 1.6. Classification of TFO. ...................................................................................... 33 
Figure 1.7. Putative mechanism of TNE by D-loop forming oligonucleotides. ................... 43 
Figure 1.8. Chemical structure of antiretroviral nucleoside analogues used in HAART .... 45 
 
Figure 2.1. Overview of the methodology used to detect triplex formation within genomic 
DNA. .................................................................................................................................. 61 
 
Figure 3.1. DNA quadruplex formation. ............................................................................. 92 
Figure 3.2. Investigating the triplex forming capability of TFO27 and SCR27 ................... 95 
Figure 3.3. Investigating the capability of oligonucleotides to protect duplex DNA from 
DNase I cleavage. ............................................................................................................. 95 
Figure 3.4. Evaluating the transfection efficiency of TK6 cells using siPORT NeoFX and 
NTER. ................................................................................................................................ 97 
Figure 3.5. Investigating the genotoxic effect of 1μM oligonucleotide treating 3x106 human 
TK6 cells. ......................................................................................................................... 100 
Figure 3.6. Investigating the genotoxic effect of 1μM, 2μM and 5μM oligonucleotide 
treating 3x106 human TK6 cells. ...................................................................................... 100 
Figure 3.7. Investigating the genotoxic effect of 1μM, 2μM and 5μM oligonucleotide 
treating 10x106 human TK6 cells using a regulatory acceptable mutation assay ............ 102 
Figure 3.8. Investigating the genotoxic effect of TFO27 in a regulatory acceptable 
mutation assay treating 10x106 TK6 cells. ....................................................................... 102 
Figure 3.9. Investigating the genotoxic effect of TFO27 up to 9.8μM in a regulatory 
acceptable mutation assay treating 10x106 TK6 cells. ..................................................... 103 
Figure 3.10. The serum stability of oligonucleotides. ...................................................... 105 
Figure 3.11. Validating the putative TFO27 target sequence in exon 3 of the HPRT locus 
in human lymphoblastoid TK6 cells. ................................................................................ 106 
Figure 3.12. Optimising PCR conditions for triplex detection. ......................................... 108 
 13 
 
Figure 3.13. Detecting triplex formation and optimising streptavidin bead concentration.
 ......................................................................................................................................... 109 
Figure 3.14. Optimising genomic DNA purification. ......................................................... 110 
Figure 3.15. Optimising purification of genomic DNA using the Qiagen DNA extraction 
column.. ........................................................................................................................... 111 
Figure 3.16. Investigating the quadruplex forming ability of the SupFG1 system. ........... 113 
Figure 3.17. Confirmation of DNA quadruplex formation in the SupFG1 duplex. ............ 114 
 
Figure 4.1. The Dloop27 target sequence in exon 3 of the HPRT locus. ........................ 123 
Figure 4.2. The AD3-HPRTPM target sequence in exon 3 of the HPRT locus. .............. 123 
Figure 4.3. Investigating the mutagenic effect of Dloop27 at the HPRT locus after treating 
10x106 human lymphoblastoid TK6 cells. ........................................................................ 125 
Figure 4.4. Evaluating the clastogenic activity of Dloop27 in human lymphoblastoid TK6 
cells using the in vitro micronucleus assay.. .................................................................... 125 
Figure 4.5. The antisense activity of AD3-HPRTPM. ...................................................... 127 
Figure 4.6. Investigating the mutagenic effect of an ASO containing a single mismatched 
base. ................................................................................................................................ 129 
Figure 4.7. Quantitation of MSH2 knockdown in human TK6 cells treated with (S) or 
without (U) 10nM Silencer Select siRNA for 24h. ............................................................ 130 
Figure 4.8. Optimising MSH2 knockdown using Silencer Select siRNA. ......................... 130 
Figure 4.9. Investigating the genotoxic effect of AD3-HPRTPM using human TK6 cells 
pre-treated with MSH2 Silencer Select siRNA. ................................................................ 131 
Figure 4.10. Investigating the genotoxic effect of AD3-HPRTPM using human TK6        
cells.................................................................................................................................. 132 
Figure 4.11. Mbo I restriction enzyme digestion of PCR products. ................................. 134 
Figure 4.12. Investigating the genotoxic effect of Val-HPRTPM using human TK6 cells.136 
Figure 4.13. Investigating the genotoxic effect of AD3-HPRTPM and Val-HPRTPM in a 
mismatch repair deficient cell line. ................................................................................... 136 
Figure 4.14. Inducing the homologous recombination repair pathway. ........................... 138 
Figure 4.15. Investigating the genotoxic effect of AD3-HPRTPM in a HR repair induced 
system. ............................................................................................................................ 140 
Figure 4.16. Mbo I restriction enzyme digestion of HPRT mutant PCR products. ........... 143 
Figure 4.17. Distribution of AD3-HPRTPM mediated mutation in exon 3 of the HPRT 
locus.. .............................................................................................................................. 144 
 14 
 
 
Figure 5.1. Template used in the in vitro primer extension assay. .................................. 152 
Figure 5.2. The chemical structure of adenine based nucleotides. ................................. 153 
Figure 5.3. Single nucleotide incorporation of dATP.. ..................................................... 154 
Figure 5.4. Incorporation of dATP using an extended template. ..................................... 154 
Figure 5.5. Incorporation kinetics of phosphorothioate nucleotide analogue dATPαS. ... 155 
Figure 5.6. Incorporation kinetics of 2’O-methyl ribose modified nucleotide analogue 
2’OMe-ATP. ..................................................................................................................... 156 
Figure 5.7. The chemical structure of cytidine based nucleotides.. ................................. 157 
Figure 5.8. Incorporation kinetics of dCTP and 5Me-dCTP. ............................................ 158 
Figure 5.9. Genotoxicity of canonical nucleotides. .......................................................... 161 
Figure 5.10. Genotoxicity of a non-canonical phosphorothioate nucleotide analogue. ... 164 
Figure 5.11. Clastogenic/ aneugenic activity of dAMPαS in human TK6 cells. ............... 166 
Figure 5.12. PCR amplification of cDNA from isolated dAMPαS induced TK mutants. ... 167 
  
 15 
 
List of tables 
 
Table 2.1. Triplex Forming Oligonucleotide sequences ..................................................... 57 
Table 2.2. D-loop forming oligonucleotides ....................................................................... 57 
Table 2.3. Oligonucleotides used in gel retardation assays............................................... 64 
Table 2.4. Primer sequences used for PCR amplification. ................................................ 65 
Table 2.5. Oligonucleotides used in primer extension assays ........................................... 67 
Table 2.6.  Antibodies used in immunoblot analysis. ......................................................... 89 
  
 16 
 
Chapter 1  
General introduction 
 
1.1. Introduction 
Approximately 7.1 million deaths worldwide are attributed to cancer, according to the 2002 
World Health Report, with lung, stomach, colon, liver, breast and oesophageal cancers the 
most prevalent (http://www.who.int/whr/2002/en/). More frightful is that in 20 years the 
incidence of cancer related death is expected to increase by 50% 
(http://www.iarc.fr/en/publications/pdfs-online/wcr/2003/index.php). Sequencing of the 
human genome has helped inform the role of genes involved in cancer development/ 
susceptibility and provide novel drug targets for human therapy (Dean & Bennett, 2003, 
Pirollo et al., 2003). One of the major limitations for drug development against molecular 
targets is the time required to design a functional molecule (Dean & Bennett, 2003). 
However, this limitation can be avoided by using antisense oligonucleotide (ASO) 
technologies which can be used to modulate expression of theoretically any gene 
(Davidson & McCray, 2011, Pirollo et al., 2003, Agrawal, 1999); although the testing and 
validation procedure is the same for small molecule drugs and oligonucleotide based 
pharmaceuticals, the time taken to design an ASO is faster (Davidson & McCray, 2011, 
Pirollo et al., 2003). It is important to acknowledge the difference between ASO and small 
interfering ribonucleic acids (siRNA). siRNA are short double stranded ribonucleic acid 
(RNA) sequences which require processing and assembly into the RNA-induced silencing 
(RISC) complex for target messenger RNA (mRNA) binding and degradation (Elbashir et 
al., 2001, Zamore, 2001, Hammond et al., 2000, Zamore et al., 2000). However, ASO are 
single stranded oligonucleotide sequences that do not require endogenous processing and 
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bind to target mRNA independent of the RISC complex. This study has focused on ASO 
therapeutics and not siRNA.  
 
1.2. Antisense oligonucleotides (ASO) 
ASO are short oligonucleotide sequences, typically 12-25 nucleotides, designed to bind 
complimentary to the mRNA sequence via Watson-Crick base pairing (Geary, 2009, Dean 
& Bennett, 2003, Pirollo et al., 2003, Dias & Stein, 2002, Stephenson & Zamecnik, 1978, 
Zamecnik & Stephenson, 1978). In theory, providing the mRNA sequence is known, 
expression of any gene can be modulated (Davidson & McCray, 2011, Pirollo et al., 2003, 
Agrawal, 1999). Antisense activity of ASO therapeutics is governed by several factors, 
including: the stability of oligonucleotide from nuclease digestion, cellular uptake, selective 
and high affinity binding to target mRNA and the ability to evoke target degradation by 
RNase H (described in section 1.2.3), repress translation or modulate alternative splicing 
(Dean & Bennett, 2003, Pirollo et al., 2003, Sazani & Kole, 2003, Dias & Stein, 2002, 
Agrawal, 1999).  
 
1.2.1. Chemical modifications 
The first ASO contained phosphodiester linkages and was reported to inhibit Rous 
sarcoma virus translation and transformation of cells (Stephenson & Zamecnik, 1978, 
Zamecnik & Stephenson, 1978). The limitation of using unmodified ASO was that they 
were found to be rapidly degraded (Akhtar, Kole & Juliano, 1991). For ASO to be efficient 
therapeutic tools improving resistance to serum and intracellular nucleases and effective 
cellular uptake is critical for their future use (Pirollo et al., 2003). Amongst the first 
chemical modifications employed in ASO design was the replacement of a non-bridging 
oxygen in the phosphate backbone with either a CH3 group (methylphosphonates) (Miller, 
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1989, Miller et al., 1979) or a sulphur atom (phosphorothioate) (Stein & Cohen, 1988) 
(Fig.1.1).  
From the various chemical modifications that can be adopted in ASO design, the 
most prevalent amongst ASO used in clinical trials are phosphorothioate linkages (Pirollo 
et al., 2003). Besides the increased nuclease resistance provided by this modification 
(Eckstein, 1985), phosphorothioate ASO are one of the few capable of stimulating (RNase 
H mediated) degradation of hybridised mRNA which offers potent antisense activity (Stein 
et al., 1988). However, phosphorothioate ASO administration in humans can result in 
thrombocytopenia, anaemia, hyperplasia of the liver, spleen and kidneys and activation of 
the immune system in a sequence independent manner (Geary, 2009, Krieg, 1999, 
Agrawal et al., 1997, Henry et al., 1997). In particular, ASO containing unmethylated CpG 
dinucleotide motifs are capable of stimulating B cell proliferation through Toll-like receptor 
recognition (TLR 7,8 and9) and activation of the mitogen-activated protein kinase pathway 
(Bafica et al., 2004, Hemmi et al., 2000, Krieg, 1999, Yi & Krieg, 1998, Krieg et al., 1995, 
Tanaka, Chu & Paul, 1992). The activation of B cells by CpG ASO is thought to be a result 
of immune system recognition of an invading pathogen as bacterial deoxyribonucleic acid 
(DNA) has higher frequency of CpG motifs that are unmethylated compared to vertebrate 
DNA (Krieg, 1999, Krieg et al., 1995, Kuramoto et al., 1992, Adrian P., 1987). However, 
replacing the cytosine with 5’-methyl-cytosine in the CpG motif mitigates immune system 
activation by oligonucleotides (Krieg et al., 1995). These limitations have created a niche 
for new chemical modifications which provide improved ASO pharmacokinetics, 
pharmacodynamics and reduced side effects associated with administration.  
Modification of the sugar-phosphate backbone has also been adopted in ASO 
design in hope of replacing phosphorothioate linkages. Such modifications include peptide 
nucleic acids (PNA) (Egholm et al., 1993), phosphoroamidates (Froehler, Ng & Matteucci, 
1988) and morpholinos (Summerton & Weller, 1997) (Fig.1.1) (Egholm et al., 1993). 
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Although PNA, methylphosphonates, phosphoroamidates and morpholino oligonucleotides 
are almost completely nuclease resistant and can hybridise to mRNA targets with very 
high affinity, they cannot penetrate the cell membrane, have reduced solubility and cannot 
elicit degradation of target mRNA via RNase H and are often found to be weak antisense 
molecules (Dias & Stein, 2002, Dias et al., 1999, Summerton & Weller, 1997, Egholm et 
al., 1993, Furdon, Dominski & Kole, 1989, Miller, 1989, Miller et al., 1979).   
More recent modifications of ASO include replacing the 2’-OH group in the ribose 
moiety with O-methyl (2’-OMe) (Fig.1.1). Complete modification of ASO with 2’-OMe 
permits higher binding affinity to target mRNA compared to phosphorothioate ASO; for 
example, a phosphorothioate ASO hybridised to target mRNA had a melting temperature 
of 45°C whereas the 2’-OMe ASO increased the melting temperature by ~50% (Metelev, 
Lisziewicz & Agrawal, 1994). However, 2’-OMe ASO do not possess potent antisense 
activity because they cannot elicit degradation of target mRNA via RNase H; ASO which 
are RNase H independent can only exert antisense activity by physically blocking the 
progression/initiation of the translation or splicing machinery (discussed in section 1.2.3) 
(Sazani & Kole, 2003, Dias & Stein, 2002, Shibahara et al., 1989). To improve on this, 
ASO have been further engineered to contain central phosphorothioate linkages which are 
flanked by 2’-OMe ribose nucleotides. These phosphorothioate/ 2’-OMe ASO are reported 
to have reduced side effects, increased nuclease resistance and target binding affinity 
whilst retaining the ability to evoke an RNase H response (Yoo et al., 2004, Agrawal & 
Zhao, 1998, Peng Ho et al., 1998, Yu et al., 1996, Metelev, Lisziewicz & Agrawal, 1994, 
Shibahara et al., 1989); for example, the addition of a single 2’-OMe nucleotide at the 5’ 
and 3’ end increased the melting temperature of the ASO/mRNA duplex by 3.4°C. 
Furthermore, snake venom phosphodiesterase fully degraded a phosphorothioate 
oligonucleotide within 7 hours (h) but failed to degrade a 2’-OMe and phosphorothioate 
modified oligonucleotide (Metelev, Lisziewicz & Agrawal, 1994).  
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Figure 1.1. Chemical modifications used in ASO design. Figure taken and manipulated from Dias et 
al. 2002 
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A 2’-OMe modified ASO has been reported to retain antisense activity by eliciting 
RNase H activation providing at least 4 or 5 deoxyribonucleosides, containing 
phosphorothioate linkages, are included (Yoo et al., 2004, Monia et al., 1993). In one 
particular study, including a stretch of 6 deoxyribonucleosides on the 5’ end of a                   
2’-OMe modified ASO, as opposed to the middle or 3’ end, radically improved the ability of 
the hybridised ASO to elicit RNase H mediated cleavage of target mRNA by 2-4 fold 
(Shen, Kandimalla & Agrawal, 1998). In the design of these 2’-OMe phosphorothioate 
ASO, the 2’-OMe domain serves to increase ASO target binding affinity and the 
deoxyribonucleosides activate RNase H. This observation has also been made for other 
ASO chemical modifications which fail to elicit RNase H activity. Using human U1 small 
nuclear RNA as a target, an unmodified (canonical phosphodiester linkages, sugar and 
base moieties) and phosphorothioate ASO were biologically active in downregulating U1 
small nuclear RNA whereas a methylphosphonate modified ASO failed to have such 
effect. However, inclusion of 6 phosphorothioate linkages into the methylphosphonate 
ASO was reported to possess antisense activity through RNase H activation (Agrawal et 
al., 1990).  
The objective of engineering ASO with various chemical modifications is to enhance 
biologically stability and efficacy such that ASO can be administered less frequently to 
exert pharmacological activity which would also reduce toxic side effects associated with 
current ASO administration (Agrawal, 1999).  
 
1.2.2. Biological activity of ASO 
ASO are carefully designed to contain various chemical modifications to facilitate biological 
activity. Often ASO are employed to modulate splicing of pre-mRNA or down regulate 
protein expression either through translational repression or degradation of target mRNA 
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in a sequence specific manner. Examples are discussed below and ASO used in clinical 
trials are discussed in section 1.2.4. 
The murine double minute 2 (MDM2) protein is over expressed in 40-60% of human 
osteogenic sarcomas and 30% of soft tissue sarcomas implicating a role of the MDM2 
gene in the development of these cancers (Cordon-Cardo et al., 1994, Oliner et al., 1992). 
MDM2 protein function is to bind p53 protein in a negative feedback loop and inhibit its 
function as a transcription factor (Momand et al., 1992). Using 100-400nM of a 
phosphorothioate ASO, MDM2 protein expression was reduced 3-5 fold in JAR 
(choriocarcinoma) and SJSA (osteosarcoma) cell lines by eliciting RNase H mediated 
degradation of MDM2 mRNA (Chen et al., 1998). Down regulation of MDM2 protein 
expression increased susceptibility of treated cells to apoptosis and the cytotoxic effects of 
camptothecin by up to 30 fold. 
 Including novel chemical modifications in ASO design such as locked nucleic acids 
(LNA), which contain a methylene bridge that connects the 2’-oxygen of ribose with the 4’ 
carbon (Petersen & Wengel, 2003, Orum & Wengel, 2001), facilitates potent antisense 
activity compared to phosphorothioate molecules (Grunweller et al., 2003, Kurreck et al., 
2002). In a comparative study, an ASO containing a central deoxyribonucleoside moiety of 
8-10 nucleotides, to activate RNase H, flanked by 4-5 LNA monomers was almost 1000 
fold more potent than its comparative phosphorothioate ASO in mediating knockdown of a 
green fluorescent protein (GFP) based reporter construct in monkey COS-7 cells 
(Grunweller et al., 2003). Even though phosphorothioate ASO have been reported to be 
more potent than 2’-OMe, PNA and methylphosphonate ASO in inhibiting reverse 
transcription of the human immunodeficiency virus type 1 (HIV-1) (Boulme et al., 1998), 
the combination of chemical modifications (once optimised) in ASO design may eventually 
become prevalent in clinical trials to mitigate human diseases. 
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ASO have also been engineered to modulate alternative splicing of pre-mRNA 
which occurs in up to 60% of human genes and almost 50% of genetic disorders are a 
result of defective pre-mRNA splicing, including various cancers, Duchenne Muscular 
dystrophy (DMD), thalassemia and cystic fibrosis (Sazani & Kole, 2003). ASO can be 
designed to target mutations in pre-mRNA that cause aberrant splicing, to physically block 
the aberrant splice site or induce exon skipping, to restore function to a defective gene. In 
the design of these ASO, chemical modifications adopted must not elicit RNase H to 
degrade target mRNA; as discussed above, ASO completely modified with 2’-OMe, 
methylphosphonate, LNA and phosphoroamidate can bind with high affinity to target 
mRNA without activation of RNase H.   
For example, DMD is caused by mutations which disrupt the reading frame or result 
in a premature stop codon in the dystrophin gene creating a non-functional protein (Koenig 
et al., 1989, Sicinski et al., 1989, Monaco et al., 1988). DMD, characterised by progressive 
muscle wasting and weakness, affects 1 in 3500 male births (Koenig et al., 1989, Koenig, 
Monaco & Kunkel, 1988). Almost 90% of those with DMD do not make it to their 20th 
birthday due to cardiac and respiratory complications (Hoffman, Brown & Kunkel, 1987). 
ASO have been employed for the treatment of DMD using the mdx mouse animal model. 
The mdx mouse model has a premature stop codon in exon 23 of the dystrophin gene 
resulting in a non-functional protein (Bulfield et al., 1984). ASO targeting the 5’ splice site 
of intron 23 in pre-mRNA have been reported to cause skipping of exon 23 restoring the 
reading frame of mRNA from immortalised mdx myoblast cells in vitro (Wilton et al., 1999) 
and in vivo, following intramuscular injection into mdx mice, resulting in the production of a 
truncated semi-functional protein which produces the milder phenotype of Becker 
muscular dystrophy (Fig. 1.2) (Mann et al., 2001). A similar observation has been made 
with LNA ASO directed to the splice site of exon 46 in the dystrophin pre-mRNA (Aartsma-
Rus et al., 2004). Treating primary human myoblasts from a DMD patient with 500nM LNA 
 24 
 
ASO caused exon skipping in pre-mRNA up to 75% compared to 20% with the 2’-OMe 
ASO. Currently, an ASO (AVI-4658, AVI BioPharma) that has finished Phase I/II clinical 
trials was reported to be well tolerated for treatment of DMD by modulating alternative 
splicing of pre-mRNA (http://clinicaltrials.gov/ct2/show/NCT00159250?term=antisense+ 
oligonucleotide&rank=2).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3. ASO mechanism of action  
ASO can be categorised into two groups depending on their mechanism of action: (1) 
RNase H dependent ASO which result in degradation of target mRNA and (2) RNase H 
independent ASO which physically inhibit the initiation or progression of splicing or 
translational machinery (Fig.1.3) (Sazani & Kole, 2003, Dias & Stein, 2002, Dias et al., 
1999, Baker et al., 1997).  
RNase H is an intracellular enzyme that cleaves the RNA strand of a DNA/RNA 
duplex producing shorter oligonucleotide fragments (Hausen & Stein, 1970, Stein & 
Figure 1.2. Exon skipping by ASO targeting the DMD pre-mRNA. ASO targeting to the 5’ splice site of 
intron 23 in pre-mRNA results in exclusion of exon 23 in the mature mRNA by physically blocking 
splicing machinery access. Elimination of exon 23 carrying the premature stop codon (*) restores the 
open reading frame resulting in a truncated yet semi-functional protein. Vertical arrows indicate the 
intron/exon splice sites.  
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Hausen, 1969). RNase H from E. coli was reported to be vital for DNA replication in the 
bacterium (Zamaratski, Pradeepkumar & Chattopadhyaya, 2001, Dasgupta, Masukata & 
Tomizawa, 1987). Following this, it was proposed the enzyme may be important for 
degradation/elimination of the RNA primer in the RNA/DNA duplex following DNA 
replication.  
The majority of ASO in current clinical trials depend on RNase H activation to exert 
antisense activity provided by the phosphorothioate backbone (Dias & Stein, 2002). 
RNase H mediated degradation of target mRNA is highly efficient reaching up to 95% 
knockdown of protein expression (Dias & Stein, 2002). Further to this, RNase H dependent 
ASO can be theoretically directed to any region of the target mRNA whilst ASO 
independent of RNase H activity are only biologically active when directed to the AUG 
translation start codon or to a splice site (Sazani & Kole, 2003, Dean et al., 1994, Larrouy 
et al., 1992). For example, phosphorothioate ASO targeting the translation start codon in 
the Protein kinase C (PKC)-α mRNA have been reported to be the most biologically active 
(Dean et al., 1994). However, phosphorothioate ASO targeting most positions in the 
mRNA down regulated PKC-α protein expression; ASO containing 2’-OMe ribose failed to 
reduce PKC-α protein expression unless the AUG initiation codon was targeted and in this 
case, PKC-α mRNA levels were not affected suggesting an RNase H independent 
mechanism which confirms translational repression as the mechanism of action (Dean et 
al., 1994).  
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1.2.4. ASO used in clinical trials 
ASO have been actively recruited as therapeutic tools to modulate protein expression to 
treat genetic diseases. In 2003, there were at least 46 ASO in clinical trials, 10 of which 
were in phase III and 20 in phase II, the majority of which contained phosphorothioate 
modifications (Dean & Bennett, 2003, Pirollo et al., 2003, Hogrefe, 1999). According to the 
United States National Institute of Health, there are currently 51 ASO in clinical trials that 
have recently completed Phase I or are still on-going (www.clinicaltrials.gov). Almost half 
of the 2003 ASO trials were designed as anticancer therapeutics including molecular 
targets such as C-RAF-1, RAS and Protein Kinase A- type I (Cunningham et al., 2001, 
Chen et al., 2000, Cunningham et al., 2000). Many tumours have altered or increased 
Figure 1.3. ASO mechanism of action. ASO oligonucleotide enter the cytoplasm via endocytosis and 
then the nucleus (1 and 2) (Lorenz et al., 2000, Loke et al., 1989, Yakubov et al., 1989). ASO 
hybridises to complimentary target mRNA (3) and reduces target protein expression by physically 
blocking initiation/progression of mRNA translation (4-6) or stimulating RNase H mediated 
degradation of mRNA (7 and 8). Image extrapolated from Dean et al. 2003. 
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gene expression, and since ASO act in a sequence specific manner, they can be designed 
to modulate expression of mutant or tumour associated genes without affecting expression 
in normal cells (Pirollo et al., 2003). 
The lack of site specific delivery methods for ASO remains the biggest obstacle in 
their use as therapeutics (Akhtar et al., 2000). ASO are typically administered systemically, 
but the dose limiting toxicity associated with intravenous administration includes 
hypotension, fever and fatigue, as described in section 1.2.1. (Pirollo et al., 2003). The 
similarity in the toxicity profile between different ASO is a reflection on the 
phosphorothioate backbone common to most of the compounds tested. Sequence 
independent interactions of phosphorothioate ASO with hydrophilic groups of serum 
albumin reduces elimination and increases systemic cellular uptake mainly into the liver, 
kidneys, bone marrow and lymph nodes resulting in the toxic side effects that are reported 
following administration (Geary, 2009, Levin, 1999).  
The first ASO approved, by the United States Food and Drug Administration (FDA), 
was a phosphorothioate ASO called Vitravene™ (ISIS 2922, Isis Pharmaceuticals) for the 
treatment of cytomegalovirus (CMV) retinitis in 1998 (Crooke, 1998). Treating CMV 
infected human fibroblast cells with 1µM ISIS 2922 inhibited antigen production by 99% 
and virus production by 104 fold demonstrating the efficacy of antisense technology (Cinatl 
et al., 2000).  
G3139 (Genta Inc., CA, USA) is an 18 nucleotide phosphorothioate ASO targeting 
the first 6 codons of the BCL-2 gene mRNA (Banerjee, 2001). The BCL-2 gene is an anti-
apoptotic mitochondrial protein which is over expressed in many cancers (Gross, 
McDonnell & Korsmeyer, 1999, Reed, 1999). Daily subcutaneous treatment of 16 non-
Hodgkin’s lymphoma patients with G3139, for 14 days, in phase I trials resulted in 
reduction of BCL-2 expression in 7 patients (Waters et al., 2000). In a larger cohort, 35 
patients with advanced solid tumours (predominantly in the prostate) were treated with 
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G3139 with continuous intravenous infusion over 14 or 21 days (Morris et al., 2002). 
Although antitumour activity was not seen following treatment, immunoblot analysis using 
peripheral blood mononuclear cells showed a reduction in BCL-2 protein expression.  
G3139 has also been used in combination with the chemotherapeutic drug 
mitoxantrine to treat patients with prostate cancer (Chi et al., 2001). The ASO was 
intravenously administered continuously for 14 days with a single administration of 
mitoxantrine on day 8. BCL-2 protein expression from peripheral blood mononuclear cells 
was decreased in all 5 patients. The addition of G3139 with dacarbazine for treatment of 
malignant melanoma (currently in Phase III clinical trial; WWW.clinicaltrials.gov) was shown 
to increase the median survival rate by 2 months which was paralleled with an increase in 
the median progression free survival from 49 days (dacarbazine alone) to 78 days (G3139 
+ dacarbazine) (Dean & Bennett, 2003, Banerjee, 2001).  
Similarly to G3139, ISIS 3521 (Isis Pharmaceuticals) is a 20 nucleotide 
phosphorothioate ASO designed to target the 3’ untranslated region of the PKC-α gene 
mRNA (McGraw et al., 1997, Dean et al., 1996). PKC-α is a serine-threonine protein 
kinase involved in signal transduction pathways that controls cell proliferation; 
overexpression of PKC-α has been implicated in many cancers making it an appropriate 
molecular target for therapeutic agents (McGraw et al., 1997, Yazaki et al., 1996, Gescher, 
1992). Mice with subcutaneous glioblastoma U-87 xenografts treated daily for 21 days with 
2 or 20mg/kg ISIS 3521 resulted in suppression of tumour growth by 3 or 5 fold, 
respectively, compared to control oligonucleotide (Yazaki et al., 1996). ISIS 3521 also 
suppressed intracranial U-87 tumour growth in mice treated daily for up to 82 days with 
ISIS 3521 whereas control oligonucleotide treated mice did not survive past day 42. 
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1.3. Concerns with oligonucleotide based pharmaceuticals 
Genotoxicity testing of pharmaceuticals that are not biotechnology derived is regulated by 
the International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) guidelines S2A and S2B 
(http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/St
ep4/S2R1_Step4.pdf). The battery of genotoxicity tests are designed to inform the 
potential for compounds to induce genetic damage. Providing the methodology of each 
test does not deviate from the standardised protocol set by the Organisation for Economic 
Co-operation and Development (OECD) without scientific justification, those compounds 
which are found to be genotoxic are likely to be human mutagens/carcinogens that cause 
heritable alterations to the DNA sequence. The standard genotoxicity battery of tests is 
comprised of the following: 
 
(1) A bacterial gene reverse mutation assay, typically using Salmonella typhimurium 
(Ames test) or Escherichia coli to detect point mutations and frameshift mutations.  
(2) An in vitro gene mutation assay such as the Thymidine kinase (TK) forward 
mutation assay using mouse lymphoblastoid L5178Y cells or a cytogenetics assay 
for evaluation of chromosomal damage using mammalian cells such as the in vitro 
micronucleus assay. 
(3) An in vivo test for chromosome damage such as the in vivo bone marrow 
micronucleus assay using rodents where the frequency of micronuclei in 
polychromatic erythrocytes is a marker of clastogenic/ aneugenic activity.  
 
According to the ICH S6 guideline for pre-clinical safety evaluation of biotechnology 
derived pharmaceuticals, including ASO therapeutics and monoclonal antibodies, routine 
genotoxicity testing as described above is not appropriate and these molecules are not 
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expected to interact with DNA (www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ 
Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf). 
 However, publication of oligonucleotide mediated mutagenesis using engineered 
reporter constructs has raised concern from the EMA regarding the capability of 
oligonucleotide based pharmaceuticals, such as ASO, to bind genomic DNA and cause 
heritable sequence alterations (European Medicines Agency, 2004). Single strand 
oligonucleotides have been reported to be capable of forming secondary structures with 
duplex DNA, in a sequence specific manner, to form triplex or D-loop structures which 
have been reported to be mutagenic in engineered reporter constructs (Bonner & Kmiec, 
2009, Maguire & Kmiec, 2007, Radecke et al., 2006, Dekker, Brouwers & te Riele, 2003, 
Faruqi et al., 2000, Vasquez et al., 1999, Wang, Seidman & Glazer, 1996, de Wind et al., 
1995). 
 As discussed in section 1.2.1, ASO therapeutics are chemically modified to offer 
pharmacological activity. The EMA has also highlighted concern regarding the fate of 
degradation products from chemically modified oligonucleotide therapeutics (European 
Medicines Agency, 2004). Degradation of chemically modified ASO may release 
nucleotide analogues that may enter intracellular deoxyribonucleoside triphosphate 
(dNTP) pools and become substrates for DNA polymerase facilitating insertion into newly 
synthesised genomic DNA. If base pairing with nucleotide analogue occurs with reduced 
fidelity the probability of mutation is increased.   
 
1.3.1. Triplex forming oligonucleotides (TFO) 
The first triplex structure was described in 1957 by Felsenfeld et al. (Felsenfeld, Davies & 
Rich, 1957) composed of two polyribouradylic acid chains (poly-rU) and one 
polyriboadenylic acid chain (poly-rA). The structure was described as having an increased 
sedimentation rate relative to the duplex formed from single chains of poly-rA and poly-rU. 
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The triplex structure appeared to be stabilised in the presence of divalent cations 
presumed to neutralise the negative charges of the phosphate backbones in the 
oligoribonucleotide strands. 
Since its discovery, DNA containing a purine rich stretch has been shown to be 
capable of binding a third oligonucleotide strand in a sequence specific manner to form a 
triplex structure (Fig.1.4) (Duca et al., 2008, Jain, Wang & Vasquez, 2008, Kalish et al., 
2005, Guntaka, Varma & Weber, 2003, Washbrook & Fox, 1994, Durland et al., 1991, 
Hoogsteen, 1959). TFO bind in the major groove of duplex DNA where acceptor and donor 
groups present in the purine nucleotides are capable of hydrogen bonding with the 
nucleotides of the TFO (Fig.1.5) (Guntaka, Varma & Weber, 2003, Cooney et al., 1988). 
The hydrogen bonds between duplex DNA and TFO are not identical to the interactions 
between Watson-Crick base pairs and are referred to as Hoogsteen type hydrogen bonds 
(Hoogsteen, 1959).  
 
 
 
 
 
 
 
 
  
Figure 1.4. DNA triplex formation. TFO bind the major groove of duplex DNA containing purine tracts 
via Hoogsteen hydrogen bonds. Blue and green strands form duplex DNA. The red strands 
represents the TFO. Image taken from Guntaka et al. 2003.     
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There are three classifications of TFO, in which the rules for triplex formation are 
well described (Fig.1.6) (Buchini & Leumann, 2003, Chan & Glazer, 1997, Frank-
Kamenetskii & Mirkin, 1995); (i) The pyrimidine (TC) motif TFO composed of thymidine 
and cytosine binds parallel to the triplex target sequence forming T:A•T and C:G•C triplets. 
Triplex formation by TC motif TFO is limited by pH as the cytosine requires protonation in 
order to bind duplex DNA. Hence, pyrimidine motif TFO are not readily applicable for 
triplex formation at physiological pH without replacing the cytosine base with 5’-methyl-
cytosine to mitigate the pH dependence of binding (Xodo et al., 1991, Lee et al., 1984).    
(ii) The purine (GA) motif TFO composed of guanine and adenine is capable of binding 
antiparallel to the triplex target sequence independent of pH, forming C:G•G and G:A•A 
triplets. (iii) The mixed (GT) motif TFO composed of guanine and thymidine is capable of 
binding parallel or antiparallel to the triplex target sequence forming C:G•G and T:A•T 
triplets depending on the sequence composition [“:” indicates Watson-Crick hydrogen 
bonds; “•” indicates Hoogsteen hydrogen bonds]. 
  
Figure 1.5. Hoogsteen hydrogen bonding between nucleotides of TFO and duplex DNA. ‘IIIII’ 
indicates Watson-Crick hydrogen bonding between base pairs in duplex DNA and ‘••••’ indicates 
Hoogsteen hydrogen bonds between nucleotides in TFO and purine nucleotides in duplex DNA to 
form A•A:T and G•GC triplets. Image taken from Chan and Glazer, 1997. 
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1.3.1.1. Mutagenicity of TFO 
Using mammalian cells, triplex formation has been reported to induce sequence specific 
repression of target gene transcription (Kochetkova & Shannon, 1996, Grigoriev et al., 
1992, Cooney et al., 1988) and sequence specific mutagenesis using reporter constructs 
containing selectable loci or transgenic mice; in these studies, triplex mediated 
mutagenesis was described for populations of cells containing an engineered target 
sequence (Kalish et al., 2005, Datta et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, 
Xu, Glazer & Wang, 2000, Vasquez et al., 1999, Wang, Seidman & Glazer, 1996); with 
TFO covalently linked to a DNA intercalator (psoralen or acridine) (Macris & Glazer, 2003, 
Vasquez et al., 2001, Xu, Glazer & Wang, 2000, Vasquez et al., 1999); by pre-incubating 
the target vector with TFO under non-physiological conditions (Ye, Guntaka & Mahato, 
2007, Datta et al., 2001, Xu, Glazer & Wang, 2000) or with electroporation to deliver 
oligonucleotide (Puri et al., 2002, Puri et al., 2001, Faruqi et al., 2000, Majumdar et al., 
1998) and thus do not necessarily reflect biologically relevant events. To the best of my 
knowledge, no study has examined triplex mediated mutagenesis at genomic coding 
sequences using a non-conjugated TFO.  
Figure 1.6. Classification of TFO. TFO (red) are classified according to nucleotide composition and 
binding orientation relative to the polypurine target sequence (green) in duplex DNA. Image taken 
and modified from Duca et al. 2008.  
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Nevertheless, Cooney et al. (Cooney et al., 1988) demonstrated a 27mer 
oligonucleotide was capable of binding to a plasmid construct encompassing the c-myc 
gene. The TFO target was a purine rich stretch upstream of the transcription initiation site. 
Through the use of electrophoretic mobility shift assays (EMSA) and DNase 1 protection 
assays TFO binding was estimated to have a dissociation constant (Kd) around 4nM. The 
TFO was shown to be effective in downregulation of c-myc gene transcription through 
inhibition of transcription initiation. This was hypothesised to be a result of the occupancy 
of a putative protein binding site vital to the target gene’s expression, which was later 
confirmed in several systems (Kochetkova & Shannon, 1996, Grigoriev et al., 1992).  
Wang et al. (Wang, Seidman & Glazer, 1996) demonstrated the capability of a TFO 
to induce mainly point mutations and small deletions around the triplex target sequence. 
Within monkey COS cells, three phosphodiester oligonucleotides (AG10; AG20; AG30 
named according to TFO composition and length) targeted a Simian virus 40 (SV40) 
based shuttle vector containing the supFG1 reporter gene. Modified to enclose a purine 
stretch, the supFG1 reporter was used to assess the mutagenic potential of the TFO. 
Wang et al. (1996) reported mutation frequencies using the supFG1 system in the order of 
0.27% (2700x10-6), 13 fold above background, using 2micromolar (μM) AG30 TFO (Kd; 
20nM) incorporated into the cell growth media for 48h. AG10 (Kd; 30μM) and AG20 (Kd; 
300nM) TFO produced a mutant frequency 3 and 5 fold above background, respectively. It 
is notable that the reported background mutant frequency in this model is extraordinarily 
high. 
More recently, Kalish et al. (Kalish et al., 2005) reasoned the mutagenic potential of 
TFO to be dependent on the helical distortion produced upon triplex formation inferred 
from a nuclear magnetic resonance based structural study; oligonucleotides containing 
substitutions at the 2’ position of ribose were found to produce less helical distortion i.e. 
the relative degrees of distortion were DNA>RNA>2’-OMe (Asensio et al., 1999). In 
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agreement with the mutant frequency in their system, those chemical modifications 
promoting the C3’-endo conformation (RNA and 2’-OMe) were not mutagenic; the 
deduction was that those TFO which produced a significant helical distortion possess the 
ability to provoke the DNA repair pathway, initiated by the recruitment of the XPA/RPA 
DNA damage recognition complex to the triplex site, resulting in mutation (Vasquez et al., 
2002). 
 A possible reason for using engineered reporter constructs, such as SupF and 
GFP, to demonstrate triplex mediated mutagenesis is due to the fact triplex formation is 
governed by such stringent conditions i.e. a purine stretch and divalent cations. The 
availability of a 20-30 nucleotide purine stretch is limited in selectable genomic loci that 
can be used as a reporter of mutation but these reporters readily allow manipulation of 
reporter constructs and high-throughput screening using previously established assays. 
 
1.3.2. D-loop forming oligonucleotides  
Single strand oligonucleotides have also been shown to be capable of binding to 
complementary sequences in duplex DNA during transcription and DNA replication such 
that one of the duplex strands becomes displaced forming a D-loop structure (Wu et al., 
2005). Oligonucleotides which have a mismatched base upon binding to their 
complementary sequence in duplex DNA are capable of directing mutation to the site of 
the mismatched base in a process known as targeted nucleotide exchange (TNE). 
Oligonucleotide mediated mutagenesis via TNE is thought to be a 2-stage process: firstly, 
the oligonucleotide binds to its complimentary strand in duplex DNA to form a D-loop 
structure and secondly, mutation is directed to the mismatched base (Maguire & Kmiec, 
2007, Wu et al., 2005). Typically, oligonucleotides used in TNE are over 45 nucleotides in 
length and chemically modified to contain phosphorothioate linkages to provide nuclease 
resistance (Kenner et al., 2002). 
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 Unlike TFO where binding to duplex DNA is dictated by the presence of a purine 
stretch, in theory, D-loop forming oligonucleotides can bind to any complementary 
sequence in duplex DNA. Also, D-loop formation is irrespective of divalent cations which 
are reported to be necessary for stabilisation of triplex structures (Kalish et al., 2005, 
Felsenfeld, Davies & Rich, 1957). For example, an ASO designed to bind within the coding 
region of mRNA may also be capable of binding to the same complementary sequence in 
genomic DNA and induce mutation via TNE but in order for ASO to form a triplex at 
genomic DNA they must bind a purine stretch otherwise triplex formation will not occur.  
 
1.3.2.1. Mutagenicity of D-loop forming oligonucleotides 
D-loop forming oligonucleotides have been reported to be capable of inducing site specific 
mutation in a process known as TNE providing the oligonucleotide contains a mismatched 
base upon binding to its complimentary sequence in duplex DNA. Oligonucleotides 
(typically >45 nucleotides) are usually engineered to target reporter constructs such as 
enhanced GFP (eGFP) (Bonner & Kmiec, 2009, Olsen et al., 2009, Papaioannou, Disterer 
& Owen, 2009, Morozov & Wawrousek, 2008, Maguire & Kmiec, 2007, Aarts et al., 2006, 
Radecke et al., 2006, Olsen et al., 2005, Dekker, Brouwers & te Riele, 2003, de Wind et 
al., 1995, te Riele, Maandag & Berns, 1992). This system allows high throughput 
screening using flow cytometry by monitoring the correction of a point mutation that reverts 
the mutant eGFP protein functional and fluorescent.  
The precise mechanism of TNE by oligonucleotides is not known but the efficiency 
of TNE has been reported to be modulated by transcription (Igoucheva et al., 2003), DNA 
replication (Brachman & Kmiec, 2005, Olsen et al., 2005, Wu et al., 2005), the mismatch 
repair (MMR) pathway (Dekker et al., 2011, Papaioannou, Disterer & Owen, 2009, 
Maguire & Kmiec, 2007, Aarts et al., 2006, Dekker, Brouwers & te Riele, 2003, de Wind et 
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al., 1995) and homologous recombination (HR) repair (Radecke et al., 2006, te Riele, 
Maandag & Berns, 1992). See Fig.1.7 for an overview. 
The rate of transcription has been reported to positively modulate TNE. Using a 
LacZ reporter construct integrated into two different cell populations, from the same cell 
line, with different levels of transcription (20 fold difference in LacZ protein expression), a 
45mer oligonucleotide was able to direct site specific mutation in cells with elevated LacZ 
gene transcription almost 100 fold greater than the same cell line with reduced LacZ 
transcription (Igoucheva et al., 2003). This was proposed to be a result of an open 
chromatin structure around highly transcribed genes making the target site more 
accessible for oligonucleotide binding.  
Oligonucleotides targeting the non-transcribed (sense) strand have also been 
reported to be more efficient in gene correction via TNE, rather than oligonucleotides 
targeting the transcribed (antisense) strand, by up to 200 fold (Bonner & Kmiec, 2009, Wu 
et al., 2005, Igoucheva et al., 2003). It was postulated that the strand bias is due to limited 
accessibility of the transcribed strand during transcription (Igoucheva et al., 2003).  
Furthermore, oligonucleotides bound to the transcribed strand have been reported to be 
unwound by a progressing transcription fork, thus, preventing TNE (Liu et al., 2002). 
Controversially, Dekker and colleagues did not report a difference in the frequency of TNE 
when oligonucleotides were directed to the sense or antisense strands (Dekker, Brouwers 
& te Riele, 2003). 
To investigate the effect of cell cycle on TNE, Wu and co-workers (Wu et al., 2005) 
synchronised HeLa cells, containing a mutant eGFP plasmid, at G1, S and M phase by 
treatment with specific inhibitors, L-mimosine, thymidine and nocodazole, respectively, 
followed by treatment with oligonucleotide. Correction of mutant eGFP was up to 0.54% 
(5,400x10-6) in S phase treated cells whilst much lower in the remaining phases.  Taking 
the study a step further, they used various S phase inhibitors (thymidine, hydroxyurea and 
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aphidicolin), which reduce the rate of DNA replication to varying degrees (Saintigny et al., 
2001), to investigate the relationship between the rate of replication and frequency of TNE. 
They observed that reducing the rate of replication, using 2mM thymidine, was optimum 
for TNE whilst complete inhibition of replication, using hydroxyurea or aphidicolin, 
mitigated mutant eGFP gene correction (Wu et al., 2005). Thus, reducing (not inhibiting) 
the rate of DNA replication during S phase has a positive modulatory effect on TNE which 
is in contrast to the modulatory effects of transcription (Igoucheva et al., 2003). The 
authors proposed this effect was a result of a prolonged open chromatin structure that 
facilitates efficient annealing of oligonucleotide to duplex DNA by increasing the “window 
of opportunity” for binding (Wu et al., 2005). This conclusion was also made by Bachman 
and Kmiec (Brachman & Kmiec, 2005); pre-treating cells with 2’,3’-dideoxycytidine 
nucleoside resulted in an extended S-phase by stalling replication forks and increased 
oligonucleotide mediated gene correction of mutant eGFP by 3 fold. In this study also, 
gene correction was absent when DNA replication was completely inhibited. Similar to Wu 
et al. (Wu et al., 2005), the authors proposed a prolonged open chromatin structure 
increases target site availability for oligonucleotide binding.  
Bonner and co-workers reported that prior to electroporation of HCT116 cells with 
8µM oligonucleotide, synchronisation of cells in early S phase, using aphidicolin, resulted 
in gene correction frequencies of 2% (Bonner & Kmiec, 2009). Importantly, the authors 
reported that gene correction of mutant eGFP was coupled to DNA double strand breaks 
(DSBs), measured using the alkaline comet assay. However, DNA DSBs following 
oligonucleotide treatment were not observed above control (spontaneous or control 
oligonucleotide treatments) until the average comets per field were normalised to the cell 
number following treatment (i.e. cytotoxicity) which is an unorthodox approach for this 
assay. It seems the authors correlated the extent of cytotoxicity following treatment with 
the frequency of DNA DSBs. However, cytotoxicity following treatment is not necessarily 
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caused by DNA damage and therefore, is not the most appropriate method of 
normalisation for this assay. 
The DNA repair pathways have also been implicated as modulators of TNE. For 
instance, the MMR protein, mut S homologue 2 (MSH2), has been proposed to be a 
negative modulator of TNE which contradicts initial speculation on the mechanism of gene 
correction (Gamper et al., 2000, Cole-Strauss et al., 1999). MSH2 can complex with MSH6 
or MSH3 to form MutS-α or MutS-β, respectively, both of which are involved in mismatch 
recognition and initiation of DNA repair (Kunkel & Erie, 2005); MutS-α preferentially 
recognises 1 or 2 base mismatches whereas MutS-β recognises larger mismatches. It is 
also reported that the MSH2 protein possesses anti-recombinogenic activity, if there is 
greater than 0.6% sequence divergence between homologous pairs, by directly interacting 
with HR repair protein factors and inhibiting their function, (Brown et al., 2003, Wang et al., 
2000, de Wind et al., 1995, te Riele, Maandag & Berns, 1992). Further to this, it is believed 
that oligonucleotides employed in TNE physically incorporate into duplex DNA as a result 
of HR repair or by oligonucleotides acting as Okazaki fragments during DNA replication 
(Radecke et al., 2006, Parekh-Olmedo et al., 2005). Thus, it has been proposed that 
reducing MSH2 protein expression increases the efficiency of TNE by mitigating the 
associated antirecombinogenic activity (Papaioannou, Disterer & Owen, 2009, Maguire & 
Kmiec, 2007, Aarts et al., 2006, Dekker, Brouwers & te Riele, 2003, de Wind et al., 1995, 
te Riele, Maandag & Berns, 1992). Alternatively, oligonucleotides may act as primers 
during DNA synthesis where the mismatched base stimulates the MMR pathway in wild-
type cells to correct the mismatched base in the newly synthesised strand including the 
oligonucleotide (Parekh-Olmedo et al., 2005, Dekker, Brouwers & te Riele, 2003); a 
deficiency in MMR may allow the cell to tolerate the mismatched base until cell division 
where the mutation becomes fixed. 
 40 
 
In mouse embryonic fibroblast cells, a 47mer oligonucleotide was able to correct a 
single base deletion in an eGFP reporter plasmid to restore the wild-type sequence but 
silencing of MSH2 protein, by RNA interference (RNAi), enhanced gene correction by 3 
fold (Maguire & Kmiec, 2007). Furthermore, oligonucleotide mediated gene correction of a 
neomycin gene carrying (i) a single point mutation (ATG → AAG) that inactivates the 
transcription start codon or (ii) a two base pair insertion to disrupt the open reading frame, 
was only observed in mouse embryonic stem cells when MSH2 protein expression was 
reduced by RNAi, up to a frequency of 70x10-6 (Aarts et al., 2006). Using this MSH2 
deficient system, an oligonucleotide with 4 mismatched bases was also capable of 
restoring the neomycin gene open reading frame at a frequency of 20x10-6. In a similar 
study, gene correction of 2 tandem frameshift mutations, in a neomycin gene, was 
reported in ~32 mouse embryonic stem cells when 7x105 were treated with 
oligonucleotide, in an MSH2 deficient system (Dekker, Brouwers & te Riele, 2003). In wild-
type cells, gene correction was as low as 0.5x10-7. 
Data has been presented that implicates the involvement of the HR repair pathway 
(or at least proteins involved in the initiation of HR repair) in the process of TNE. Co-
injection of a 74mer oligonucleotide targeting a mutant αβ-crystallin gene with recombinant 
RAD51 protein (important for HR repair initiation) was capable of correcting a premature 
stop codon at a frequency of 2.8% (Morozov & Wawrousek, 2008). Targeted gene 
correction was absent with oligonucleotide treatment alone. However, microinjection of 
oligonucleotide and an antibody against the Ku70/80 heterodimer increased the correction 
efficiency up to 9.9%. The Ku70/80 heterodimer is a critical DNA DSB binding protein vital 
for signalling the non-homologous end joining (NHEJ) repair pathway (Jeggo, 1998, 
Takata et al., 1998). It is believed that resolution of DNA DSBs is governed by competitive 
binding of critical initiation factors to direct repair via NHEJ or HR repair (Pierce et al., 
2001); silencing of Ku protein expression is reported to enhance the HR repair pathway. 
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This study was the first to highlight the positive and negative modulatory roles of HR and 
NHEJ repair on oligonucleotide mediated TNE, respectively (Morozov & Wawrousek, 
2008).  
 In fact, Radecke and colleagues (Radecke et al., 2006) demonstrated that a 
biotinylated oligonucleotide was capable of physically incorporating into the genome of 
cells following TNE with correction frequencies up to 5%. Most interesting was that 
modification of the 5’ or 3’ oligonucleotide termini with 5’-OH or 3’-H in place of a 5’-
phosphate moiety or 3’-OH group, respectively, significantly reduced the efficiency of gene 
correction suggesting canonical termini were important for TNE, supporting oligonucleotide 
integration into the host cell genome prior to gene correction. A low level of gene 
correction was observed possibly as a result of exonuclease metabolism of 
oligonucleotides releasing terminal nucleotides carrying non-canonical ends resulting in 
oligonucleotides with termini capable of integration. The authors proposed that TNE was a 
result of physical incorporation of targeting oligonucleotides into duplex DNA possibly 
through (i) HR repair or (ii) oligonucleotides serving as Okazaki fragments during DNA 
replication.  
A similar observation was made by Olsen et al. (Olsen et al., 2005) when the 5’ and 
3’ ends of an oligonucleotide were blocked by an octyl moiety. Targeted gene correction of 
a mutant GFP gene was reduced to 16% of that observed with oligonucleotide treatment 
without the octyl blocking groups. The authors suggested that functional 5’ and 3’ moieties 
may be important for physical incorporation of oligonucleotides into duplex DNA.  
To summarise, the rate of gene transcription has been reported to positively 
modulate TNE possibly by facilitating oligonucleotide annealing through increased 
accessibility of the target sequence due to an open chromatin structure (Fig.1.7, step 1). 
The contrary mechanism may apply to oligonucleotide annealing during S-phase DNA 
replication; reducing the rate of DNA replication may increase the probability of 
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oligonucleotide annealing due to a prolonged open chromatin structure (Fig.1.7, step1). 
RAD51 protein is likely to facilitate strand invasion of duplex DNA by oligonucleotides to 
form a D-loop structure (Fig.1.7). This aberrant structure may result in the stimulation of 
the HR repair pathway. Following this, oligonucleotides may physically incorporate into 
duplex DNA via HR repair creating a mismatched base with the opposing strand (Fig.1.7, 
step 2). Alternatively, oligonucleotides may physically integrate into the host cell genome 
by serving as a primer for DNA replication (Fig.1.7, step 2). If the MMR repair pathway is 
active, the mismatched base is removed and restored, or, HR of oligonucleotide is 
inhibited due to the anti-recombinogenic activity of MSH2 protein. In either case, TNE will 
not occur. Inactivation of the MMR pathway, by silencing MSH2 protein expression, may 
facilitate HR of oligonucleotides and tolerance of the mismatched base until cell division 
where it becomes fixed in the genome of a daughter cell (Fig.1.7, step 3). 
Studies addressing the influence of other critical MMR proteins on TNE may clarify 
the mechanism of oligonucleotide mediated gene correction. For example, other proteins 
in MMR, such as mut L homolog 1 (MLH-1), are vital for downstream signalling (Li, 2008, 
Kunkel & Erie, 2005). Silencing of MLH-1 mitigates activity of the MMR pathway but MSH2 
protein remains active as an anti-recombinogenic protein (Li, 2008). Thus, if TNE in MLH-1 
deficient cells is less than that in MSH2 deficient cells, this may imply that MMR may not 
be involved in TNE and it is the HR repair pathway which incorporates oligonucleotide into 
genomic DNA when the anti-recombinogenic activity of MSH2 is silenced. Alternatively, if 
MLH-1 and MSH2 deficient cells have a similar magnitude of TNE, it may imply that the 
MMR pathway serves to correct the mismatched base within newly synthesised DNA upon 
incorporation via serving as a DNA primer and that the HR repair pathway may not be 
involved. These studies may highlight RAD51 as an important factor in the annealing 
process of oligonucleotides but not in HR repair. An important consideration is that 
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oligonucleotide incorporation into genomic DNA may not be unique to a single mechanism 
but possibly a combination of both.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Putative mechanism of TNE by D-loop forming oligonucleotides. Step1: Oligonucleotide 
binds to its complimentary target sequence in duplex DNA, during DNA replication or transcription, 
forming a D-loop structure. Duplex DNA contains a mismatched base relative to the oligonucleotide 
sequence (*). Step 2: oligonucleotide physically incorporates into genomic DNA via HR repair or by 
acting as an Okazaki fragment during DNA replication. Step 3: once oligonucleotide is incorporated, 
the mismatched base is either corrected by MMR or tolerated until another cycle of DNA replication 
fixing the mutation. Image adapted from Radecke et al.2006. 
Step 1 
 
Step 2 
 
Step 3 
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1.3.3. Nucleotide analogues 
Unmodified oligonucleotides containing a canonical phosphodiester backbone, sugar and 
base moieties tend to be degraded by nucleases to release monophosphate nucleotide 
units (Spitzer & Eckstein, 1988). Degradation of oligonucleotides tends to initiate on the 3’ 
end as 3’ exonucleases are more prevalent in serum than 5’ exonucleases or 
endonucleases (Shaw et al., 1991, Tidd & Warenius, 1989, Wickstrom, 1986). Due to such 
limitations, it has become routine to chemically modify oligonucleotides to facilitate 
biological activity, as discussed in section 1.2.1. Most of these modifications do not offer 
complete resistance to nucleases and because of this are slowly degraded to release 
nucleotide analogues (Shaw et al., 1991).  
Although nucleotide analogues can be derived from oligonucleotide degradation, 
nucleoside analogues have also been engineered as antiretroviral therapies to be used as 
part of the highly active antiretroviral therapy (HAART) to treat HIV-1 (Fig.1.8) (Olivero, 
2008, Olivero, 2007, Wutzler & Thust, 2001).  
It has been estimated that around 30 million adults and 2.5 million children 
worldwide were living with HIV-1 or acquired immunodeficiency syndrome (AIDS) by the 
end of 2009 (http://www.avert.org/worldstats.htm). Typically, antiretroviral nucleoside 
analogues are targeted to virus encoded reverse transcriptase. The antiretroviral activity of 
nucleoside analogues is mediated by their ability to cause viral DNA chain termination 
and/or block the HIV-1 reverse transcriptase nucleotide binding site (Wutzler & Thust, 
2001, Huang, Farquhar & Plunkett, 1990, St Clair et al., 1987, Furman et al., 1986).  
AZT (3’-azido-2’, 3’-dideoxythymidine; Fig.1.8A) has been recommended for use 
since 1994 to prevent vertical transmission of HIV-1 from infected mothers to foetus 
(Olivero, 2007). Since then, AZT (Zidovudine) has become one of the most important 
components of HAART to treat HIV-1 (Olivero, 2008, Olivero, 2007). AZT administration to 
the mother during pregnancy and labour and to the new born baby following birth reduces 
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the frequency of HIV-1 transmission to children from 30% to 8% (Connor et al., 1994).  
AZT used in combination therapy with the antiretroviral nucleoside analogue Lamivudine 
(2’, 3’-dideoxy-3’-thiacytidine; Fig.1.8B) and coupled to caesarean section can reduce 
vertical transmission to 2% (Panburana et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The biological efficacy of antiretroviral nucleoside analogues depends on cytosolic 
phosphorylation to mono-, di- and tri-phosphate forms (Wutzler & Thust, 2001, St Clair et 
al., 1987). For example, AZT is mono, di and triphosphorylated by TK, thymidylate kinase 
and pyrimidine nucleoside diphosphate kinase (St Clair et al., 1987). This highlights 
Figure 1.8. Chemical structure of antiretroviral nucleoside analogues used in HAART. AZT (A), 
Lamuvidine (B), Ganciclovir (C) and Didanosone (D). Image taken from Wutzler et al. 2001. 
A B 
C D 
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potential for nucleoside analogue entry into endogenous dNTP pools following 
phosphorylation by endogenous pathways.  
Although AZT is a potent HIV-1 reverse transcriptase inhibitor the drug limiting 
toxicity of AZT has been proposed to be a result of genomic insult to host cell DNA. This is 
supported by previous studies demonstrating AZT incorporation into the genomic DNA of 
mouse, hamster and human cell lines (Olivero, Beland & Poirier, 1994).  
 
1.3.3.1. Mutagenicity of non-canonical nucleotide analogues 
The majority of nucleoside analogues subject to the battery of genotoxicity testing 
(described in section 1.3) are not positive in bacterial gene mutation assays, such as the 
Ames test, and tend not to induce point mutations (Wutzler & Thust, 2001); this effect has 
been hypothesised to be a result of the mechanism of nucleoside analogue mediated 
genotoxicity which is thought to be gross chromosomal damage as a result of obligate 
chain termination following nucleoside analogue incorporation. According to Wutzler et al. 
(Wutzler & Thust, 2001), most nucleoside analogues tested cause chromosomal damage 
albeit at concentrations above physiological plasma levels used in therapeutic treatments.  
Ganciclovir (9-[(1,3-dihydroxy-2-propoxy)-methyl]-guanine; Fig.1.8C) causes 
cytogenetic damage including chromosome aberrations and sister chromatid exchange 
(SCE) (Thust, Schacke & Wutzler, 1996). In Chinese hamster ovary cells expressing the 
herpes virus TK gene, Ganciclovir is a very potent genotoxin causing chromosome breaks, 
translocations and SCE at concentrations as low as 1nM (Thust et al., 2000a, Thust et al., 
2000b). These data suggest that the drug can be monophosphorylated for its utilisation by 
endogenous cellular machinery (Wutzler & Thust, 2001). This is supported by several 
groups demonstrating incorporation of radiolabelled Ganciclovir into genomic DNA, 
presumably during DNA replication, where chromosomal damage was hypothesised to be 
at sites of Ganciclovir incorporation (Thust et al., 2000a, Thust et al., 2000b, Rubsam, 
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Davidson & Shewach, 1998, St Clair, Lambe & Furman, 1987). Lifetime carcinogenicity 
testing in mice was found to be positive with tumours induced in the forestomach (male 
and female mice), mammary gland and preputial gland in females. Thus, Ganciclovir is 
considered to be a human carcinogen (Physicians' Desk Reference, 2000).   
AZT has been reported to be positive in genotoxicity tests including the mouse 
lymphoma assay (MLA) using L5178Y cells, in vitro micronucleus assay and in vivo bone 
marrow micronucleus assay, SCE, in vitro cell transformation and in vivo carcinogenicity in 
mice (Sussman et al., 1999, Ayers et al., 1996, Gonzalez Cid & Larripa, 1994, Phillips et 
al., 1991) (http://monographs.iarc.fr/ENG/ Monographs/vol76/mono76.pdf). AZT is also 
reported to epigenetically alter the methylation profile of the TK gene causing its 
inactivation (Wu et al., 1995, Nyce et al., 1993). 
Treatment of human blood lymphocytes in vitro with AZT from 50 micrograms (µg) 
per millilitre (ml) (187μM) induced micronuclei and SCE as well as inducing transformed 
foci in BALB/c 3T3 cells from 2μM (Ayers et al., 1996, Gonzalez Cid & Larripa, 1994). 
Transformation assays are ideally used for suspected non-genotoxic carcinogens which 
act via altering the epigenome without genomic sequence alteration. The assay relies on 
normal growth of cells and contact inhibition; following treatment with a drug, 
transformation of cells results in the development of foci that are no longer regulated by 
contact inhibition (Heidelberger et al., 1983, Thust, 1976) (http://ecvam.jrc.it/publication/ 
WorkshopReport39.pdf).  
Oral administration of 30mg/kg/day AZT to female mice induced vaginal carcinomas 
and vaginal epithelial neoplasias in rats after administration of 300mg/kg/day (Ayers et al., 
1996). Tumourigenic activity of AZT was not observed in male mice. This was proposed to 
be a result of local vaginal epithelium exposure to urine containing high levels of the drug 
(Ayers et al., 1996). In a separate study, oral administration of AZT to female mice resulted 
in incorporation of AZT into the genomic DNA of vaginal epithelial cells which may explain 
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the mechanism of AZT tumourigenesis (Olivero et al., 1994, Olivero, Beland & Poirier, 
1994).  
The exact mechanism of DNA damage caused by nucleoside analogues is not 
known. It is likely that genomic insult can occur via two processes: (1) nucleoside 
analogues perturb the intracellular balance of dNTP pools altering the fidelity of DNA 
polymerase and/or (2) physical incorporation of nucleoside analogues into genomic DNA; 
the majority of nucleoside analogues have unmodified bases so it is presumed the fidelity 
of base pairing is not affected (Wutzler & Thust, 2001, Kunz et al., 1994, Kunz, 1988). 
However, they are modified on the side chain to contain a single functional hydroxyl group 
similar to the 5’ hydroxyl group of the sugar ring in standard nucleotides. They do not 
contain a 3’ hydroxyl group capable of forming phosphodiester linkages (Olivero, 2007). 
Thus, incorporation of nucleoside analogues into newly synthesised DNA causes chain 
termination. It has been hypothesised that exonuclease mediated removal of the terminal 
nucleoside may trigger error prone DNA repair and when the repair pathway becomes 
saturated the apoptotic pathway is triggered (Meng et al., 2002, Wutzler & Thust, 2001, 
Olivero et al., 1999a, Olivero et al., 1999b).  
The above describe that antiretroviral nucleoside analogues can act as substrates 
for nuclear DNA polymerase mediated incorporation into genomic DNA. However, 
mitochondrial DNA polymerase γ mediated incorporation of antiretroviral nucleoside 
analogues into mitochondrial DNA can also result in dose limiting toxicity (Olivero, 2007, 
Johnson et al., 2001). Johnson et al. (Johnson et al., 2001) tested the kinetics of 
incorporation and excision of all FDA approved antiretroviral nucleoside analogues into 
mitochondrial DNA. The study reported a correlation of highly toxic nucleoside analogues 
such as 2’,3’-dideoxyinosine (Didanosone; Fig.1.8D) with increased rate of incorporation 
into mitochondrial DNA with inefficient removal. Low toxicity associated with nucleoside 
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analogues such as AZT and Lamivudine correlated with reduced mitochondrial DNA 
incorporation and high rates of removal.  
Concerns over toxicity and potential carcinogenicity, associated with antiretroviral 
nucleoside analogues (in particular AZT treatment used to prevent vertical transmission of 
HIV-1 in pregnant women) have been expressed by regularity authorities in South Africa 
where the HIV/AIDS pandemic is on the rise (Birmingham, 2000). This concern is 
supported by data confirming AZT incorporation into maternal and infant leukocyte DNA up 
to 350 AZT molecules per 106 nucleotides following treatment as part of the HAART 
protocol (Olivero et al., 1999b). However, conclusive carcinogenicity in humans by 
nucleoside analogues is lacking and suggestions of carcinogenicity are speculative and 
based on the fact that these drugs interfere with nucleic acid metabolism and utilisation 
therefore make hereditary sequence alterations possible (Wutzler & Thust, 2001). The 
validity of these concerns will become clear over the next decade.  
An important point to consider is that the genotoxicity of antiretroviral nucleoside 
analogues is well established, however, these nucleoside analogues are not used in ASO 
design and such genotoxicity data cannot be used to extrapolate mutagenicity of 
nucleotide analogues derived from ASO degradation. The data can be used to highlight 
the potential for such aberrant nucleoside structures to be substrates for intracellular 
kinases and DNA polymerase.  
  
1.3.3.2. Mutagenicity of canonical nucleotides 
A continuous and balanced supply of intracellular dNTP pools is essential to maintain the 
integrity of DNA during replication (Fersht, 1979, Kunkel & Loeb, 1979, Reichard, 1978). 
Supplementing Chinese hamster ovary cells with 1millimolar (mM) thymidine has been 
reported to reduce the rate of DNA synthesis by 90% as well as cause an expansion in the 
2’-deoxyadenosine triphosphate (dATP), 2’-deoxyguanosine triphosphate (dGTP) and 2’-
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deoxythymidine triphosphate (dTTP) pools while decreasing the 2’-deoxycytidine 
triphosphate (dCTP) pools 10 fold (Bjursell & Reichard, 1973). Thymidine deprivation and 
excess can also induce DNA breaks, deletions, SCE and heritable sequence alterations 
(Seno et al., 1985, Perry, 1983, Potter, 1971).  
Treatment of human CEM cells with 50μM 2’-deoxyguanosine for 6h increased the 
dGTP levels by 43 fold and induced the HPRT mutant frequency 40 fold above control 
(Mattano, Palella & Mitchell, 1990). A similar induction of HPRT mutants was observed 
with 20μM 2’-deoxyadenosine treatment.  
The magnitude and duration of dNTP pool perturbation can affect the rate of 
misincorporation of nucleotides in excess (Mattano, Palella & Mitchell, 1990). It is likely 
that DNA polymerase slippage at sites of repeating bases is enhanced following 
perturbation of dNTP pools facilitating nucleotide misincorporation (Mattano, Palella & 
Mitchell, 1990).  
DNA polymerase tends to misincorporate the nucleotide in excess to produce 
mainly transition point mutations (Phear, Nalbantoglu & Meuth, 1987). In a molecular 
study, Phear et al. sequenced several adenine phosphoribosyltransferase gene mutant 
clones derived from excess thymidine treatment (Phear, Nalbantoglu & Meuth, 1987). 
Sequencing data revealed mainly C→T transition mutations at sites that were followed by 
thymidine. For example, mixed sequences containing cytosine and thymidine were 
mutated following excess thymidine treatment to runs of thymidine. 
A similar affect was observed in thymidine depleted conditions (high cytosine to 
thymidine ratio); T→C transition mutations were reported when cytosine was the 3’ 
nucleotide in sequence. The authors proposed the local sequence context influences the 
position of base substitutions. Typically, the nucleotide in excess is downstream of most 
misincorporated nucleotides. This mechanism of mutation by excess nucleotides is known 
as the next nucleotide effect model (Phear, Nalbantoglu & Meuth, 1987, Bernardi & Ninio, 
 51 
 
1978); an outcome based on a compromise between the proof-reading activity of the 3’ to 
5’ exonuclease activity and the rate of polymerisation; when a misincorporated nucleotide 
is followed 3’ by a nucleotide in excess, polymerisation of this nucleotide is favoured rather 
than excision of the incorrect one thereby causing a point mutation (Fersht, 1979).   
Nucleotide pool perturbations have also been reported to increase the susceptibility 
of Chinese hamster ovary (CHO) cells to mutation by the DNA alkylating agents ethyl 
methanesulphonate (EMS) and N-methyl-N’-nitro-N-nitrosoguanidine (Meuth, 1981a, 
Peterson et al., 1978). For instance, Meuth et al. (Meuth, 1981a) reported an imbalance of 
dCTP to dTTP increased the cytotoxic and mutagenic activity of EMS. When intracellular 
dCTP concentrations were 10 fold greater than dTTP, the concentration of EMS that 
induced 10% survival was 3mM; the converse resulted in 10% survival with 1mM EMS 
treatment.  
In CHO cells, mutation at the sodium-potassium exchanging adenosine 
triphosphatase gene co-treated with 0.4mM EMS and 100µM thymidine produced a similar 
mutagenic response as 1.6mM EMS treatment alone (Meuth, 1981a). Increasing the 
thymidine concentration was coupled to an increase in the mutagenicity of EMS. The 
authors proposed that an increased dCTP to dTTP ratio can protect cells from the lethality 
of EMS treatment by reducing the misincorporation frequency of thymidine at O6-
alkylguanine residues (Meuth, 1981a). Competitive incorporation of the correct nucleotide 
(dCTP) prevents a transition mutation that would occur if dTTP were incorporated. Thus, 
increasing the dTTP to dCTP ratio facilitates misincorporation of thymidine to                            
O6-alkylguanine enhancing the cytotoxicity and mutagenicity of EMS. 
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1.4. Aims and objectives 
Subjecting ASO pharmaceuticals to the standard battery of genotoxicity testing is not 
appropriate due to the putative mechanisms of oligonucleotide-genomic DNA interactions; 
the sequence specific nature for triplex and D-loop formation makes it highly unlikely for 
routine tests to detect genomic insult. As antiretroviral nucleoside analogues used as part 
of HAART are not used in ASO design the established genotoxicity associated with these 
nucleoside analogues cannot be used to extrapolate the genotoxic risk posed by 
nucleotide analogues released as degradation products from chemically modified ASO.  
 
Hypothesis under investigation: ASO as therapeutic modalities do not carry a 
genetic toxicology risk. 
 
Thus, this study has aimed to: 
 Characterise the binding affinity and genotoxicity of a TFO targeting genomic DNA 
in viable human cells. 
 
 Design and evaluate the genotoxicity of an ASO capable of D-loop formation at 
genomic DNA and inform the modulatory roles of distinct DNA repair pathways in 
the mechanism of mutation. 
 
 Inform the potential for nucleotide analogues, derived from ASO degradation, to be 
utilised by DNA polymerase and cause mutation. 
 
The outcomes from this study can be used to highlight the risk posed by oligonucleotide 
based pharmaceuticals that may be used in human therapies and the requirement for 
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novel pre-clinical safety assessment methods for such drug candidates on a case-by-case 
basis.  
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Chapter 2  
Materials and Methods 
 
2.1. Oligonucleotides 
All oligonucleotides contained a deoxyribose sugar moiety. Oligonucleotides were 
synthesised by Sigma Genosys (Haverhill, UK) and purified (>95%) by reverse phase 
cartridge. Psoralen and biotin conjugated oligonucleotides were HPLC purified. All 
oligonucleotides were chemically modified to contain 4 terminal phosphorothioate linkages 
at the 5’ and 4 at the 3’ ends to increase nuclease resistance (Kenner et al., 2002), unless 
otherwise stated. Oligonucleotides were supplied lyophilised and stored at -20°C. On the 
day of use, dried oligonucleotides were dissolved to a final concentration of 200μM using 
sterile DNase/RNase free water (Invitrogen, Paisley).  
 
2.1.1. Triple-helix forming oligonucleotide design 
A purine motif TFO, twenty seven nucleotides in length (TFO27), was designed to target a 
purine rich segment within exon 3 of the human Hypoxanthine-guanine 
phophoribosyltransferase (HPRT) locus (gene ID 3251). The TFO27 triplex target 
sequence (nucleotides 113-139 from exon 3) is highlighted in Table 2.1. Antiparallel 
binding of TFO27 to the triplex target sequence forms A•A:T and G•G:C triplets stabilised 
by reverse Hoogsteen hydrogen bonds as discussed in further detail in section 1.3.1. A 
scrambled oligonucleotide (SCR27), with the same base composition as TFO27 but in a 
random order was employed as an oligonucleotide control throughout experiments. 
SCR27 has no sequence similarity to the HPRT locus, confirmed using National Center for 
Biotechnology Information-Basic Local Alignment Search Tool (NCBI-BLAST). TFO 
sequences are listed in Table 2.1. 
 55 
 
2.1.2. Displacement loop/ antisense oligonucleotide design 
An oligonucleotide, twenty seven nucleotides in length, was engineered to bind to the 
HPRT gene which was complementary to the TFO27 triplex target sequence via D-loop 
formation (Dloop27). Dloop27 contains four terminal phosphorothioate linkages at either 
end to facilitate nuclease resistance (Kenner et al., 2002) (Table 2.2).  
In a similar approach using NCBI-BLAST, an ASO, twenty three nucleotides in 
length, was engineered to bind complementary to the A disintegrin and metalloproteinase 
with thrombospondin type 1, motif 3 (ADAMTS3) gene (gene ID 9508) mRNA as well as 
contain sequence homology to the HPRT locus except a single mismatched base (AD3-
HPRTPM). AD3-HPRTPM was engineered to act as an ASO to modulate ADAMTS3 
protein expression. Additional to this, it was proposed that off-target genotoxicity caused 
by the presence of AD3-HPRTPM would result in point mutation at the site of the 
mismatched base within the HPRT locus. The single point mutation would result in a G>T 
transversion changing the codon from AGA (arginine) to ATA (isoleucine). AD3-HPRTPM 
mediated mutation at the HPRT locus was informed using the HPRT mutation assay 
described in section 2.4. AD3-HPRTPM was chemically modified to contain four terminal 
phosphorothioate linkages at either end to facilitate nuclease resistance (Kenner et al., 
2002) (Table 2.2).  
Further to AD3-HPRTPM, a positive control oligonucleotide (Val-HPRTPM) was 
engineered to contain sequence homology to the HPRT locus, except a single mismatched 
base (Table 2.2). Point mutation at the site of the mismatched base in Val-HPRTPM has 
previously been reported to result in a mutant HPRT phenotype (Meng et al., 2002). 
Hence, Val-HPRTPM is predicted to cause a C>T transition mutation in exon 3 (position 61 
from exon 3 or position 202 in mRNA) changing the codon from leucine to phenylalanine.   
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Throughout D-loop studies, a negative control oligonucleotide (control), which 
contained the same base composition as AD3-HPRTPM but in a random order, was 
employed (Table 2.2). 
 
2.1.3. Serum stability of oligonucleotides 
The serum stability of TFO27 and SCR27 (Table 2.1) was determined as previously 
described by (Grunweller et al., 2003) with slight modification. Oligonucleotides were 
diluted in RPMI 1640 media supplemented with 10% horse serum to a final concentration 
of 10μM in DNase/RNase free eppendorf tubes in triplicate. Samples were incubated at 
37°C and 10μL aliquots removed at 0 minutes (mins), 15 mins, 30 mins, 1 hour (h), 2h, 4h, 
8h and 24h. Reactions were terminated by 10μL addition of urea-TBE loading buffer 
(1xTBE, 7M urea and 0.1%w/v bromophenol blue) and subsequent freezing in -80°C. 
Oligonucleotides were resolved on 1.5% agarose gels containing 0.5μg/mL ethidium 
bromide at 80 volts (V) for 1h. Gels were visualised under UV using BioRad ChemiDoc 
XRS+ and bands quantified by densitometry using Image Lab software. Data was 
processed using GraphPad prism 5.0 (GraphPad software, USA). Average band 
intensities were normalised to the average band intensity of the 0h oligonucleotide.  
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Table 2.1. TFO sequences  
 
Sequence (5’ to 3’) Length 
TFO target sequence                              AAAGCACTGAATAGAAATAGTGATAGA                                            27 
 
TFO27 A*G*A*T*AGTGATAAAGATAAGTCAC*G*A*A*A 27 
SCR27 A*A*G*A*ATTAGAGCAGTAGTAACAG*A*A*T*A 27 
PO-TFO27 AGATAGTGATAAAGATAAGTCACGAAA 27 
6FAM-TFO27 6FAM - A*G*A*T*AGTGATAAAGATAAGTCAC*G*A*A*A 27 
Pso-TFO27-biot Psoralen (C6) - A*G*A*T*AGTGATAAAGATAAGTCAC*G*A*A*A – biotin (C2) 27 
Pso-SCR27-biot Psoralen (C6) - A*A*G*A*ATTAGAGCAGTAGTAACAG*A*A*T*A – biotin (C2) 27 
* indicates a phosphorothioate linkage. 
C6 indicates a 6 carbon linker to the 5’ phosphate moiety. 
C2 indicates a 2 carbon linker to the 3’ hydroxyl moiety. 
 
 
 
Table 2.2. D-loop forming oligonucleotides  
 
Sequence (5’ to 3’) Length 
   
Dloop27 T*C*T*A*TCACTATTTCTATTCAGTG*C*T*T*T 27 
AD3-HPRTPM A*C*A*G*TCATAGGAATGGATa*T*A*T*C 23 
Val-HPRTPM T*A*G*C*CCCCCTTGAaCAC*A*C*A*G 21 
Control  A*C*C*T*TGATGGCAAATAGGT*A*A*T*A 23 
* indicates a phosphorothioate linkage. 
Lowercase letters represent the site of the mismatched base  
 
 58 
 
2.1.4. Oligonucleotide third strand binding assay 
Third strand binding efficiency of TFO27 and SCR27 to the HPRT target motif enclosed 
within a synthetic duplex was measured using EMSA. Duplex DNA 35 base pairs (bp) in 
length was made by annealing HPRT-S-35 and HPRT-AS-35 (Table 2.3) in annealing 
buffer 1 (50mM sodium chloride) at 60°C for 30 mins followed by cooling at room 
temperature for 60 mins.  
Serial dilutions of TFO27 or SCR27 were incubated with a fixed concentration of 
duplex DNA (0.2µM) in either triplex binding buffer (10mM Tris, pH 7.2 and 10mM MgCl2) 
or triplex binding buffer supplemented with 2.5mM spermidine in a 20 microlitre (µL) 
reaction volume at room temperature for 3-4 h. The negative control in each experiment 
was duplex DNA without oligonucleotide. Samples (20μL) were mixed with 4μL of 6x gel 
loading buffer (0.25%w/v bromophenol blue and 40% w/v sucrose in water) then subject to 
electrophoresis through 15% polyacrylamide gel at 70-80V in triplex running buffer 
(17.8mM Tris pH 7.2, 17.8mM boric acid and 10mM MgCl2) on ice. Gels were stained with 
0.5µg/mL ethidium bromide for 25-30 mins followed by a 5 minute wash in demineralised 
water. Gels were visualised using the Kodak IS4000MM with an excitation/emission of 535 
nanometers (nm)/600nm. 
 
2.1.5. Detecting triplex formation at genomic DNA 
The ability of TFO27 to bind the triplex target sequence in genomic DNA (gDNA) within 
exon 3 of the HPRT locus was investigated in an approach adapted from Besch et al. 
(Besch et al., 2004) (Fig. 2.1). 
For this, TFO27 was conjugated to a psoralen moiety on the 5’ end via a 6 carbon 
linker and to a biotin moiety on the 3’ end via a 2 carbon linker (Pso-TFO27-biot; Table 
2.1). The control oligonucleotide, SCR27, was modified the same way (Pso-SCR27-biot; 
Table 2.1). 
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Two or sixteen micrograms of gDNA extracted from human lymphoblastoid TK6 
cells (described in section 2.2.3) was incubated with 20μM Pso-TFO27-biot or Pso-
SCR27-biot in triplex binding buffer (10mM Tris, pH 7.2 and 10mM MgCl2) in a 25μL 
volume (Fig.2.1, step A). Samples were allowed to incubate at room temperature for 3h. 
Following this, samples were irradiated with UVA (5J/cm2) to covalently crosslink the 
psoralen moiety to the 5’-AT-3’ sequence upstream of the HPRT triplex target sequence 
within exon 3 (Fig. 2.1, step A). 
Following covalent linkage of Pso-TFO27-biot to the gDNA, samples were digested 
overnight at 37°C with 10-15 units of Bgl II restriction enzyme in a 30μL volume. Bgl II 
digestion of gDNA yields a 3.4kb fragment of the HPRT locus containing the covalently 
bound Pso-TFO27-biot (Fig.2.1, step B).  
To remove unbound biotinylated oligonucleotide from the reaction mixture (Fig. 2.1, 
step C), samples were either purified through the Qiagen DNA extraction column (as 
described in section 2.2.3) or subject to electrophoresis through a 0.6%w/v agarose gel 
containing 0.5μg/mL ethidium bromide for 10-15 mins (agarose gel electrophoresis is 
described in section 2.5.4). Gels were visualised under UV and bands excised and purified 
using the Qiaquick gel extraction kit as described in section 2.5.6. 
Meanwhile, the desired concentration of BioMag® streptavidin coated paramagnetic 
beads (Qiagen, Crawley) were aliquoted into a 0.2mL nuclease free polymerase chain 
reaction (PCR) tube. Beads were pelleted using a magnet for 1 minute and the 
supernatant carefully discarded. Pelleted beads were resuspended in biotin binding buffer 
(20mM Tris, pH 7.8, 1M NaCl, 1mM ethylenediaminetetraacetic acid (EDTA), 0.02%v/v 
Triton X-100). To isolate the biotinylated 3.4kb HPRT fragment, the required concentration 
of streptavidin beads were mixed with 70μL of purified gDNA (containing the covalently 
linked Pso-TFO27-biot) in biotin binding buffer in a 100μL volume for 30 mins at room 
 60 
 
temperature (Fig. 2.1, step C). Samples were agitated every 8-10 mins to avoid beads 
sedimenting to the bottom of the reaction tube.  
Following incubation, beads were pelleted using a magnet for 1 minute and the 
supernatant discarded. Beads were gently washed three times in 50μL of DNase/RNase 
free water and suspended in a final volume of 20μL. Resuspended beads bound to the 
biotinylated oligonucleotide linked to a 3.4kb HPRT fragment were subject to PCR 
amplification of a 364 bp stretch downstream of the TFO27 triplex target sequence using 
primer pair 1 (Table 2.4) (Fig. 2.1, step D). PCR amplification is described in section 2.5. 
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Figure 2.1. Overview of the methodology used to detect triplex formation within genomic DNA. In 
brief, TFO27 conjugated on 5’ to psoralen and 3’ biotin was incubated with genomic DNA to allow 
triplex formation within the HPRT locus, then UVA irradiated to form psoralen crosslinks with DNA (A). 
Genomic DNA containing covalently linked TFO27 was digested overnight with Bgl II restriction 
enzyme (B). Samples were then purified using a column or by electrophoresis through a gel to remove 
free biotinylated TFO27 (C). Purified samples were then incubated with streptavidin coated 
paramagnetic beads to isolate genomic DNA covalently linked to Pso-TFO27-biot (C). Following 
several washes, samples were PCR amplified using primers specific to HPRT (D). 
  
Incubate and UVA 
Bgl II digestion 
Purification and 
Isolation 
 Magnet 
PCR 
A 
B 
C 
D 
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2.1.6. DNase I protection assay 
The ability of TFO27 to protect the triplex target sequence within a synthetic duplex was 
measured by means of a DNase I protection assay, as previously reported by (Washbrook 
& Fox, 1994) with slight modification.  
Duplex DNA, 50 bp in length, was made by annealing oligonucleotides HPRT-S-50 
and HPRT-AS-50 as described in section 2.1.4 (Table 2.3). Duplex DNA (5μM) was 
incubated overnight at 37°C with 2μM or 5μM TFO27 in triplex binding buffer (10mM Tris, 
pH 7.2 and 10mM MgCl2) supplemented with 2.5mM spermidine, in a final reaction volume 
of 20μL. Duplex DNA incubated without oligonucleotide and with 5μM SCR27 was used as 
a control.  
Complexes were digested using 5μL of 0.01units/mL DNase 1 for 15 mins at room 
temperature. Digestion was stopped by adding 10μL formamide containing 10mM EDTA. 
Products of digestion were mixed with 6x gel loading buffer and resolved on 10%w/v 
polyacrylamide (19:1) gels at 60V for 7 h in triplex running buffer (17.8mM Tris pH 7.2, 
17.8mM boric acid and 10mM MgCl2). Gels were stained with 0.5μg/mL ethidium bromide 
and visualised under UV using BioRad ChemiDoc XRS+ with Image Lab software. 
 
2.1.7. Quadruplex forming ability of SupFG1 
The quadruplex forming ability of the SupFG1 purine stretch previously described (Kalish 
et al., 2005, Datta et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Wang, Seidman & 
Glazer, 1996) was assessed using a 40bp duplex. Duplex DNA was made by annealing 
SupF-S and SupF-AS or SupF-S-4MM and SupF-AS-4MM (Table 2.3) as described in 
section 2.1.4. A fixed concentration of duplex DNA (0.2μM) was incubated with serial 
dilutions of targeting oligonucleotide (AG30 or AG30-4MM; Table 2.3) in quadruplex buffer 
(10mM Tris pH 7.2, 0.1mM MgCl2 and 140mM KCl) in a 20µL reaction volume for 3h at 
room temperature. Samples were then electrophoresed through 15% polyacrylamide gel at 
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70-80V in triplex running buffer (17.8mM Tris, pH 7.2, 17.8mM boric acid and 10mM 
MgCl2). Gels were stained with 0.5μg/mL ethidium bromide and visualised using a Kodak 
Imaging Station 4000MM with an excitation/emission of 535nm/600nm. Bands were 
quantitated by densitometry using Kodak Imaging software.  
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Table 2.3. Oligonucleotides used in gel retardation assays  
 
Sequence (5’ to 3’) Length 
   
AG30 AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG 30 
AG30-4MM AGGAAGGAGGAGGTGGTGGAGGAGGAGGAG    30 
   
HPRT-S-35 CATCAAAGCACTGAATAGAAATAGTGATAGATCCA 35 
HPRT-AS-35 TGGATCTATCACTATTTCTATTCAGTGCTTTGATG 35 
   
HPRT-S-50 CTGGATTACATCAAAGCACTGAATAGAAATAGTGATAGATCCATTCCTAT 50 
HPRT-AS-50 ATAGGAATGGATCTATCACTATTTCTATTCAGTGCTTTGATGTAATCCAG 50 
   
SupF-S GAGGGGGAGGGGGTGGTGGGGGGGGAAGGATTCGAACCTT    40 
SupF-AS AAGGTTCGAATCCTTCCCCCCCCACCACCCCCTCCCCCTC     40 
   
SupF-S-4MM GAGGAGGAGGAGGTGGTGGAGGAGGAAGGATTCGAACCTT    40 
SupF-AS-4MM AAGGTTCGAATCCTTCCTCCTCCACCACCTCCTCCTCCTC     40 
  Underlined sequence highlights the position of the replaced guanine nucleotide 
‘S’ means sense strand of duplex; ‘AS’ means antisense strand of duplex 
Bold sequence highlights the TFO27 triplex target sequence within exon 3 of the HPRT locus 
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Primer 
Pair 
 
Genomic 
or cDNA 
Target 
sequence 
      
         Sequence (5’―> 3’) 
Primer 
annealing 
Temperature 
(°C) 
PCR 
Polymerisati
on time 
(secs) 
Length of 
product (bp) 
1 Forward 
Reverse 
Genomic 
HPRT 
locus 
Intron 3 
 
CCTGTAGGTGATTGGGCAGCCA 
TGATGGGGATGGGGAAGGAGGC 
66 60 364 
2 
Forward 
Reverse 
Genomic 
HPRT 
locus  
exon 3 
 
CTGCTGGATTACATCAAAGCACTG 
TGAAAGCAAGTATGGTTTGCAGAGA 
64 30 177 
3 Forward 
Reverse 
Genomic 
HPRT 
locus 
exon 3 
 
AGGGCAAAGGATGTGTTACG 
AGTGGTTTCTGGTGCGACTT 
58 60 1018 
4 
Forward 
Reverse 
Genomic GAPDH* 
 
GTATTGGGCGCCTGGTCAC 
CTCCTGGAAGATGGTGATGG 
60 30 290 
5 
Forward 
Reverse 
CDNA TK 
 
TACTGCGGGACGGCCTTGGA 
GAGTGGCTGGGCAGCATGCA 
64 60 837 
         
* Primer sequences were taken from Donovan et al. (Donovan et al., 2000)
Table 2.4. Primer sequences used for PCR amplification.  
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2.1.8. Primer extension assay 
The ability of DNA polymerase to incorporate nucleotide analogues was investigated using 
a primer extension assay extrapolated from Lacenere et al. (Lacenere et al., 2006). 
Nucleotide analogues were obtained from Jena Bioscience, Germany. Unmodified 
nucleotides were obtained from Sigma Aldrich, Poole. 
Primed template was made by annealing template strand with the complementary 5’ 
6-carboxyfluorescein labelled primer strand (25nt) in annealing buffer 2 (75mM Tris, pH 
7.2 and 75mM NaCl). Oligonucleotide sequences are listed in Table 2.5. The mixture was 
heated to 95°C for 5 mins and allowed to cool for 1h at room temperature. A typical 
reaction mixture contained 25nM of the primed template, 4U Tfi DNA polymerase, 3.5mM 
MgCl2, 1x Tfi PCR buffer and nucleotide in a 20μL volume. As a negative control in 
experiments, nucleotide was omitted.  Reactions were allowed to incubate for the required 
length of time at 72°C to permit extension of the primed template. Following this, 5μL of 
1M EDTA was added to stop the reaction. Primed template in the reaction mixture was 
then denatured by adding 25μL of urea gel loading buffer (1.5M sucrose, 7M urea, 10mM 
EDTA, 0.1% bromophenol blue) and heated at 95°C for 5 mins with immediate transfer to 
ice slurry. Samples were then subject to electrophoresis through a 14% 8M urea-
polyacrylamide gel at 120V for 3h, unless stated otherwise. 6-carboxyfluorescein (6FAM) 
labelled primer strand was visualised at 490nm/530nm using the Kodak imaging station 
4000MM.  
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Table 2.5. Oligonucleotides used in primer extension assays  
 
Sequence (5’ to 3’) Length 
   
Primer strand 6FAM-TGTGTCTGGGCTTTTGGTTTGTGGG 25 
  
 
Template strands   
A1-template TCCCACAAACCAAAAGCCCAGACACA 26 
A5-template TTTTTCCCACAAACCAAAAGCCCAGACACA 30 
   
C5-template GGGGGCCCACAAACCAAAAGCCCAGACACA 30 
  
Underlined and bold sequence highlights the position of the overhang 
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2.2. General cell culture 
RPMI 1640, heat inactivated horse serum (HIHS), heat inactivated foetal bovine serum 
(HIFBS), L-glutamine and penicillin/streptomycin and RNase/DNase free water (sterile) 
were obtained from Invitrogen (Paisley, UK) while the remaining reagents were obtained 
from Sigma Aldrich (Poole, UK), unless otherwise stated. Tissue culture consumables 
were obtained from VWR (Leicestershire, UK). All cell culture procedures were carried out 
in a Class II biological safety cabinet. Cell lines were grown in a humidified incubator at 
37°C, 5% CO2.  
 
2.2.1. Human lymphoblastoid TK6 cells 
Human lymphoblastoid TK6 cells were obtained from ATCC (Teddington, UK). TK6 cells 
were cultured in RPMI 1640 media containing 10%v/v HIHS, 2mM L-Glutamine, 
100units/mL penicillin and 100µg/mL streptomycin, referred to as complete media 
(R10HIHS). Culture media without serum is referred to as incomplete media (R0).  
TK6 cells were resuscitated from a frozen vial containing 2-3x106 cells stored in the 
vapour phase of liquid nitrogen. In brief, vials of frozen cells were rapidly thawed in a pre-
warmed water bath (37°C). The cells were transferred to a 15mL centrifuge tube and 
centrifuged at 200xg for 5mins. The cell pellet was slowly resuspended drop-wise in pre-
warmed R10HIHS media and transferred to a 75cm
2 flask followed by further drop-wise 
addition of pre-warmed R10HIHS media up to a final volume of 10mL and incubated as 
described above.  
TK6 cells were maintained in exponential growth by passaging populations between 
5x104/mL and 1x106/mL. In brief, cultures were gently shaken to ensure single cell 
suspensions. Accurate quantification of viable cells was carried out using the trypan blue 
exclusion assay. An 80μL aliquot of the single cell suspension was mixed with 20μL of 
trypan blue solution (0.4%w/v) with incubation at room temperature for 1-2 mins to allow 
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uptake/exclusion of the dye. An aliquot (10μL) was transferred to a Neubauer 
haemocytometer by capillary action. Viable cells were scored as those which excluded the 
blue dye and appear clear, as opposed to non-viable cells appearing blue.  The cell 
concentration per millilitre was determined as follows:  
 
The average count from 4 grids x (1/10-4; volume of grid cm3) x dilution factor. 
 
The Beckman Coulter counter Z2 series (Beckman Coulter UK ltd) was used for 
rapid quantification of cell populations during high throughput experiments. The lower and 
upper size for TK6 cells were found to be optimum between 7.45 micrometers (μm) and 
18.62μm (cell counts were in consensus with the trypan blue exclusion assay using the 
haemocytometer). In the first instance, Isoton II diluent (excluding cells) was counted to 
ensure the background count was below 150. As described above, cultures were briefly 
shaken to ensure single cell suspensions as multiple cell clumps are not differentiated by 
the coulter counter. A 0.5mL aliquot of single cell suspension was added to 9.5mL Isoton II 
diluent, shaken and counted. The concentration of cell suspensions were adjusted to 
maintain exponential growth, as described above.  
Human TK6 cells were grown for up to 7 days to accumulate sufficient cells to store 
aliquots with the same passage number as working stocks for subsequent mutation 
assays. This was to reduce variability between experiments. For cryopreservation, 1mL of 
2-3x106 TK6 cells in R10HIHS media containing 10%v/v dimethylsulphoxide (DMSO) were 
transferred to 1.5mL cryovials and stored in a container overnight at -80°C before being 
transferred to liquid nitrogen. Cells were thawed as described above for subsequent 
experiments. 
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2.2.2. Human colon epithelial HCT116 cells 
Human colon epithelial cells were obtained from ATCC. HCT116 cells were cultured in 
RPMI 1640 media containing 10% HIFBS, 2mM L-Glutamine, 100units/mL penicillin and 
100µg/mL streptomycin, referred to as complete media (R10HIFBS). Culture media without 
serum is referred to as incomplete media (R0).  
HCT116 cells were resuscitated as described in section 2.2.1. Confluent flasks 
were passaged by aspirating the media and washing cells with 5mL phosphate buffered 
saline (PBS). In order to detach cells, 3-4mL of Trypsin-EDTA (1x; 0.05%) was added per 
75cm2 flask for 3-5 mins at 37°C. Flasks were examined by light microscope to ensure all 
cells had become detached. Trypsin was inactivated by adding an equal volume of 
R10HIFBS. Detached cells were transferred to 15mL centrifuge tubes and centrifuged at 
200xg for 5 mins. Cell pellets were then suspended in R10HIFBS and counted using the 
haemocytometer as described in section 2.2.1. and maintained in exponential growth by 
seeding at least 0.5x106-1x106 cells per 75cm2 flask with regular passaging every 2-3 
days. 
 
2.2.3. Genomic DNA extraction from cultured cells  
gDNA was extracted from cultured cells using the QIAamp DNA Blood mini kit (Qiagen, 
Crawley) according to manufacturer’s instructions. Lysis buffer AL, wash buffers AW1 and 
AW2, proteinase K solution and elution buffer AE were provided in the manufacturer’s kit. 
In brief, up to 5x106 TK6 cells were centrifuged at 200xg for 5 mins. The pellet was 
suspended in 200μL PBS and transferred to a 1.5mL eppendorf tube. Qiagen proteinase K 
(20μL) was added along with 200μL lysis buffer AL. The samples were then mixed by 
pulse vortexing and incubated at 56°C for 10 mins. Samples were briefly centrifuged and 
200μL ethanol (>99.6%) added with gentle inverting to precipitate gDNA. The mixture was 
applied to a spin column in a collection tube (provided with the manufacturer’s kit) and 
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centrifuged at 6,000xg for 1 min. The spin column was placed in a fresh collection tube 
and the filtrate discarded. gDNA in the spin column was washed with 500μL ethanol wash 
buffer AW1 and centrifuged at 6,000xg for 1 min. The spin column was placed in a fresh 
collection tube and the filtrate discarded. Five hundred microliters (500µL) ethanol wash 
buffer AW2 was added to the spin column and centrifuged at 20,000xg for 3 mins. The 
spin column was placed into a fresh RNase/DNase free eppendorf tube and the filtrate 
discarded. The spin column was centrifuged once more at 20,000xg for 1 minute to 
remove traces of ethanol. DNA was eluted out of the spin column by addition of 50-200μL 
buffer AE and incubation for 5 mins at room temperature followed by centrifugation at 
6,000xg for 1 minute. DNA was quantified using the NanoDrop ND1000 
spectrophotometer (Labtech, Sussex). Samples with 260nm/280nm ratios above 1.8 were 
used in subsequent experiments and stored at -20°C. 
  
2.2.4. RNA extraction  
Cellular RNA was extracted using the SV total RNA Isolation System (Promega, 
Southampton) according to manufacturer’s protocol. RNA lysis buffer, RNA dilution buffer, 
RNA wash solution, DNase I and DNase stop solution were provided with the 
manufacturer’s kit. 
In brief, cells were pelleted at 200xg for 5 mins and washed in cold PBS. Cell 
pellets were suspended in 175μL RNA lysis buffer and transferred to a 1.5mL eppendorf 
tube with the subsequent addition of 350μL RNA dilution buffer. Extracts were inverted 
several times and heated at 70°C for 3 mins. Samples were centrifuged at 12,000xg for 10 
mins and the supernatant collected. Ethanol (200µL, >99.6%) was added to the 
supernatant and inverted several times. Samples were then transferred to a spin column 
with a collection tube (provided with the manufacturer’s kit) and centrifuged at 12,000xg for 
1 min. Columns were washed with 600μL ethanol based RNA wash solution and again 
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centrifuged. DNase (50μL) was added to each column for 15 mins at room temperature 
followed by the addition of 200μL DNase stop solution. Columns were then centrifuged at 
12,000xg for 1 minute. Columns were washed twice with RNA wash solution. The spin 
column was placed in a fresh eppendorf tube and RNA eluted by the addition of RNase 
free water followed by centrifugation at 14,000xg for 1 minute. Samples were then stored 
at -70°C until the time of analysis. RNA samples were quantified as described in Section 
2.2.3. 
 
2.2.5. Protein extraction and quantification 
Total cell protein content was extracted as described previously (Sambrook, 2001). In 
brief, cell pellets were suspended in 100μL freshly made master lysis buffer (1μL Halt 
protease inhibitor + 99μL lysis buffer [150mM NaCl, 0.1%v/v igepal, 1mM Tris, pH 7.4 and 
1mM EDTA]) on ice for 20 mins. Samples were then centrifuged at 10,000xg for 10 mins at 
4°C. Supernatants were collected in fresh eppendorf tubes and stored at -20°C. 
Total protein was determined using the bicinchoninic acid (BCA) assay (Thermo 
Scientific, Surrey UK), according to manufacturer’s protocol. In brief, protein extracts were 
diluted 10 or 20 fold and 10μL transferred to a single well of a 96 well plate. Additionally, 
known concentrations of bovine serum albumin were used to produce a standard curve. 
Samples were overlaid with 200μL of BCA working reagent (made by mixing 50 parts of 
reagent A with 1 part reagent B provided with the manufacturer’s kit) and shaken gently for 
30 seconds. Plates were then incubated for 30 mins at 37°C and allowed to cool to room 
temperature. The absorbance at 562nm was measured and protein concentration in 
extracts was determined from the standard curve. 
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2.3. Cell treatments  
2.3.1. MSH2 protein knockdown in TK6 cells using Silencer Select siRNA 
Where MSH2 protein knockdown was required, exponentially growing TK6 cells were 
treated for 24h with Silencer Select siRNA (Applied Biosystems, UK) using siPORT NeoFX 
transfection reagent (Applied Biosystems, UK). The following day, TK6 cells were treated 
with oligonucleotide (section 2.3.4).  
As the manufacturer’s protocol is designed for low volume transfection ie 2.5mL, 
transfection was scaled to treat 8x106 TK6 cells in a 50mL volume to provide sufficient 
cells for subsequent mutagenicity studies. To treat 8x106 TK6 cells in a 50mL volume with 
10nM MSH2 siRNA, 500μL 1μM Silencer Select siRNA was diluted up to 4mL with R0 
media. The siRNA dilution was mixed with 4mL of diluted siPORT (210μL of siPORT 
NeoFX diluted up to 4.2mL with R0) in a flask and allowed to stand for 10 mins. The 
siRNA/siPORT transfection complexes were overlaid with 8x106 TK6 cells in a 42mL 
volume and allowed to incubate for 24h at 37°C, 5%CO2. As a negative control, the 
siRNA/siPORT mixture was replaced with R0 culture media  
 Following siRNA transfection, TK6 cells were harvested by centrifugation and 
suspension in R10HIHS media. siRNA treated TK6 cells were counted using the coulter 
counter (section 2.2.1) and diluted for oligonucleotide treatment (section 2.3.4).  
 To confirm Silencer Select siRNA mediated knockdown of MSH2 protein 
expression, 5x106 TK6 cells were removed and washed in ice cold PBS for immunoblot 
analysis at 24h, 48h and 72h after treatment, unless stated otherwise. Protein extraction 
was performed as described in section 2.2.5. Protein expression was determined by 
immunoblot analysis as described in section 2.6.  
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2.3.2. Induction of RAD51 protein expression in TK6 cells 
Exponentially growing TK6 cells were treated with methyl methanesulphonate (MMS) for 
24h to induce RAD51 protein expression. In a 50mL volume, 8x106 TK6 cells were treated 
for 24h with 0μg/mL, 0.1μg/mL, 0.2μg/mL or 0.5μg/mL MMS (0.1%v/v DMSO solvent). 
Following treatment, TK6 cells were washed in R10HIHS media and maintained in 
exponential growth for up to 72h. Aliquots of treated TK6 cells (5mL) were removed at 2h, 
4h, 8h, 24h, 48h and 72h and then washed in 1mL PBS and pellets stored at -20°C for 
protein extraction (section 2.2.5). RAD51 protein expression was determined by 
immunoblot analysis as described in section 2.6.  
 The concentration of MMS found to significantly induce RAD51 protein expression 
was used to pre-treat TK6 cells for 24h the day before oligonucleotide treatment (section 
2.3.4).  
 
2.3.3 Oligonucleotide transfection efficiency using siPORT NeoFX and NTER in TK6 
cells 
siPORT NeoFX (Applied Biosystems, UK) and NTER (Sigma Aldrich, UK)  transfection 
facilitators were evaluated for transfection efficiency in human TK6 cells using 6-
carboxyfluorescein labelled TFO27 (6FAM-TFO27; see Table 2.1). The ratio of 
transfection facilitator (μL) to oligonucleotide (μg) was explored for optimal delivery of 1μM 
and 2μM 6FAM-TFO27. The ratios of oligonucleotide (μg): transfection facilitator (μL) 
examined were 2:1, 1:1, 1:2 and 1:4.  
For siPORT NeoFX, the respective volume of transfection reagent was diluted in R0 
media up to a volume of 10μL, in triplicate wells of a 96-well plate and allowed to stand for 
10 mins. Following this, 6FAM-TFO27 was diluted in serum free media and 10μL added to 
the siPORT mixture in each respective well and allowed to incubate for 10 mins to allow 
complex formation.  
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For NTER, the respective volume of transfection reagent followed by 6FAM-TFO27 
was diluted in serum free media up to a volume of 20μL, in triplicate wells of a 96-well 
plate. Complex formation was allowed to occur by incubation at room temperature for 20 
mins.  
Meanwhile, TK6 cells were counted using the coulter counter (section 2.2.1) and 
adjusted to 1.9x106 cells/mL in R10HIHS media. An 80μL aliquot of cells was added to each 
well in the 96-well plate and transfection was carried out at 37°C for 4 h.  
As a blank for each concentration of oligonucleotide, a mock transfection was 
carried out in parallel as described above, except the oligonucleotide was replaced with 
water. 
Following transfection, TK6 cells were pelleted at 200xg for 5 mins, washed in PBS 
twice and re-suspended in 100μL PBS. Fluorescence was quantified using the Polarstar 
Galaxy (BMG labtech, UK) with excitation/emission around 490nm/520nm. Following 
measurement, TK6 cells in each well were counted using the trypan blue exclusion assay 
on the haemocytometer (section 2.2.1) to normalise arbitrary fluorescence units per viable 
104 cells. 
 
2.3.4. Treatment of TK6 cells with oligonucleotide 
Oligonucleotides do not require metabolic activation like meat derived carcinogens and so 
cell treatments were conducted in the absence of a metabolic activation system (Yu et al., 
2009, Boobis et al., 1994). 
In the first instance, oligonucleotides were thawed at room temperature while the 
siPORT NeoFX was allowed to equilibrate to room temperature. The optimal volume of 
siPORT required for transfection of oligonucleotide was determined previously (section 
2.3.3). A 2:1, DNA (μg): siPORT (μL) ratio was employed for large scale oligonucleotide 
transfection.  
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Exponentially growing TK6 cells (or pre-treated TK6 cells with MSH2 siRNA section 
2.3.1 or MMS section 2.3.2) were counted using the coulter counter (section 2.2.1). TK6 
cells were aliquoted to 50mL centrifuge tubes and centrifuged at 200xg for 5 mins. The 
supernatant from cell pellets was collected. Cells were then suspended at a density of 
1.9x106/mL in conditioned R3.125 media (made by diluting the cultured R10HIHS 
supernatant from the cell pellets with R0). Three million cells (1.6mL) from the cell 
suspension were aliquoted to 15mL centrifuge tubes per culture. To treat 10x106 cells, 
5.6mL of cells were aliquoted per tube. 
Meanwhile, the siPORT NeoFX was diluted in R0 media and mixed with 
oligonucleotide to allow complex formation. For example, to transfect 3x106 cells with 5μM 
oligonucleotide per culture, 108μL of siPORT was mixed with 542μL of R0 media and 
allowed to stand for 10 mins. Oligonucleotide (158μL) was diluted with 472μL of R0 media 
and overlaid with 630μL of the siPORT mixture. The oligonucleotide/siPORT mixture was 
allowed to incubate at room temperature for 10 mins to allow complex formation. Following 
this, 0.4mL of the oligonucleotide/siPORT mixture was added to 1.6mL of cells (3x106) or 
scaled further such that 1.4mL of oligonucleotide/siPORT mixture was added to 5.6mL of 
cells to treat 10x106.  
To measure the spontaneous mutant frequency at the HPRT and TK (gene ID 
7083) loci, TK6 cells were treated as above, except the oligonucleotide/siPORT NeoFX 
mixture was replaced with R0 media. As a positive control, 5µg/mL EMS or 1µM 4-
nitroquinoline-1-oxide (4NQO) were used (0.1%v/v DMSO solvent). 
Transfection was allowed to occur for 4h at 37°C, 5%CO2. Following this, cells were 
pelleted at 200xg for 5 mins and washed with 5mL of R10HIHS media. Cell pellets were 
then suspended up to 10mL and transferred to a 75cm2 flask. Flasks were allowed to 
incubate overnight at 37°C, 5%CO2.  
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TK6 cells were counted using the coulter counter (section 2.2.1) and adjusted to 
3x105/mL in a minimum volume of 10mL R10HIHS. Treated cultures with cell counts below 
3x105/mL were not adjusted. Cells were counted daily up to Day 3 to determine the 
relative suspension growth (RSG) and plated to determine the TK mutant frequency as 
described in section 2.4.1. RSG is a measure of cell death and proliferative ability of cells 
following treatment and calculated as previously described (Clements, 2000, Clive et al., 
1995). Cells were also maintained in exponential growth up to Day 7 to determine the 
HPRT mutant frequency as described in section 2.4.2.  
 
2.3.5. Treatment of TK6 cells with nucleosides and nucleotides 
Exponentially growing TK6 cells were counted using the coulter counter (section 2.2.1). 
TK6 cells were aliquoted to 50mL centrifuge tubes and centrifuged at 200xg for 5 mins. 
The supernatant from cell pellets was collected. Cells were then suspended at a density of 
8x105/mL in conditioned R10 media (made by using the cultured R10HIHS supernatant from 
the cell pellets). Four million cells (5mL) from the cell suspension were aliquoted into 
75cm2 flasks per culture.  
Nucleotides and nucleosides were supplied in a lyophilised state and stored as 
recommended by the manufacturer (Jena Bioscience, Germany). On the day of use, a 
weighed amount of nucleotide was dissolved in R0 media up to a 2mM solution. From this, 
serial dilutions were made using R0 media so nucleotides were as 2x solutions. A 5mL 
aliquot of test compound was used to supplement 5mL of cells (4x106) in R10 media into 
flasks. This gave a final treatment volume of 10mL in conditioned R5 media (equal parts of 
R0 and R10 media). As the negative control, 5mL of R0 media replaced nucleotides. As a 
positive control, 5μg/mL EMS was used. Cells were exposed to test compounds for 24 h. 
Following treatment, cells were pelleted at 200xg for 5 mins and washed with 5mL 
of R10HIHS media. Cell pellets were then suspended in 10mL of R10HIHS media and 
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counted using the coulter counter (section 2.2.1). Cells were adjusted to 3x105/mL in a 
minimum volume of 12mL R10HIHS. Treated cultures with cell counts below 3x10
5/mL were 
not adjusted. 
Cells were counted daily up to Day 3 to determine the RSG (described in section 
2.3.4) and plated to determine the TK mutant frequency as described in section 2.4.1. 
Cells were also maintained in exponential growth up to Day 7 to determine the HPRT 
mutant frequency as described in section 2.4.2. 
 
2.4. HPRT and TK forward mutation assays 
The HPRT and TK forward mutation assays were conducted as recommended by the 
OECD guideline 476 (http://www.oecd.org/dataoecd/18/32/1948426.pdf).   
 
2.4.1. Determining the TK mutant frequency (Day 3) 
TK6 cells were counted using the coulter counter (section 2.2.1) and adjusted to 1x105/mL 
in a minimum volume of 30mL of R10HIHS for a further 4 days phenotypic expression of 
HPRT mutants. 
To determine the TK mutant frequency, remaining TK6 cells were adjusted to 
1x105/mL in 65mL of R20HIHS media. From this, a 100μL aliquot of cells (1x10
5/mL) was 
removed and diluted up to 10mL in R10HIHS media (1000cells/mL). From this, a 360μL 
aliquot was removed and added to 45mL R20HIHS media (8cells/mL). To determine cloning 
efficiency following treatment and plating efficiency during mutant selection, 200μL of this 
cell suspension was plated in each well of two 96 well plates (1.6cells/well). This cloning 
efficiency was used to correct the RSG to give the relative total growth (RTG) as a 
measure of cytotoxicity following treatment (Clements, 2000, Clive et al., 1995). 
For TK mutant selection, cells adjusted to 1x105/mL in 65mL were supplemented 
with 0.65mL trifluorothymidine (TFT, 400µg/mL) in subdued light.  From this, a 200μL 
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aliquot of cells was plated in each well of three 96 well plates (20,000 cells/ well). Plates 
were incubated at 37°C, 5%CO2 for a minimum of 14 days to allow colony formation and 
empty wells scored using a light box. The mutant frequency was calculated as previously 
described (Clements, 2000, Clive et al., 1995). The proportion of small and large TK 
mutant colonies were also noted for each treatment. A small TK mutant clone is defined as 
one which has a diameter less than ¼ of the well width in the microtitre plate (Clements, 
2000). An increase in small TK mutant colonies may suggest large inter-gene deletions or 
chromosome aberrations involving the TK gene in these clones which may affect the rate 
of growth due to the extent of genomic insult or perhaps a result of mutation within an 
adjacent growth regulatory gene (Liechty et al., 1998, Applegate et al., 1990, Moore et al., 
1985, Hozier et al., 1981). 
Clones selected for molecular analysis were picked for expansion in a well of a 6-
well plate. Individual clones were grown for 7-10 days in R10HIHS culture media. Following 
expansion, clones were isolated, centrifuged and pellets stored at -20°C for gDNA 
extraction (section 2.2.3).  
 
2.4.2. Determining the HPRT mutant frequency (Day 7) 
TK6 cells were maintained in exponential growth from Day 3 until Day 7 by routine 
culturing. To determine the HPRT mutant frequency, TK6 cells were counted using the 
coulter counter (section 2.2.1) and adjusted to 1x105/mL in 65mL of R20HIHS media. From 
this, a 100μL aliquot of cells (1x105/mL) was removed and diluted up to 10mL in R10HIHS 
media (1000 cells/mL). From this, a 360μL aliquot was then removed and added to 45mL 
R20HIHS media (8 cells/mL). To determine the plating efficiency during mutant selection, 
200μL of this cell suspension was plated in each well of two 96 well plates (1.6 cells/well). 
For HPRT mutant selection, cells adjusted to 1x105/mL in 65mL were supplemented with 
0.65mL of 500µg/mL 6-thioguanine (6-TG).  From this, 200μL of cells were plated in each 
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well of three 96 well plates (20,000 cells/well). Plates were incubated at 37°C, 5%CO2 for 
a minimum of 14 days to allow colony formation and empty wells scored using a light box 
in aseptic conditions. The mutant frequency was calculated as previously described 
(Clements, 2000, Clive et al., 1995). Clones selected for molecular analysis were picked 
for expansion in a well of a 6-well plate. Individual clones were grown for 7-10 days in 
R10HIHS culture media. Following expansion, clones were isolated, centrifuged and pellets 
stored at -20°C for gDNA extraction (section 2.2.3). 
 
2.4.3. The in vitro micronucleus assay 
The in vitro micronucleus assay was conducted as recommended by the OECD guideline 
487 (http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/OECD-TG487.pdf). 
Following two population doublings of treated TK6 cells, 2x105 cells were removed, 
centrifuged at 200xg for 5 mins and suspended in 2mL of R02P (R0 media containing 
0.2%v/v pluronic F-68). Cells were mixed thoroughly then 200μL were cytospun on to clean 
microscope slides at 200xg for 5 mins. Two microscope slides were used per culture. 
Slides were allowed to air dry for 20 mins, then fixed in 100% methanol for 1 minute. 
Slides were washed in PBS for 1 minute and then stained in acridine orange (0.12mg/mL) 
for 1 minute. Stained slides were washed in PBS for 10 mins then again in fresh PBS for 
15 mins. Slides were visualised using the Leitz Diaplan fluorescence microscope. One 
thousand viable mononucleate cells were scored per slide whilst scoring the incidence of 
micronucleated mononucleate cells, binucleate cells and micronucleated binucleate cells. 
Cytotoxicity and proliferative ability of cells following treatment was informed by the relative 
population doubling as described in OECD guideline 487 (http://iccvam.niehs.nih.gov/ 
SuppDocs /FedDocs/OECD/OECD-TG487.pdf). 
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2.4.4. Treatment of HCT116 cells with oligonucleotide 
HCT116 cells were detached from flasks and counted using a haemocytometer (sections 
2.2.1 and 2.2.2). Cells were adjusted to 1.9x106/mL and transfected as described in 
section 2.3.4 but in 25cm2 flasks. Transfection was allowed to occur for 6 h. Following this, 
the transfection media was collected and replaced with 2mL of fresh R10HIFBS. The 
transfection media was centrifuged at 200xg for 5 mins to pellet any unattached cells. Cell 
pellets were suspended in 2mL of R10HIFBS media and replaced back into the respective 
flask for incubation overnight. 
 
2.4.5. Cytotoxicity following treatment of HCT116 cells 
Following overnight incubation of treated HCT116 cells, cells were washed with PBS, and 
detached using trypsin for counting using a haemocytometer (sections 2.2.1and 2.2.2). 
The volume for 10,000 viable cells was added to 10mL of R10HIFBS media (1000 cells/mL). 
From this, 450μL was added to 22mL of R10HIFBS media (20 cells/mL). Three millilitres of 
this cell suspension was plated per well in an entire 6 well plate (60 cells/well) to determine 
cloning efficiency. Plates were incubated for 10 days to allow colony formation and scored 
using a light box. The remaining treated cells were maintained in exponential growth for a 
further 6 days to allow phenotypic expression of HPRT mutants.  
 
 2.4.6. Determining the HPRT mutant frequency following treatment of HCT116 cells 
HCT116 cells were washed with PBS, detached using trypsin and counted using a 
haemocytometer (section 2.2.1). The volume for 1.32x106 viable cells was added up to 
99mL of R10HIFBS media. From this, 18μL was added to 12mL of R10HIFBS media                   
(20 cells/mL). Three millilitres of this cell suspension was plated per well, in 3 wells of a 6 
well plate (60cells per well) to determine plating efficiency. HPRT mutants were screened 
by adding 0.99mL of 500µg/mL 6-TG to cells diluted in 99mL media. From this, 3mL of 
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cells were plated per well in five 6 well plates (40,000 cells/well). Plates were incubated for 
10 days to allow colony formation and scored using a light box under aseptic conditions. 
(Mutant frequency (x10-6) was calculated as the total number of 6-TG resistant clones 
divided by the total number of cells plated multiplied by 106 and corrected for plating 
efficiency). 
 
2.5. Polymerase Chain Reaction (PCR) 
2.5.1. First strand cDNA synthesis from RNA extracts 
First strand complementary DNA (cDNA) was synthesised from RNA extracts using the 
superscript VILO cDNA synthesis kit (Invitrogen, Paisley) according to manufacturer’s 
protocol. In brief, each cDNA synthesis reaction contained 2μL of superscript enzyme mix, 
RNA (<2.5μg) and 4μL of 5x VILO mix composed of random hexamer primers, MgCl2 and 
dNTP in a total reaction volume of 20μL. Reactions were performed using a Peltier thermal 
cycler (PTC-200, MJ Research) with a heated lid to prevent sample evaporation; 
conditions for cDNA synthesis were as follows: 10mins at room temperature, 60 mins at 
42°C and termination at 85°C for 5 mins. cDNA samples were then stored at -20°C until 
analysis. As a negative control, RNA was omitted in a reverse transcription reaction and 
replaced with water to evaluate the possibility of RNA introduction during experimentation. 
Additionally, to eliminate the possibility of genomic DNA amplification in ensuing 
experiments, superscript enzyme was omitted from a cDNA synthesis reaction containing 
RNA. 
 
2.5.2. PCR primer design 
Unless otherwise stated, primer sequences were designed using NCBI-primer BLAST 
design tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC= 
BlastHome). Primers were selected to be approximately 20-25 nucleotides in length. The 
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melting temperature (TM) of primers was calculated using the following formula: 4(G+C) + 
2(A+T). The difference in annealing temperature (TA) between primer pairs was no greater 
than 4°C. The primers designed using NCBI-primer BLAST were subject to further analysis 
using Integrated DNA Technologies oligonucleotide analyser 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/). Primer sequences were 
assessed for the capability to form intramolecular hairpins, self-dimers and hetero-dimers. 
Those which failed to do so were used in subsequent PCR reactions. PCR primers were 
synthesised by Invitrogen (Paisley, UK). The primer sequences used for PCR amplification 
are listed in Table 2.4.  
 
2.5.3. PCR amplification of genomic DNA and cDNA 
All PCR reagents were obtained from Invitrogen (Paisley, UK). PCR was performed using 
a Peltier thermal cycler (PTC-200, MJ Research) using a heated lid. In a final reaction 
volume of 50μL, a typical reaction mixture contained at least 300ng of gDNA or 1-2µL of 
cDNA, 200nM of each forward and reverse primer (Table 2.4), 200μM dNTPs, 5 units of Tfi 
polymerase and 1x Tfi PCR buffer supplemented with 2mM MgCl2.  
Unless otherwise stated, standard PCR amplification conditions were as follows: 
initial denaturation step at 94°C for 4 mins, followed by 30 cycles of denaturing at 94°C for 
30 secs, primer annealing at 64°C for 25secs and polymerisation at 72°C for 30secs. The 
final polymerisation step was extended to 7 mins and samples stored at 4°C until analysis. 
PCR conditions for each primer pair can be found in Table 2.4. 
 
2.5.4. Agarose gel electrophoresis 
All PCR products were resolved using agarose gel electrophoresis. Aliquots of PCR 
products (20μL) were mixed with 4μL of 6x gel loading buffer (0.25%w/v bromophenol blue 
and 40% w/v sucrose) and typically electrophoresed through a 1.2%w/v agarose gel 
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containing 0.5μg/mL ethidium bromide. Electrophoresis was carried out for 60-90 mins at 
100V in 1x TBE buffer (89 mM Tris, pH 8.3, 89mM boric acid and 2 mM EDTA). Gels were 
visualised under UV using BioRad ChemiDoc XRS+ with Image Lab software.  
 
2.5.5. Restriction enzyme digestion of PCR products  
PCR products from HPRT amplification (primer pairs 2 and 3; Table 2.4) were subject to 
Mbo I restriction enzyme digestion to inform the integrity of the 5’-GATC-3’ restriction 
enzyme recognition sequence. A wild-type 5’-GATC-3’ sequence results in cleavage of 
PCR product into two fragments; 137 and 40bp for 177bp PCR product (primer pair 2) or 
474bp and 544bp for 1018bp PCR product (primer pair 3). Mutation within the 5’-GATC-3’ 
sequence results in resistance to Mbo I digestion. Typically, 5-15μL of PCR product were 
restriction enzyme digested with 1 unit of Mbo I for 1h-2h at 37°C. A typical reaction 
mixture contained PCR product, 1x enzyme reaction buffer K and 1 unit of Mbo I enzyme 
in a 20μL volume. Digested PCR products were resolved on 1.2%w/v agarose gels and 
visualised as described in section 2.5.4.  
 
2.5.6. PCR product purification and DNA sequencing 
PCR products were extracted from agarose gels and purified using the QIAquick gel 
extraction kit (Qiagen, Crawley) according to manufacturer’s protocol. Gel solubilisation 
buffer QG, wash buffer PE and elution buffer EB were included in the manufacturer’s kit. In 
brief, the DNA fragment(s) were excised from the agarose gel and weighed. Up to 400mg 
of the gel fragment containing the PCR product was placed in a DNase/RNase free 
eppendorf tube overlaid with three volumes of gel solubilisation buffer QG i.e. 1.2mL of 
buffer QG per 0.4g gel piece. The samples were incubated at 50°C for at least 10 mins 
with occasional mixing until the agarose gel slice had dissolved. For optimal recovery, one 
gel volume of isopropanol was added to the dissolved gel slice and mixed. The solution 
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was then added to the extraction column within a wash tube and centrifuged at 18,000xg 
for 1 minute. The filtrate was discarded and 500μL of gel solubilisation buffer QG added to 
the column and centrifuged at 18,000xg for 1 minute. The flow through was discarded and 
0.75mL of wash buffer PE added to the column and incubated for 5 mins at room 
temperature. The column was centrifuged at 18,000xg for 1 minute and the filtrate 
discarded. The spin column was placed in a fresh wash tube and centrifuged again at 
18,000xg for 1 minute to remove residual PE wash buffer. The spin column was then 
transferred to a clean eppendorf tube (DNase/RNase free) with the addition of 20-50μL of 
elution buffer EB. Columns were incubated for 1 minute at room temperature and 
centrifuged at 18,000xg for 1 minute. Eluant containing the purified PCR product was 
stored at -20°C until the time of analysis. 
For DNA sequencing, purified PCR products were quantitated using a quantitative 
agarose gel (section 2.5.4). An aliquot of purified PCR product (5μL) was mixed with 1μL 
of 6x gel loading buffer and electrophoresed simultaneously with a quantitative DNA ladder 
(Fisher Scientific, Leicester) through a 1.2%w/v agarose gel in 1x TBE. Samples were 
diluted to 10ng/μL in a 10μL volume to be sent for sequencing. In separate PCR tubes, 
each primer used for PCR amplification was diluted to 3.2μM in a 10μL volume per sample 
to be sequenced. Diluted DNA and primers were sent for DNA sequencing by Source 
Bioscience ltd (University College London, UK).   
DNA sequence data was visualised using the Applied Biosystems Sequence 
Scanner version 1.0 (Applied Biosystems, UK). Sequence data was compared to the wild-
type sequence using the European Bioinformatics Institute (EBI) ClustalW2 multiple 
sequence alignment tool. Individual sequences were manually screened to confirm 
mutation using NCBI-BLAST. 
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2.6. Immunoblot 
All antibodies were obtained from Abcam (Cambridge, UK), unless specified otherwise. 
Chemiluminescent ladder was obtained from Cell Signalling Technology (Hertfordshire, 
UK). Tracking ladder was obtained from Invitrogen (Paisley, UK). 
Protein from cell pellets was extracted and quantitated as described in section 
2.2.5. Protein expression was assessed using a denaturing immunoblot. 
 
2.6.1. Preparation and electrophoresis of samples 
Typically, between 20-40μg of protein were loaded per well depending on the protein 
under investigation. For example, protein extracts (10μL) were diluted with water (up to 
16μL) and mixed with 4μL (5x) sodium dodecyl sulphate (SDS) loading buffer (66mM Tris 
pH6.8, 26%w/v glycerol, 2.1%w/v SDS, 0.01%w/v bromophenol blue and 5%v/v β-
mercaptoethanol (only added on the day of use)). Samples were then heated at 95°C for 5 
mins to denature native protein. Meanwhile, 3μL of chemiluminescent ladder was heated 
to 95°C for 2 mins. Following heating, samples were briefly centrifuged and loaded on to a 
reducing SDS polyacrylamide gel. To ensure resolution of the intended protein, a pre-
stained protein tracking ladder was used.  
Gels were cast such that 1/3 of the top of the gel was a 5%w/v stacking gel (5%w/v 
acrylamide, clean water, 0.07%w/v ammonium persulphate (made fresh) and 1x SDS 
stacking gel buffer composed of 0.125M Tris pH6.8 and 0.1%w/v SDS) whilst the lower 2/3 
of the gel was a 10%w/v resolving gel (10%w/v acrylamide, water, 0.07%w/v ammonium 
persulphate (made fresh) and 1x SDS resolving gel buffer composed of 0.6M Tris pH8.8 
and 0.16%w/v SDS). 
Samples were electrophoresed at 60V for ~30 mins in 1x SDS running buffer 
(2.5mM Tris pH8.3, 25mM glycine, 0.01%w/v SDS) through the stacking gel and then 100V 
through the resolving gel. Typical length of electrophoresis ranged from 90-120mins.  
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2.6.2. Transfer of protein  
Protein within SDS polyacrylamide gel was transferred to a polyvinylidine fluoride (PVDF) 
membrane for immunoblotting as follows. To make the transfer sandwich, two sponges 
were soaked in freshly prepared 1x transfer buffer (25mM Tris, 186mM glycine and 20% 
methanol). Two filter cards (cut to the size of the PVDF membrane) were overlaid on to a 
sponge followed by the SDS polyacrylamide gel. The PVDF membrane was briefly soaked 
in water then placed over the gel in the 1x transfer buffer taking care not to introduce 
bubbles. A further two filter cards were placed on top of the PVDF membrane followed by 
a pre-soaked sponge. The transfer sandwich was in the following order: 
 
Sponge - 2x filter card - SDS gel – PVDF membrane – 2x filter card – sponge 
 
The transfer of the protein occurs from the gel on to the PVDF membrane to facilitate 
immunoblotting. Thus, the SDS gel should be closest to the negative electrode whilst the 
PVDF membrane to the positive. Transfer was allowed to occur in 1x transfer buffer at 
150V, 400mA at 4°C for 75 mins.  
To confirm transfer of protein on to the PVDF membrane, a Ponceau S stain was 
employed. In brief, membranes are removed from the transfer apparatus and stained with 
20mL of Ponceau S stain for 5 mins. Images were visualised on the Kodak IS4000MM. 
The blots were destained by three 5 minute washes in PBS-T wash buffer (1x phosphate 
buffered saline and 0.1%v/v Tween-20).  
 
2.6.3. Immunoblotting  
Following successful transfer of protein on to PVDF membrane, immunoblotting was used 
to determine protein expression.  
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Membranes were blocked for 1h in 20mL blocking buffer (PBS-T plus 5%w/v semi-
skimmed milk powder). Blots were then stained overnight at 4°C with primary antibody 
diluted in blocking buffer to the desired concentration (see Table 2.6 for individual antibody 
dilutions). Following this, membranes were washed for 5 mins three times in 25mL PBS-T 
wash buffer. Membranes were then stained with horse radish peroxidise (HRP) conjugated 
secondary antibody for 1h at room temperature. The secondary antibody used was 
(1:2000) goat anti-mouse HRP conjugated, unless otherwise stated (see Table 2.6 for 
individual antibody targets). Membranes were then washed for 5 mins three times in 25mL 
PBS-T wash buffer. 
Blots were visualised using 4mL of the west pico chemiluminescent substrate 
(Thermo Scientific, Surrey UK) with a 5 minute incubation at room temperature on the 
Kodak IS4000MM.  
As a loading control and for normalisation of target protein expression, either          
β-ACTIN or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein expression was 
assessed. Membranes were washed to remove chemiluminescent substrate three times 
for 5 mins in PBS-T wash buffer.  
Membranes were blocked in blocking buffer for 3 h then overlaid with a primary 
antibody specific to either β-ACTIN or GAPDH. Primary antibody staining for β-ACTIN was 
for 1h at room temperature whilst GAPDH staining was overnight at 4°C (see Table 2.6).  
Following staining, the primary antibody was removed and membranes washed 
three times in PBS-T for 5 mins. Membranes were further stained with secondary antibody 
for 1 h at room temperature (See Table 2.6 for details). Blots were washed three times for 
5 mins in PBS-T wash buffer and visualised using the west pico chemiluminescent 
substrate as described above.  
 
All buffers described above are listed in appendix 1.  
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1
 Primary and secondary antibodies were obtained from Abcam (Cambridge, UK). 
2 Primary GAPDH antibody was obtained from Cell Signalling Technology (Hertfordshire, UK). 
3 RT: room temperature. 
4 All 2° Antibodies are conjugated to HRP. 
Table 2.6.  Antibodies used in immunoblot analysis. 
Protein 
 
Primary (1°) Ab1 1° Dilution 
Incubation length(h)/ 
temperature(°C) 
Secondary (2°) Ab 4 2° dilution 
MSH2  Mouse anti-human 1:1,000 Overnight/4°C Goat anti-mouse 1:2,000 
ADAMTS
3 
 Rabbit anti-human 1:2,000 Overnight/4°C Donkey anti-rabbit 1:10,000 
RAD51  Mouse anti-human 1:2,000 Overnight/4°C Goat anti-mouse 1:2,000 
β-ACTIN  Mouse anti-human 1:40,000 1h/RT 3  Goat anti-mouse 1:2,000 
GAPDH  Rabbit anti-human 2 1:1,000 Overnight/4°C Donkey anti-rabbit 1:10,000 
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Chapter 3  
The Genotoxicity of a triplex forming oligonucleotide targeting 
genomic DNA 
 
3.1. Introduction 
As described in section 1.3.1, purine tracts in duplex DNA can bind third oligonucleotide 
strands in a sequence specific manner to form triplex structures (Duca et al., 2008, 
Hoogsteen, 1959). TFO designed to bind within engineered reporter constructs have been 
reported to be mutagenic (Kalish et al., 2005, Puri et al., 2002, Puri et al., 2001, Vasquez 
et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Majumdar et al., 1998, Wang, 
Seidman & Glazer, 1996).  
In particular, a 30 nucleotide TFO was reported to be capable of inducing mutation 
in the order of 0.27% (13 fold above the spontaneous mutant frequency) in a SupFG1 
based reporter construct (Wang, Seidman & Glazer, 1996). Sequencing mutant SupFG1 
clones revealed mainly point mutations and some small deletions and insertions around 
the triplex target sequence. The mechanism of mutation was proposed to be a result of a 
stalled transcription fork at the site of the triplex generating a re-iterative repair patch 
(Hanawalt, 1994). Repeated attempts in “gratuitous” and “error prone” repair, (introduced 
by the natural error frequency of DNA-repair polymerases) may have resulted in mutation 
around the triplex target sequence (Wang, Seidman & Glazer, 1996). It was further 
postulated that multiple cycles of triplex formation, transcription inhibition and stimulation 
of repair can occur at a single site increasing the probability of a mutagenic event. 
Triplex formation has also been reported to induce HR (Faruqi et al., 2000). A TFO 
conjugated to the DNA intercalator psoralen was reported to induce recombination 
between two tandem supF genes, each containing an inactivating point mutation, at a 
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frequency of 0.4%. Triplex induced recombination produced a single functional supF gene 
detected by a phenotypic change (White vs. blue colonies). These non-conservative 
events are controversial in comparison to the study presented by Luo et al. (Luo et al., 
2000); there, they used a reporter construct composed of two tandem TK genes, flanking 
the triplex target sequence, each containing an inactivating insertion mutation. These cells 
formed a wild-type TK gene through conservative events at a frequency of 1%, while 
maintaining one of the mutant TK loci.  
Although ASO appear to be powerful tools for sequence specific manipulation of 
gene expression (Grunweller et al., 2003, Pirollo et al., 2003, Kurreck et al., 2002, 
Zamaratski, Pradeepkumar & Chattopadhyaya, 2001), the studies described above 
present a concern for oligonucleotide based therapies; specifically, they are suggestive 
that triplex formation at genomic DNA may be ensued with heritable sequence alterations. 
Indeed, the EMA has raised concern as to whether such oligonucleotide based 
pharmaceuticals could present with off-target genotoxicity through triplex formation at 
genomic DNA (European Medicines Agency, 2004).  
Of particular relevance to these highlighted concerns is that previous reports of 
triplex mediated mutagenesis have been described for populations of cells containing an 
engineered target sequence with (1) TFO covalently linked to a DNA intercalator (psoralen 
or acridine) (Macris & Glazer, 2003, Vasquez et al., 2001, Xu, Glazer & Wang, 2000, 
Vasquez et al., 1999); (2) by pre-incubating the target vector with TFO under non-
physiological conditions to assess a mutation endpoint (Ye, Guntaka & Mahato, 2007, 
Datta et al., 2001, Xu, Glazer & Wang, 2000); (3) using electroporation to deliver 
oligonucleotide (Puri et al., 2002, Puri et al., 2001, Faruqi et al., 2000, Majumdar et al., 
1998) and thus do not necessarily reflect biologically relevant events. 
Additionally, critical review of the 30 nucleotide SupFG1 target sequence previously 
used (Kalish et al., 2005, Datta et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, 
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Figure 3.1. DNA quadruplex formation. Guanine rich sequences in duplex DNA can adopt a DNA 
quadruplex structure provding there are 4 units of GGG each separated by at least one nucleotide.   
Vasquez et al., 1999, Wang, Seidman & Glazer, 1996) has highlighted the particular 
abundance of guanine nucleotides (23nt). In a study by Todd (Todd, 2007), a sequence 
with a guanine composition of 23/30 nucleotides is almost 90% likely to form a DNA 
quadruplex structure (Fig. 3.1). However, a targeting oligonucleotide has never been 
reported to interact with a duplex to facilitate or stabilise quadruplex formation.  
Considering the limitations of previous studies, the purpose of this study was to 
examine the hypothesis that triplex formation within the coding region of genomic DNA is 
mutagenic. Furthermore, the study has assessed the potential for DNA quadruplex 
formation by the previously employed SupFG1 target sequence. 
 
 
 
 
 
 
 
 
 
3.2. Experimental outline 
To investigate triplex mediated mutagenesis at genomic DNA, a TFO (TFO27), 
twenty seven nucleotides in length, was engineered to target the genomic coding region of 
the hemizygous HPRT locus in human lymphoblastoid TK6 cells. Following treatment of 
TK6 cells, TFO27 mediated mutagenesis at the targeted HPRT locus was assessed using 
the regulatory acceptable HPRT forward mutation assay. Mutation at the HPRT locus can 
be detected and quantified through cellular resistance to the toxic effects of 6-TG. The 
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HPRT forward mutation assay has been previously employed using TK6 cells to assess 
the genotoxic potential of small molecule compounds (Carter et al., 2007, Meng et al., 
2002, Zhuang et al., 2000). Additionally, non-target specific genotoxicity caused by the 
presence of oligonucleotide could be screened through cellular resistance to TFT 
informing the integrity of the TK locus (gene ID 7083). 
As a negative control, an oligonucleotide with the same base composition as 
TFO27 but in a random order was adopted (SCR27). SCR27 served as the reference for 
which the biological activity of TFO27 was compared. The spontaneous mutant frequency 
at the genomic HPRT or TK loci was assessed using an untreated population of TK6 cells; 
the known mutagen, EMS, was used as a positive genotoxic control. 
In the first instance, oligonucleotide target binding affinity was determined using an 
EMSA and a DNase I protection assay. Following this, the mutagenicity of oligonucleotides 
treating 3x106 and then 10x106 TK6 cells was determined using the HPRT forward 
mutation assay. DNA quadruplex formation by the SupFG1 target sequence was also 
assessed using an EMSA technique.  
 
3.3. Methods  
1. TFO design is described in section 2.1.1. 
2. EMSA are described in section 2.1.4 and 2.1.7. 
3. DNase I protection assay is described in section 2.1.6. 
4. Serum stability of oligonucleotides is described in section 2.1.3. 
5. Oligonucleotide transfection efficiencies and mutation assays are described in 
sections 2.3 and 2.4. 
6. Detecting triplex formation at genomic DNA is described in section 2.1.5. 
7. Genomic DNA extraction and PCR amplification/sequencing is described in section 
2.2.3 and 2.5. 
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3.4. Results 
3.4.1. High affinity triplex formation 
In the first instance, it was important to assess the capability of TFO27 to form a triplex at 
its target motif. For this, an EMSA was employed. Duplex DNA encompassing the purine 
rich tract in exon 3 of the HPRT locus was incubated with serial dilutions of TFO27 or 
SCR27. Following this, samples were electrophoresed through polyacrylamide gel. Bands 
of reduced migration relative to duplex are indicative of triplex formation. In triplex binding 
buffer, TFO27 bound duplex DNA with high affinity at concentrations as low as 10-10M (Fig. 
3.2A). As expected, SCR27 failed to form triplex structures at concentrations as high as 
10-5M (Fig. 3.2B). These data indicate sequence specific triplex formation by TFO27 at its 
target motif with a Kd in the sub-nanomolar range.  
Previous studies examining triplex mediated mutagenesis have incubated target 
plasmid DNA with TFO in the presence of spermidine (Ye, Guntaka & Mahato, 2007, Datta 
et al., 2001, Xu, Glazer & Wang, 2000). Using similar conditions, triplex binding buffer 
containing 2.5mM spermidine, we found both TFO27 and SCR27 to be capable of 
producing bands of reduced migration (Fig. 3.2, C and D). 
Additionally, the ability of TFO27 to protect the triplex target sequence in a 50mer 
duplex from DNase I mediated degradation was assessed (Fig. 3.3). TFO27 appeared to 
protect duplex DNA from digestion in a dose dependent manner. SCR27 also appeared to 
partially protect duplex DNA from digestion. This effect is likely to be due to the presence 
of spermidine in the reaction buffer, in support of our initial observation (Fig. 3.2D).  
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Figure 3.3. Investigating the capability of oligonucleotides to protect duplex DNA from DNase I 
cleavage. A synthetic 50mer duplex containing the triplex target sequence in exon 3 of the HPRT 
locus was annealed using oligonucleotides HPRT-S-50 and HPRT-AS-50 (Table 2.3). Duplex DNA 
was incubated without oligonucleotide (lane 1), with 5μM SCR27 (lane 2), 2μM TFO27 (lane 3) or 
5μM TFO27 (lane 4) in triplex binding buffer supplemented with 2.5mM spermidine. Samples were 
then digested with DNase I and electrophoresed. TFO27 appeared to protect duplex DNA from 
DNase I digestion in a dose dependent manner. SCR27 also appeared to partially protect duplex 
DNA from DNase I digestion. This is likely to be caused by the presence of spermidine in the reaction 
buffer. 
Figure 3.2. Investigating the triplex forming capability of TFO27 and SCR27. A synthetic 35mer 
duplex containing the triplex target sequence in exon 3 of the HPRT locus was annealed using 
oligonucleotides HPRT-S-35 and HPRT-AS-35 (Table 2.3) and incubated with serial dilutions of 
oligonucleotide in triplex binding buffer (A and B) or triplex binding buffer containing 2.5mM 
spermidine (C and D). Samples were then electrophoresed through polyacrylamide gel. In triplex 
binding buffer, bands of reduced migration are observed with TFO27 at nanomolar concentrations 
representing triplex formation (A) whereas SCR27 fails to form such structures (B). High affinity triplex 
formation is also evident with TFO27 (C) in the presence of spermidine. However, SCR27 also 
appears capable of associating to duplex DNA in a sequence independent manner in the presence of 
spermidine (D). Bands ‘T’ and ‘D’ represent the triplex and duplex structures, respectively. 
 
  
A B 
D
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3.4.2. Transfection efficiency 
Due to the scale of transfection and concentration of oligonucleotide required for ensuing 
mutagenicity studies, the manufacturer’s protocol for small interfereing RNA (siRNA) 
transfection was not appropriate. Thus, the transfection efficiency of human TK6 cells was 
investigated, in a 96 well format, using 6-carboxyfluorescein (6FAM) labelled TFO27 
(6FAM-TFO27) with siPORT NeoFX (Applied Biosystems) or NTER (Sigma Aldrich) as the 
transfection facilitators. Transfection of TK6 cells was allowed to occur at 37°C for 4 h. 
Following fluorescence measurements, the viable cell population in each well was 
determined using the trypan blue exclusion assay. Arbitrary fluorescence units were 
normalised to cell number following transfection to correct for cell death during treatment. 
The following ratios of oligonucleotide (μg) to transfection facilitator (μL) were 
evaluated for both siPORT and NTER using 1μM and 2μM 6FAM-TFO27; 2:1, 1:1, 1:2 and 
1:4, respectively (Fig. 3.4). 
Using 1μM 6FAM-TFO27, 2:1 DNA (μg): transfection facilitator (μL) appeared to be 
the most efficient transfection ratio for both siPORT NeoFX and NTER. However, no 
significant difference was observed between either transfection facilitator using 1μM 
oligonucleotide (Fig. 3.4A). Transfection efficiency between siPORT NeoFX and NTER 
appeared to be markedly increased using 2μM 6FAM-TFO27 with an almost 3 fold 
difference in transfection efficiency between siPORT and NTER using 2:1 or 1:1 DNA (μg) 
to transfection facilitator (μL) (Fig. 3.4B). Furthermore, no difference in transfection 
efficiency between 2:1 or 1:1 DNA (μg) to siPORT NeoFX (μL) was observed using either 
1μM or 2μM 6FAM-TFO27.  
Based on these results, siPORT NeoFX was selected as the transfection facilitator 
using a 2:1 DNA (μg) to siPORT (μL) ratio for large scale transfection of TK6 cells in 
oligonucleotide mutagenicity studies. 
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Figure 3.4. Evaluating the transfection efficiency of TK6 cells using siPORT NeoFX and NTER. 
Human TK6 cells were transfected for 4h with 6FAM-TFO27 using either siPORT NeoFX or NTER 
using 2:1, 1:1, 1:2 or 1:4 DNA (μg) to transfection facilitator (μl) ratios. siPORT NeoFX appeared to be 
more efficient than NTER in delivery of 1μM (A) and 2μM (B) 6FAM-TFO27 using a 2:1 or 1:1 DNA 
(μg) to transfection facilitator (μl) ratio. Data represent mean ± standard deviation (SD) of three 
independent wells of a 96 well plate. 
 
  
A 
B 
1µM 6FAM-TFO27 
2µM 6FAM-TFO27 
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3.4.3. Evaluating the genotoxic potential of a TFO at genomic DNA 
To evaluate the genotoxicity of TFO27 at the genomic HPRT locus, the HPRT forward 
mutation assay was employed using the human lymphoblastoid TK6 cell line. Off-target 
genotoxicity caused by the presence of oligonucleotide was determined by screening the 
mutant frequency at the non-targeted TK locus. 
TK6 cells were transfected with oligonucleotide using siPORT NeoFX over 4h since 
electroporation stress induces an altered biochemical and genetic milieu and such cells 
tend to be more susceptible to mutation (Oberly & Garriot, 1996, Seetharam & Seidman, 
1992, Trump & Berezesky, 1987). In this study, cytotoxicity following treatment was 
assessed by the RTG, which accounts for cell death during treatment and subsequent 
effects on cell growth and cloning ability (Clements, 2000, Clive et al., 1995). Cytotoxicity 
was maintained within OECD guideline 476 (http://www.oecd.org/dataoecd/ 
18/32/1948426.pdf) and therefore cell survival was no less than the minimum accepted 
20% RTG to avoid biasing the mutation endpoint (Oberly & Garriot, 1996). 
In the first instance, 3x106 TK6 cells were transfected with 1μM oligonucleotide in a 
single culture experiment (Fig. 3.5). The spontaneous mutant frequency at each locus was 
measured using an untreated population of cells (Background). The positive genotoxic 
control was 5μg/mL EMS. Cytotoxicity was not observed with oligonucleotide treatment 
(Fig. 3.5A). TFO27 appeared to result in a marginal increase in mutant frequency at the 
targeted HPRT locus, whereas SCR27 had no such effect (Fig. 3.5B). The TK mutant 
frequency was not determined in this initial experiment; thus, the mode of action of TFO27 
may not necessarily be locus specific. To reproduce this observation, 3x106 TK6 cells 
were treated in single culture with 1μM, 2μM and 5μM oligonucleotide (Fig. 3.6). Cell 
survival following treatment decreased with increasing dose (Fig. 3.6A), but the RTG was 
above the minimum accepted 20%. In this case, TFO27 appeared to induce sequence 
specific and dose dependent HPRT mutants (Fig. 3.6B), whilst no induction of TK mutants 
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were observed suggesting a locus specific mode of action (Fig. 3.6C). As expected, 
SCR27 failed to elicit a genotoxic response. 
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Figure 3.6. Investigating the genotoxic effect of 1μM, 2μM and 5μM oligonucleotide treating 3x106 
human TK6 cells. Viability following treatment was above the minimum 20% accepted RTG, although 
a dose dependent increase in cell death was evident (A). TFO27 appeared to cause a dose 
dependent increase in HPRT mutants relative to the control oligonucleotide (B) but failed to induce 
mutation at the non-targeted TK locus (C). As expected, the positive control EMS (5μg/ml) induced 
mutation at the TK and HPRT loci (B and C). Data represent the value of a single treatment. 
 
Figure 3.5. Investigating the genotoxic effect of 1μM oligonucleotide treating 3x106 human TK6 cells. 
Cytotoxicity following treatment was not observed (A). TFO27 appeared to produce a marginal 
increase in HPRT mutants relative to SCR27 (B). As expected, the positive control EMS (5μg/ml) 
induced mutation at the HPRT locus (B). Data represent the value of a single treatment. 
 
  
A 
B C 
A B 
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Conforming to a regulatory protocol outlined in the OECD guideline for the MLA 
(http://www.oecd.org/dataoecd/18/32/1948426.pdf), 10x106 TK6 cells were treated with 
oligonucleotide to reproduce the initial observation treating 3x106 cells. In this case, four 
independent negative control cultures were adopted to measure the spontaneous mutant 
frequency, whereas the remaining treatments were in duplicate cultures. One micromolar 
of 4NQO was used as a positive genotoxic control. Treating 10x106 TK6 cells with 1μM, 
2μM and 5μM oligonucleotide using a regulatory acceptable mutation assay was not 
cytotoxic (Fig 3.7A), but contrary to treating 3x106 cells, TFO27 failed to induce a dose 
dependent increase in HPRT mutants (Fig. 3.7B). As expected, 4NQO induced a 
significant increase in HPRT mutants. 
A more comprehensive dose range from 2μM to 12.2μM was used to explore the 
mutagenicity of TFO27 up to maximum acceptable cytotoxicity (Fig. 3.8). Treatment of TK6 
cells up to 12.2μM of TFO27 appeared to result in a dose dependent decrease in the RSG; 
a measure of cell death and proliferating ability following treatment (Fig. 3.8A). Three 
doses of TFO27 (2μM, 5μM and 6.25μM) were selected that resulted in maximum 
acceptable cytotoxicity following treatment, estimated using the RSG, and carried forward 
to determine the RTG, TK and HPRT mutant frequency. The selected doses of TFO27 
were not found to be cytotoxic (~60% RTG, Fig. 3.8B). Additionally, no induction of TK or 
HPRT mutants were observed (Fig. 3.8, C and D). As expected, the positive control 
significantly increased the mutant frequency at both loci. 
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Figure 3.8. Investigating the genotoxic effect of TFO27 in a regulatory acceptable mutation assay 
treating 10x106 TK6 cells. Cytotoxicity following treatment, estimated from the RSG, appeared to be 
evident from 7.8μM (A). Three doses of TFO27 (2μM, 5μM and 6.25μM) that gave maximum 
acceptable cytotoxicity were selected to determine the RTG (B), TK mutant frequency (C) and HPRT 
mutant frequency (D). Cytotoxicity up to 6.25μM was no greater than approximately 40% (A) but no 
induction of TK (C) or HPRT mutants (D) were observed. As expected the positive control 4NQO 
(1μM) was genotoxic at the TK and HPRT loci (B and C). Error bar represents mean ± SD of four 
independent treatments, whereas the remaining data are the mean of two independent treatments. 
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Figure 3.7. Investigating the genotoxic effect of 1μM. 2μM and 5μM oligonucleotide treating 10x106 
human TK6 cells using a regulatory acceptable mutation assay. Cytotoxicity following treatment was 
not observed (A) and TFO27 failed to induce HPRT mutants (B). As expected the positive control 
4NQO (1μM) was genotoxic at the HPRT locus (B). Error bar represents mean ± SD of four 
independent treatments, whereas the remaining data are the mean of two independent treatments. 
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A 
B C 
Figure 3.9. Investigating the genotoxic effect of TFO27 up to 9.8μM in a regulatory acceptable 
mutation assay treating 10x106 TK6 cells. cytotoxicity following treatment was no greater than 30% 
(A). Treatment of TK6 cells with oligonucleotide failed to result in an increase in TK (B) or HPRT 
mutants (C). Error bars represent mean ± SD of three independent cultures.   
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In a definitive study to explore the mutagenicity of TFO27 at genomic DNA, 10x106 
TK6 cells were treated in triplicate cultures up to 9.8μM (Fig. 3.9). The RTG following 
treatment was above the minimum accepted 20% (Fig 3.9A). TFO27 failed to induce 
mutation in human TK6 cells at both the TK (Fig. 3.9B) and HPRT loci (Fig. 3.9C) up to 
9.8μM. The positive control (EMS) induced mutation at both loci suggesting a viable 
experiment.  
 
 
  
 104 
 
3.4.4. Serum stability of oligonucleotides 
As described above, TFO27 targeting the genomic HPRT locus in human TK6 cells was 
found to lack reproducible genotoxic activity up to 9.8μM when treating up to10x106 cells.  
A potential cause for this may be rapid nuclease mediated degradation of oligonucleotides 
during treatment. Oligonucleotides used in mutagenicity studies were modified with four 
terminal phosphorothioate linkages at either end to offer nuclease resistance (Kenner et 
al., 2002). To validate this, a serum stability assay was employed. Additionally, we 
assessed the serum stability of TFO27 with canonical phosphodiester linkages (PO-
TFO27). 
Oligonucleotides were incubated at 37°C in the presence of cell culture media, 
which contained 10%v/v horse serum. Aliquots were removed at select time points up to 
24h and electrophoresed through a 1.5% agarose gel. Bands were quantified by 
densitometry and made relative to the zero hour band. TFO27 and SCR27 were resistant 
to degradation in cell culture media for at least 24h (Fig. 3.10). In contrast, PO-TFO27 was 
found to be significantly degraded in cell culture media within 3h (Fig. 3.10). Thus, four 
terminal phosphorothioate linkages provided nuclease resistance for TFO27 and SCR27.  
 As degradation of oligonucleotides is likely to occur 3’ to 5’ by serum 3’ 
exonucleases (Shaw et al., 1991, Tidd & Warenius, 1989, Wickstrom, 1986) the agarose 
gel is unlikely to resolve between n-1 or n-2 oligonucleotides whereas polyacrylamide gel 
electrophoresis may have been more appropriate in discerning full length and truncated 
products. However, TFO that have lost 1 or 2 terminal nucleotides still have the potential 
for triplex formation so the method used here accounts for these truncated 
oligonucleotides also, as well as the full length product.  
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Figure 3.10. The serum stability of oligonucleotides. Oligonucleotides, were incubated at 37°C with 
cell culture media containing 10%v/v horse serum. Aliquots were removed at select time points up to 
24h. Samples were electrophoresed through a 1.5% agarose gel. Bands were analysed by 
densitometry. Intensities are relative to the zero hour. TFO27 and SCR27 with 4 terminal 
phosphorothioate linkages at either end appeared to be resistant to nuclease degradation up to 24h 
(PS-TFO and PS-SCR). However, TFO27 containing canonical phosphodiester linkages was rapidly 
degraded within 3h (PO-TFO). Data represent mean ± SD of three independent samples. 
3.4.5. Human TK6 cells contain the wild-type HPRT sequence 
An alternative explanation for the lack of genotoxicity by TFO27 may be mutation of the 
triplex target sequence in exon 3 of the HPRT locus in human TK6 cells. If the wild-type 
sequence was lost, this would present with reduced target binding affinity of TFO27 with 
subsequent effects on the potential to block a transcription fork and cause mutation.  
To address this, a 177bp stretch encompassing the TFO27 target sequence in exon 
3 of the HPRT locus was PCR amplified using genomic DNA from human TK6 cells. 
Products were resolved on agarose gels and extracted for DNA sequencing. Sequencing 
confirmed that the TK6 cell line used in mutagenicity studies contained the proposed 
TFO27 target sequence and therefore the potential for triplex formation (Fig. 3.11, A and 
B).  
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Figure 3.11. Validating the putative TFO27 target sequence in exon 3 of the HPRT locus in human 
lymphoblastoid TK6 cells. Genomic DNA from TK6 cells was extracted and used for PCR 
amplification around the TFO27 target sequence. PCR products were resolved on agarose gels. The 
corresponding band was excised, purified and sequenced. The raw sequence data (A) was 
extrapolated to NCBI-BLAST (B) which revealed the wild-type sequence of the complementary strand 
to the TFO27 target sequence in exon 3, highlighted with the red box.  
B 
A 
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3.4.6. Method development to detect triplex formation at genomic DNA 
To investigate the potential for TFO27 to bind to its target sequence in genomic DNA, a 
method was developed to detect triplex formation, a procedure adapted from Besch et al. 
(Besch et al., 2004).  
 An overview of the procedure is outlined in Fig. 2.1 in section 2.1.5. In brief, 
genomic DNA extracted from TK6 cells was mixed with TFO27 or SCR27. However, 
oligonucleotides were conjugated 5’ to psoralen and 3’ to biotin (sequences listed in Table 
2.1). Incubation of Pso-TFO27-biot or Pso-SCR27-biot with genomic DNA in triplex binding 
buffer allows triplex formation and intercalation of psoralen into genomic DNA (Fig. 2.1 
step A). Once TFO27 forms a triplex at the HPRT locus, UVA (365nm) irradiation of 
samples (5J/cm2) covalently reacts the psoralen linked oligonucleotide to genomic DNA at 
5’-AT-3’ upstream of the TFO27 target sequence (Ramaswamy & Yeung, 1994, Song & 
Tapley, 1979).  
 Once Pso-TFO27-biot was covalently bound to DNA, samples were restriction 
enzyme digested overnight using Bgl II (Fig. 2.1, step B). This produces a HPRT fragment 
of ~3.4kb encompassing the covalently bound Pso-TFO27-biot. 
 To prevent competitive binding of unbound Pso-TFO27-biot with the biotinylated 
3.4kb HPRT fragment containing triplex DNA, unbound oligonucleotide was removed 
either using electrophoresis through an agarose gel followed by extraction or passing 
samples through a Qiagen DNA column (Fig. 2.1 step C).  
 Following purification, 3.4kb HPRT fragments containing covalently bound 
oligonucleotide were separated by their biotin moiety using streptavidin coated 
paramagnetic beads (Fig. 2.1, step C). After several washes to remove unbound DNA, 
beads bound to triplexed HPRT fragments via the biotin moiety were subject to PCR 
amplification across intron 3 of the HPRT locus (downstream of TFO27 target sequence) 
to yield a 364bp product using primer pair 1, Table 2.4 (Fig. 2.1, step D). 
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Figure 3.12. Optimising PCR conditions for triplex detection. In brief, 2µg of Bgl II digested genomic 
DNA from TK6 cells was used for PCR amplification of a 364bp stretch in intron 3 of the HPRT locus. 
In the first instance, the primer annealing temperature and MgCl2 concentration was optimised (A). The 
values above each row in part A represent the concentration (mM) of MgCl2 used in each PCR 
reaction. Lane 0 represents the water control. Optimum PCR was found to be with 1mM MgCl2 and a 
66°C primer annealing temperature. Following this, the lowest PCR detection limit was determined 
from 60,000 template copies to 10 (B). Lane C in part B represents a water control. 
B 
A 
 In the first instance, Bgl II digested genomic DNA extracted from TK6 cells was 
used to optimise conditions for PCR amplification of intron 3 of the HPRT locus to detect 
triplex formation (Fig. 3.12A). The concentration of MgCl2 (1mM, 2mM and 3mM) was 
optimised at primer TA of 66°C, 67°C and 68°C. Under these conditions, 1mM MgCl2 and 
Ta 66°C were found to be best resulting in a distinct band around 364bp.  
 Secondly, it was important to assess the minimum copy number of template the 
PCR could detect using these optimised parameters. For this, Bgl II digested TK6 genomic 
DNA was diluted from 60,000 copies to 10 and PCR amplified (Fig. 3.12B). The PCR 
method was able to detect a minimum of 500 copies of template. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Following optimisation, 16μg of genomic DNA from TK6 cells was incubated with 
20μM Pso-TFO27-biot or Pso-SCR27-biot for 3h at room temperature, UVA irradiated and 
Bgl II restriction enzyme digested overnight. As a control, genomic DNA was incubated 
with water to replace oligonucleotide. Samples were purified through an agarose gel and 
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A 
Figure 3.13. Detecting triplex formation and optimising streptavidin bead concentration. Briefly, 16µg 
genomic DNA extracted from TK6 cells was incubated without or with 20µM Pso-SCR27-biot (S) or 
Pso-TFO27-biot (T) at room temperature for 3h in triplex binding buffer (A). Samples were gel purified 
and mixed with 50µg of streptavidin beads, washed and PCR amplified. No PCR signal is observed 
with any mixture including the positive genomic DNA control (A). Following this, the influence of 
streptavidin coated paramagnetic beads on PCR efficiency was evaluated (B). Each PCR reaction 
contained 16µg genomic DNA mixed with streptavidin beads from 0.5µg up to 5µg. Clearly, above 
0.5µg of beads, the PCR reaction is inhibited significantly. 
B 
isolated using 50μg of streptavidin coated beads. Here, no PCR signal was observed in 
any sample including the genomic DNA control (Fig. 3.13A).  
To investigate the influence of streptavidin beads, 16μg of Bgl II digested genomic 
DNA was mixed with serial dilutions of beads from 50μg down to 10μg and PCR amplified. 
No signal was obtained using these bead concentrations (data not shown). Repeating this 
experiment with fewer streptavidin beads (5μg down to 0.5μg) for PCR amplification of 
genomic DNA showed the presence of beads drastically inhibited the efficiency of PCR 
amplification (Fig. 3.13B). Streptavidin beads at 0.5μg was the only concentration not to 
effect PCR amplification of 16μg genomic DNA. Thus, 0.5μg of streptavidin beads was 
used in subsequent experiments.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TK6 genomic DNA (16μg) incubated with 20μM oligonucleotide, UVA irradiated, Bgl 
II digested was purified through an agarose gel as described above. Here, genomic DNA 
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Figure 3.14. Optimising genomic DNA purification. Briefly, 16µg genomic DNA extracted from TK6 
cells was incubated without or with 20µM Pso-SCR27-biot (S) or Pso-TFO27-biot (T) at room 
temperature for 3h in triplex binding buffer, purified through agarose gel, then mixed with 0.5µg 
streptavidin beads for PCR amplification (A). All samples were gel purified except sample PCR gDNA 
which served as a PCR control. No signal detected in any purified sample. Comparing the control 
gDNA and PCR gDNA suggests a problem with the purification technique as no signal was obtained 
following purification of DNA (A). Additionally, the above procedure was repeated using a  Qiagen 
DNA extraction column to purify samples (B). No signal was obtained from any sample including the 
positive control. 
A 
B 
without oligonucleotide was also gel extracted (control gDNA), but additionally, genomic 
DNA without oligonucleotide and purification (PCR gDNA) was used as a PCR control 
(Fig. 3.14A). Most peculiar was that genomic DNA purified using agarose gel produced no 
distinct PCR signal except a faint smear >2kb whereas the PCR control worked. This 
suggested a problem with the purification technique and so the above experiment was 
repeated except a Qiagen DNA extraction column was employed to purify DNA (Fig. 
3.14B). In this case also, purified genomic DNA control failed to produce a distinct 364bp 
band except a smear >2kb.  
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Figure 3.15. Optimising purification of genomic DNA using the Qiagen DNA extraction column. Briefly, 
16µg genomic DNA extracted from TK6 cells was digested by Bgl II then used to optimise agarose gel 
purification. Extraction 1 included the addition of 20µL of ethanol (>99.6%) to a 20µL sample before 
addition to the spin column. Extraction 2 included addition of 20µL sample directly on to the spin 
column. Extraction 3 included addition of 100µL ethanol (>99.6%) and 100µL lysis buffer AL to 20µL 
sample before addition to the spin column. The remaining procedure is the same for all samples as 
described in section 2.2.3. Following elution of samples in a 50µL, 20µL was used for PCR 
amplification with or without 0.5µg streptavidin beads. No distinct band is apparent in any sample 
apart from a smear >2kb in length most intense with extraction 3. Also, no difference is observed 
between signals with/without beads. 
In a further attempt, DNA purification using the Qiagen spin column was investigated. 
Three different protocols were used for purification of genomic DNA. Extraction 1 involved 
the addition of 20μL of ethanol (>99.6%) before addition to the spin column, extraction 2 
was the direct addition of 20μL sample to spin column and extraction 3 involved the 
addition of 100μL ethanol (>99.6%) and 100μL of lysis buffer AL before addition to the spin 
column. The remaining procedure is as outlined in section 2.2.3. Following elution of DNA, 
samples were divided for PCR amplification with or without the addition of 0.5μg 
streptavidin beads (Fig. 3.15). In this case also, no distinct bands around 364bp were 
observed except a smear >2kb. The most intense smear was using extraction 3, and no 
difference was noted with the addition of the streptavidin beads.  
 Further work is required to determine why a smear is present instead of a distinct 
band and to optimise the purification technique either using the gel or the Qiagen spin 
column.     
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3.4.7. The previously employed SupFG1 triplex target sequence is capable of DNA 
quadruplex formation 
Previous reports of triplex mediated mutagenesis have focused on targeting extra-
chromosomal DNA mainly using the SupFG1 reporter (Kalish et al., 2005, Datta et al., 
2001, Vasquez et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Wang, Seidman & 
Glazer, 1996). In this system, a 30 bp purine stretch composed primarily of guanine (23nt) 
is targeted using a purine motif TFO. On the basis that guanine rich sequences have been 
implicated in DNA quadruplex formation (Todd, 2007), the ability of the SupFG1 triplex 
target sequence to adopt a DNA quadruplex structure was investigated using an EMSA. In 
this case, a band of reduced migration relative to the triplex structure is indicative of DNA 
quadruplex formation. 
In triplex binding buffer, the SupFG1 target sequence was capable of DNA triplex 
and quadruplex formation in the presence of the targeting oligonucleotide AG30 (Fig 
3.16A, Lane 5). Densitometric quantitation of lane 5 (Fig. 3.16A) revealed primarily triplex 
formation (79%) as opposed to quadruplex formation (18%). As a control, the same 
sequence as AG30 and the SupFG1 duplex was employed, except that 4 guanine 
nucleotides were replaced with adenine to reduce the potential for quadruplex formation 
(AG30-4MM and SupF-4MM, Table 2.3). In triplex binding buffer (Fig. 3.16A), replacing 
four guanine nucleotides was found to partially attenuate quadruplex formation (6.5%, 
Lane 2). Repeating the experiments using a quadruplex buffer containing potassium (Fig 
3.16B), where potassium has been reported to stabilise quadruplex structures (Sun et al., 
2005), quadruplex formation by AG30 and the wild-type SupFG1 target sequence was 
almost as prevalent as triplex formation (17% versus 27%, respectively; Lane 5). This 
observation was confirmed in an independent experiment (Fig. 3.17). In the quadruplex 
buffer (Fig. 3.16B), the level of quadruplex formation by AG30-4MM and SupF-4MM was 
about 50% (Lane 2) of the wild-type SupFG1 sequence (Lane 2; 9.5% versus Lane 5; 
 113 
 
Figure 3.16. Investigating the quadruplex forming ability of the SupFG1 system. Oligonucleotide 
sequences are listed in Table 2.3. Duplex DNA containing the SupFG1 sequence was incubated with 
targeting oligonucleotide in triplex binding buffer (A) or quadruplex buffer (B). As a control to the wild-
type SupFG1 sequence, 4 guanine residues were replaced in the target duplex and targeting 
oligonucleotide (SupF-4MM and AG30-4MM, respectively). In figures A and B, lanes 1-3 are 0.2μM of 
the SupF-4MM duplex incubated with 10-6M, 10-5M or zero AG30-4MM, respectively. Lanes 4-6 are 
0.2μM of the wild-type SupFG1 duplex incubated with zero, 10-5M or 10-6M AG30, respectively. 
Quadruplex formation is observed with the wild-type SupFG1 duplex incubated with AG30, to a lesser 
extent in triplex binding buffer (Lane 5, A) than quadruplex buffer (Lane 5, B). SupF-4MM and AG30-
4MM is less efficient in quadruplex formation in either buffer relative to the wild-type sequence (Lane 
2 vs. Lane 5, A and B). Bands ‘Q’, ‘T’ and ‘D’ represent the quadruplex, triplex and duplex structures, 
respectively. 
B 
A 
17%). It may be possible that AG30 interacts with the guanine based target sequence 
within the SupFG1 duplex such that it complexes with or stabilises/ facilitates quadruplex 
formation. Replacing four guanine residues to interrupt the contiguous run of guanines 
within AG30 and the SupFG1 duplex was found to partially attenuate quadruplex 
formation. 
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Figure 3.17. Confirmation of DNA quadruplex formation in the SupFG1 duplex.  Duplex DNA 
containing the SupFG1 sequence was incubated with targeting oligonucleotide (AG30) in quadruplex 
buffer. Lanes 1-4 are 0.2μM of the wild-type SupF duplex incubated with zero, 10-5M, 10-6M, 10-7M 
AG30, respectively. Quadruplex formation is observed with the wild-type SupFG1 duplex incubated 
with 10-5M AG30 (Lane 2), although less prevalent to triplex formation (16% vs. 31%, respectively). 
Bands ‘Q’, ‘T’ and ‘D’ represent the quadruplex, triplex and duplex structures, respectively. 
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3.5. Discussion 
The potential for oligonucleotides to interact with duplex DNA, in a sequence specific 
manner, with ensuing mutation has raised concern in regards to oligonucleotide therapy 
(European Medicines Agency, 2004). Oligonucleotides have previously been reported to 
induce mutation through recognition and binding of purine rich sequences within 
engineered reporter constructs to form triplex structures which block progression of 
elongating transcription forks (Datta et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, 
Vasquez et al., 1999, Wang, Seidman & Glazer, 1996). Here, the potential for 
oligonucleotide mediated mutagenesis via triplex formation at genomic DNA was 
addressed. 
In contrast to previous reports using reporter systems, this study suggests that a 
non-conjugated TFO fails to induce mutation at genomic DNA in human TK6 cells in a 
regulatory acceptable mutation assay conducted to OECD guidelines (OECD guideline 
476; http://www.oecd.org/dataoecd/18/32/1948426.pdf). TK6 cells were treated with a 
dose range of oligonucleotide that spans the concentrations employed in previous studies 
examining triplex mediated mutagenesis using reporter constructs (Puri et al., 2002, Puri 
et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Wang, 
Seidman & Glazer, 1996). Despite the lack of genotoxicity by TFO27, it was capable of 
binding to its target motif with high affinity and was not a substrate for rapid nuclease 
degradation. Additionally, the TK6 cells contained the putative HPRT target sequence 
highlighting the potential for triplex formation although it was not that TFO27 could directly 
interact with its target sequence. 
To the best of our knowledge, this is the first study to report cytotoxicity coupled to a 
mutation endpoint for an oligonucleotide. It is crucial to assess the state of cells following 
treatment, as stressed cells are more susceptible to mutation thereby biasing an 
experimental endpoint (Oberly & Garriot, 1996, Seetharam & Seidman, 1992, Trump & 
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Berezesky, 1987). For this reason, oligonucleotides were delivered using a transfection 
facilitator rather than electroporation which has been regularly employed when assessing 
triplex mediated mutagenesis (Puri et al., 2002, Puri et al., 2001, Faruqi et al., 2000, 
Majumdar et al., 1998). However, as the arbitrary fluorescence units are reported here per 
104 viable cells, and not the percentage of cells that are fluorescent, it is difficult to 
determine the variation of transfection efficiency amongst the population of treated cells. 
For this reason, confocal microscopy may have been more appropriate to quantitatively 
assess the proportion of cells that have been successfully transfected and to what extent. 
One may speculate that the transfection procedure in this study may not have been 
adequate for TFO27 to overcome the hurdles of the intranuclear milieu for triplex formation 
and subsequent mutation. However, in chapter 4, it is shown that an oligonucleotide that 
binds to genomic DNA in an alternative mechanism can induce mutation using the same 
transfection procedure so this speculation is not warranted.  
Nevertheless, using siPORT NeoFX as the transfection agent, which was found to 
be more efficient than NTER, excessive cytotoxicity was not found in our studies, thus, 
was not expected to influence the endpoint of the assay. Lepik et al. (Lepik et al., 2003) 
suggested that electroporation can change the balance of intracellular ions and even 
damage cellular DNA directly. This may then lead to activation of p53-dependent and 
independent cell cycle arrest or apoptosis. Indeed, this was reported to be the case with 
mock electroporation which increased the level of p53 and nuclear localisation of the 
protein (Lepik et al. 2003); coupling electroporation with carrier DNA augmented this 
observation further. As p53 can regulate cell cycle checkpoints, apoptosis and DNA repair 
(Vousden & Lu, 2002), this may confer an increase in cell susceptibility to triplex mediated 
mutagenesis following electroporation and therefore does not necessarily reflect 
biologically relevant events. 
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Oligonucleotides used throughout the mutation study were DNA based and 
chemically modified to contain 4 terminal phosphorothioate linkages which we found to 
permit nuclease resistance in contrast to the unmodified counterpart. Additionally, DNA 
based oligonucleotides are reported to be more likely to induce mutation by causing a 
greater helical distortion than those which are RNA based (Kalish et al., 2005, Asensio et 
al., 1999). Despite high affinity binding of TFO27 to its target motif, mutation at the 
targeted genomic HPRT locus was not reproducibly observed. In the preliminary 
experiments treating 3x106 cells in single cultures a dose dependent increase in HPRT 
mutants was observed. It is noteworthy, that the oligonucleotides used in the preliminary 
studies were from the same synthesised batch, which would be consistent with the results 
obtained. However, this observation was never reproduced treating a viable population of 
10x106 cells in three independent cultures with oligonucleotide obtained from several 
different batches of synthesis.  
It is noteworthy, that the presence of spermidine facilitated sequence independent 
DNA aggregation of SCR27 in binding studies. Thus, the conditions employed previously 
(Ye, Guntaka & Mahato, 2007, Datta et al., 2001, Xu, Glazer & Wang, 2000) incubating 
plasmid DNA with a TFO in the presence of spermidine to demonstrate triplex formation 
with a mutation endpoint should be interpreted with caution if they are to be extrapolated to 
the genomic context as they do not necessarily reflect biologically relevant events.  
It is pertinent to add that the triplex target sequence in the supFG1 based reporter 
construct previously used (Kalish et al., 2005, Datta et al., 2001, Vasquez et al., 2001, 
Faruqi et al., 2000, Vasquez et al., 1999, Wang, Seidman & Glazer, 1996) has been 
reported to be a mutagenic hotspot (Hegan et al., 2006); in a contiguous run of guanines 
located in the TFO target sequence, spontaneous small deletions and insertions have 
been reported to localise upstream, likely due to a polymerase slippage mechanism at this 
site (Narayanan et al., 1997). In the present study, the SupFG1 triplex target sequence 
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was also found to be capable of DNA quadruplex formation in the presence of the 
targeting oligonucleotide. Replacing 4 guanine residues in the SupFG1 duplex and 
targeting oligonucleotide partially attenuated quadruplex formation at this sequence. A 
plausible explanation for the partial and not complete reduction of quadruplex formation in 
the mutant SupFG1 construct is that the quadruplex structure may still be capable of 
folding with four repeating units of 2 guanine residues, but with reduced efficiency. In 
further support was that quadruplex formation in the SupFG1 sequence was favoured in a 
potassium buffer. Moreover, a DNA stretch of 30 bases containing 23 guanines (as is the 
case in the SupFG1 target sequence) is almost 90% likely to form a DNA quadruplex 
structure (Todd, 2007). It may be plausible to suggest that previous oligonucleotide 
targeting to this mutation hotspot may be facilitating or stabilising the DNA quadruplex 
structure such that it increases the susceptibility of this sequence to mutation. In further 
support of this and in accordance with previous results (Wang, Seidman & Glazer, 1996), 
DNA quadruplex formation can also result in truncated transcripts and has been implicated 
in transcriptional regulation and genomic instability (Broxson, Beckett & Tornaletti, 2011, 
Basundra et al., 2010). 
Similar to this study, Majumdar et al. (Majumdar et al., 1998) employed a psoralen 
conjugated TFO to target an intronic purine rich tract adjacent to exon 5 of the genomic 
hprt locus in Chinese hamster ovary cells. The psoralen TFO was electroporated into the 
cells and UVA treated after 90 mins. This UVA treatment caused psoralen to covalently 
react with both strands of the duplex to generate interstrand cross-links. Following this, 
hprt mutant frequencies were reported to be induced to 122 per million cells. In agreement 
with the results presented here, omitting the UVA treatment or the psoralen conjugation 
from the TFO resulted in the cessation of mutation. However, mutation caused by the un-
conjugated TFO in the intronic sequence may not have resulted in a 6-TG resistant 
phenotype. As reported here, a TFO targeting a genomic coding region was also not 
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capable of inducing mutation above the spontaneous mutation rate of this assay. This 
outcome suggests that unless triplex formation is accompanied with a covalent link to the 
genomic DNA i.e. psoralen conjugation, the structure is unlikely to result in mutation.  
Of relevance to the results presented here, nucleosome core particles have been 
shown to inhibit TFO binding to duplex DNA by hindering access to the target sequence 
(Brown & Fox, 1996). Moreover, a DNA helicase has been shown to be capable of 
unwinding triplex and duplex structures with similar efficiency (Maine & Kodadek, 1994). 
Thus, it is probable that triplex formation at genomic DNA is unlikely to block the 
progression of a transcription fork and generate a reiterative repair patch which results in 
mutation. 
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Chapter 4  
The Genotoxicity of an antisense oligonucleotide via targeted 
nucleotide exchange 
 
4.1. Introduction 
The potential for ASO to modulate protein expression by translational repression or RNase 
H mediated degradation has application as a powerful therapeutic tool (Denli & Hannon, 
2003, Zamore, 2001). However, as previously described in chapter 3, recent studies 
demonstrating the potential for oligonucleotides to induce site directed mutation have 
given rise to concerns from the EMA (European Medicines Agency, 2004). In addition to 
oligonucleotide mediated mutagenesis by triplex formation (chapter 3), oligonucleotides 
have also been reported to induce mutation in a process known as TNE.  
In the process of TNE (section 1.3.2), oligonucleotides, typically over 45 nucleotides 
in length, are designed to bind complementary to the non-transcribed (sense) strand within 
duplex DNA to form a D-loop structure where the transcribed (antisense) strand of duplex 
DNA becomes displaced. Oligonucleotides are engineered to carry a single mismatched 
base relative to its homologous sequence such that mutation is directed to the site of the 
mismatch in duplex DNA. In a previous study, a mutant GFP construct carrying a single 
inactivating point mutation was reported to be corrected to the wild-type sequence, 
restoring fluorescence, using a 74-mer oligonucleotide with correction frequencies in the 
order of 2% (Bonner & Kmiec, 2009). 
The mechanism of TNE has been proposed to be a result of physical incorporation 
of oligonucleotides into duplex DNA as a result of (i) HR repair activity or (ii) 
oligonucleotides acting as Okazaki fragments during DNA replication (Morozov & 
Wawrousek, 2008, Radecke et al., 2006). In either case, the MMR protein MSH2 has been 
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shown to negatively modulate TNE (Papaioannou, Disterer & Owen, 2009, Maguire & 
Kmiec, 2007, Aarts et al., 2006, Dekker, Brouwers & te Riele, 2003, de Wind et al., 1995, 
te Riele, Maandag & Berns, 1992).  
 It is pertinent to highlight that the genotoxicity observed with oligonucleotides 
previously employed in TNE cannot be extrapolated to ASO because (i) the length of 
oligonucleotides are greater than 21-23 nucleotides used in ASO design (Geary, 2009) 
and (ii) oligonucleotides are engineered to target synthetic reporter constructs and so do 
not reflect the complexity of the intranuclear milieu. The study presented here has 
addressed the genotoxic potential of an ASO targeting genomic DNA in human TK6 cells, 
whilst investigating the modulatory roles of MSH2 protein expression and HR repair activity 
in TNE.     
 
4.2. Experimental outline 
In a study by Bonner et al. (Bonner & Kmiec, 2009), a targeting oligonucleotide (74mer) 
was reported to induce DNA DSBs following correction of a mutant GFP construct, 
assessed using the alkaline Comet assay. However, DNA DSBs, measured as the comet 
tail intensity, following oligonucleotide treatment was not significantly different from control 
unless the comet tail intensity was normalised to cell count following treatment which is an 
unconventional approach to the analysis. Furthermore, targeting oligonucleotides were 
electroporated into aphidicolin synchronised cells where such treatments have been 
previously reported to result in DNA DSBs (Lepik et al., 2003).   
In this study, we investigated the mutagenic/ clastogenic activity of a 27mer D-loop 
forming oligonucleotide (Dloop27) which was engineered to bind the TFO27 triplex target 
sequence in exon 3 of the HPRT locus (Fig. 4.1). Dloop27 is complementary to the target 
sequence so genotoxicity resulting in cellular resistance to 6-TG is not a result of a 
mismatched base. In this instance, the oligonucleotide SCR27 (which lacks sequence 
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homology to the HPRT locus) was employed as a negative oligonucleotide control. The 
genotoxin 4-nitroquinoline (1µM) was used as a positive control.  
In a novel approach, an ASO (AD3-HPRTPM), 23 nucleotides in length, was 
engineered to bind complementary to the ADAMTS3 gene mRNA as well as contain 
sequence homology to the HPRT locus except a single mismatched base (described in 
section 2.1.2; Fig. 4.2). It was proposed that AD3-HPRTPM would act as an ASO in 
modulating ADAMTS3 protein expression whilst the HPRT locus served as a genomic 
reporter of off-target genotoxicity caused by AD3-HPRTPM which could be quantified 
using the established HPRT forward mutation assay. The integrity of the genomic TK locus 
served as a reporter of sequence independent genotoxicity following oligonucleotide 
treatment. As a negative control, an oligonucleotide with the same base composition as 
AD3-HPRTPM but in a random order was employed (control) (Fig. 4.2). Similarly, two 
other ASO molecules containing homology to a protein target and a selectable locus (such 
as HPRT or TK) were designed; however, following ASO sequence examination both were 
found to be capable of forming stable hair-pin structures that would render the 
oligonucleotides incapable of target binding and so were abandoned for further testing 
(data not shown). 
In the first instance, the genotoxicity of AD3-HPRTPM was investigated using a 
system where MSH2 protein expression was modulated using RNAi. Following this, the 
genotoxicity of AD3-HPRTPM was investigated using a system where HR repair activity 
was stimulated. 
All oligonucleotides were chemically modified at the 5’ and 3’ ends to contain four 
terminal phosphorothioate linkages to offer nuclease resistance, as described in section 
3.4.4. Oligonucleotide sequences are listed in Table 2.2.  
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Figure 4.1. The Dloop27 target sequence in exon 3 of the HPRT locus. Dloop27 is engineered to bind 
complementary to the TFO27 triplex target sequence through a displacement loop structure. Dloop27 
contains four terminal phosphorothioate linkages at either end to facilitate nuclease resistance (Table 
2.2). The red underlined sequence in duplex DNA highlights the target sequence. 
Figure 4.2. The AD3-HPRTPM target sequence in exon 3 of the HPRT locus. AD3-HPRTPM is 
engineered to bind complementary, except a single mismatched base (underlined in red), to the target 
sequence (underlined in red) through a D-loop structure. The control oligonucleotide contains the 
same base composition as AD3-HPRTPM but in a random order and has no sequence homology to 
the HPRT locus. AD3-HPRTPM and control oligonucleotide contain four terminal phosphorothioate 
linkages at either end to facilitate nuclease resistance (Table 2.2). 
4.3. Methods 
1. Antisense and Dloop oligonucleotide design is described in section 2.1.2. 
2. Cell treatments and mutation assays are described in section 2.3 and 2.4. 
3. Protein extraction is described in section 2.2.5. 
4. Immunoblot is described in section 2.6. 
5. Genomic DNA extraction is described in section 2.2.3. 
6. PCR and DNA sequencing is described in section 2.5. 
7. Restriction fragment length polymorphism (RFLP) assay is described in section 
2.5.5. 
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4.4. Results 
4.4.1. Genotoxicity of Dloop27  
Treating 10x106 human TK6 cells with 1μM, 2μM or 5μM Dloop27 or SCR27 was not 
found to be cytotoxic (Fig. 4.3A). Contrary to the study by Bonner et al. (Bonner & Kmiec, 
2009) which targeted a synthetic reporter construct, Dloop27 targeting a genomic 
sequence lacked mutagenic activity at the targeted HPRT locus (Fig. 4.3B). The in vitro 
micronucleus assay was employed to assess the clastogenic activity of Dloop27 in TK6 
cells conducted in accordance with OECD guideline 487 
(http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/OECD-TG487.pdf). Here, 
Dloop27 targeting genomic DNA failed to induce micronuclei above background in 2000 
viable mononucleate cells scored (Fig. 4.4A). Proliferative ability and cytotoxicity following 
treatment of TK6 cells was informed by the relative population doubling (RPD) according 
to OECD guideline 487 (http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/OECD-
TG487.pdf). Proliferation of TK6 cells following oligonucleotide treatment was greater than 
the minimum 45% recommended for this assay to allow expression of micronuclei and 
avoid artifactual positive results caused by excess cytotoxicity (Fig. 4.4B). Thus, the 
inability of Dloop27 to exert a clastogenic effect is not an artefact resulting from cells that 
have not undergone mitosis.  
 It is noteworthy that the genotoxicity observed in previous studies employed 
oligonucleotides which contained a single mismatched base whereas Dloop27 did not. 
Thus, the presence of the mismatched base may be the cause for genotoxicity and was 
explored further.  
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Figure 4.4. Evaluating the clastogenic activity of Dloop27 in human lymphoblastoid TK6 cells using 
the in vitro micronucleus assay. An untreated population of cells was used as a negative control 
(Background) and 1μM 4NQO was used as a positive genotoxin. Dloop27 failed to induce the 
incidence of micronuclei in 2000 mononucleate cells (A). The relative population doubling of 
oligonucleotide treated TK6 cells was greater than the minimum 45% accepted for this assay (B). 
Error bar is mean ± SD of four independent treatments whilst the remaining are the mean of two 
independent treatments.  
 
Figure 4.3. Investigating the mutagenic effect of Dloop27 at the HPRT locus after treating 10x106 
human lymphoblastoid TK6 cells. An untreated population of cells was used to measure the 
spontaneous mutant frequency (Background) and 1μM 4NQO was used as a positive genotoxin. 
Cytotoxicity is not evident treating TK6 cells up to 5μM oligonucleotide (A). Dloop27 failed to induce 
mutation at the targeted genomic HPRT locus (B). Error bar is mean ± SD of four independent 
treatments whilst the remaining are the mean of two independent treatments.  
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4.4.2. Biological activity of AD3-hprtPM 
Having reported the lack of genotoxicity of Dloop27 at genomic DNA, we sought to 
examine the consequence of introducing a single mismatched base.  
In the first instance, the antisense activity of AD3-HPRTPM was examined by 
quantifying ADAMTS3 protein expression by immunoblot (Fig. 4.5). In brief, TK6 cells were 
treated with 2µM, 5µM or 10µM AD3-hprtPM or control oligonucleotide and aliquots 
removed at 24h, 48h and 72h (Fig. 4.5, A-C). Protein expression was corrected for 
GAPDH protein expression as a loading control. ADAMTS3 protein expression following 
AD3-HPRTPM treatment was normalised to ADAMTS3 expression following control 
oligonucleotide treatment, at the corresponding dose and time (Fig. 4.5D). 
 AD3-HPRTPM induced a clear dose and time dependent knockdown of ADAMTS3 
protein expression (Fig. 4.5D). ADAMTS3 protein expression was reduced by 20-30% with 
5μM and 10μM AD3-HPRTPM treatment by 48h. This reduction in ADAMTS3 protein 
expression was 45-70% by 72h with 2µM, 5μM and 10μM AD3-HPRTPM. Thus, AD3-
HPRTPM was found to be a biologically active ASO.   
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Figure 4.5. The antisense activity of AD3-HPRTPM. TK6 cells were treated with 2μM, 5μM or 10μM 
control or AD3-HPRTPM oligonucleotide. Aliquots of cells were removed for protein extraction. 
ADAMTS3 protein expression at 24h (A), 48h (B) and 72h (C) was determined by western blot. 
ADAMTS3 expression was quantified by densitometry and normalised to GAPDH protein expression 
as a loading control. ADAMTS3 expression from AD3-HPRTPM treatment was made relative to 
control oligonucleotide treatment (D). Data represent the mean ± SD of three independent treatments. 
Normalised ADAMTS3 protein expression from AD3-HPRTPM treatment is compared to the control 
oligonucleotide at the same dose and time using a two-way students t-test. *p<0.05. 
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4.4.3. The of role of mismatch repair in antisense oligonucleotide genotoxicity 
Previous reports have highlighted the involvement of the MMR protein MSH2 as a 
negative modulator of TNE (Papaioannou, Disterer & Owen, 2009, Maguire & Kmiec, 
2007, Aarts et al., 2006, Dekker, Brouwers & te Riele, 2003, de Wind et al., 1995, te Riele, 
Maandag & Berns, 1992). In the first instance, TK6 cells were pre-treated with 10nM 
MSH2 siRNA to knockdown MSH2 protein expression followed by 5µM AD3-HPRTPM or 
control oligonucleotide treatment, to assess the influence of MMR on ASO mediated 
cytotoxicity and genotoxicity at the HPRT locus (Fig. 4.6). Cytotoxicity was not observed 
with oligonucleotide treatment (Fig. 4.6A). Interestingly, AD3-HPRTPM induced HPRT 
mutants ~2 fold above control oligonucleotide, although to a similar magnitude as the 
spontaneous HPRT mutant frequency (Fig. 4.6B). AD3-HPRTPM failed to induce mutation 
at the non-targeted TK locus suggesting a sequence specific and locus specific mode of 
action (Fig. 4.6C). 
 During MSH2 siRNA pre-treatment of TK6 cells, aliquots of cells were removed for 
analysis of MSH2 protein expression by immunoblot to confirm protein knockdown (Fig. 
4.7A). MSH2 protein expression was quantified by densitometry and corrected for the β-
ACTIN loading control and normalised to the untreated population of cells (Fig. 4.7B). The 
Silencer Select siRNA failed to knockdown MSH2 protein expression up to 72h after 
treatment. Treating TK6 cells with a dose range of MSH2 siRNA up to 20nM failed to 
knockdown protein expression (Fig. 4.8). In fact, treating TK6 cells with siRNA for 24h 
appeared to result in a dose dependent increase in MSH2 protein expression which 
peaked at 24h up to ~1.6 fold above control (Fig. 4.8B). Although this Silencer Select 
siRNA is guaranteed by the manufacturer to give a 100% knockdown, this claim was not 
experimentally verified here. However, MSH2 protein knockdown in a sub population of 
cells is not likely to be detected using an immunoblot as this technique informs average 
protein expression within a population.  
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Figure 4.6. Investigating the mutagenic effect of an ASO containing a single mismatched base. 
Human TK6 cells were pre-treated for 24h with 10nM MSH2 Silencer Select siRNA and then treated 
with 5μM oligonucleotide. An untreated population of cells was used to measure the spontaneous 
mutant frequency at each locus (Background) and 5μg/ml EMS was used as a positive genotoxin. 
Cytotoxicity is not evident following oligonucleotide treatment (A). AD3-HPRTPM induced mutation at 
the targeted HPRT locus ~2 fold above the control oligonucleotide (B) but failed to induce mutation at 
the non-targeted TK locus (C). Error bars represent mean ± SD of three independent treatments. 
**p<0.01 using two way students t-test. 
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Figure 4.7. Quantitation of MSH2 knockdown in human TK6 cells treated with (S) or without (U) 10nM 
Silencer Select siRNA for 24h. Aliquots of TK6 cells at the desired time point were harvested for 
protein extraction. MSH2 protein expression was determined by immunoblot. In brief, 20μg of protein 
was electrophoresed through an SDS-polyacrylamide gel and transferred to a PVDF membrane. 
Membrane was stained with primary mouse anti-human MSH2 antibody (1:1000) overnight and 
visualised (A). β-ACTIN protein expression was used as a loading control using primary mouse anti-
human β-ACTIN antibody (1:40,000) for 1h (A). Protein expression was quantitated using 
densitometry. MSH2 protein expression was corrected for the β-ACTIN loading control and 
normalised to the untreated population of cells at the respective time point (B). 
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Figure 4.8. Optimising MSH2 knockdown using Silencer Select siRNA. Human TK6 cells were treated 
without siRNA (0nM) or with 5nM, 10nM or 20nM MSH2 siRNA for 24h, washed and cultured for the 
remaining time. Aliquots of cells were harvested for protein extraction at the selected time points. 
MSH2 protein expression was determined by immunoblot. In brief, 20μg of protein was 
electrophoresed through an SDS-polyacrylamide gel and transferred to a PVDF membrane. 
Membrane was stained with primary mouse anti-human MSH2 antibody (1:1000) overnight and 
visualised (A). β-ACTIN protein expression was employed as a loading control using primary mouse 
anti-human β-ACTIN antibody (1:40,000) for 1h (A). Protein expression was quantitated using 
densitometry. MSH2 protein expression was corrected for the β-ACTIN loading control and 
normalised to the untreated population of cells (0nM) at the respective time point (B). 
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Figure 4.9. Investigating the genotoxic effect of AD3-HPRTPM using human TK6 cells pre-treated 
with MSH2 Silencer Select siRNA. Following 10nM siRNA pre-treatment for 24h, 3x106 TK6 cells 
were treated with 2μM, 5μM or 10μM oligonucleotide. An untreated population of cells was used to 
measure the spontaneous mutant frequency (Background) and 5μg/ml EMS was used as a positive 
genotoxin. Cytotoxicity was not evident following oligonucleotide treatment up to 10μM (A). AD3-
HPRTPM failed to induce mutation at the targeted HPRT locus (B) and the non-targeted TK locus (C). 
Data represent mean ± SD of three independent treatments. 
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Nevertheless, AD3-HPRTPM appeared to induce mutation ~2 fold above control 
oligonucleotide treatment at a single dose and so was important to reproduce this 
observation using a dose range of AD3-HPRTPM (Fig. 4.6). Thus, human TK6 cells were 
pre-treated with 10nM MSH2 siRNA as before, followed by oligonucleotide from 2µM up to 
10µM (Fig. 4.9). In this experiment, up to 45% cytotoxicity was observed with 10µM 
oligonucleotide treatment (Fig. 4.9A). However, AD3-HPRTPM failed to induce mutation at 
the HPRT and TK loci (Fig. 4.9B and C, respectively). It is important to note that although 
AD3-HPRTPM induced mutation ~2 fold above the control oligonucleotide (Fig. 4.6B), this 
mutant frequency was similar to the untreated population of cells measuring the 
spontaneous mutant frequency.  
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Figure 4.10. Investigating the genotoxic effect of AD3-HPRTPM using human TK6 cells. An untreated 
population of cells was used to measure the spontaneous mutant frequency (Background) and 5μg/ml 
EMS was used as a positive genotoxin. Cytotoxicity is not evident following treatment of 3x106 TK6 
cells with 2μM, 5μM or 10μM oligonucleotide (A). AD3-HPRTPM failed to induce mutation at the 
targeted HPRT locus (B) and the non-targeted TK locus (C). Data represent mean ± SD of three 
independent treatments. 
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The above experiments describe TK6 cells pre-treated with siRNA to knockdown 
MSH2 protein expression. However, average MSH2 protein expression following 10nM 
siRNA treatment increased 1.2-1.4 fold above control by 24h (Fig. 4.7 and 4.8). Thus, at 
the time of treatment of TK6 cells with AD3-HPRTPM, average MSH2 protein expression 
was above basal level. The next plausible approach was to examine the genotoxicity of 
AD3-HPRTPM without siRNA treatment (Fig. 4.10). Cytotoxicity following oligonucleotide 
treatment up to 10µM was no greater than 30% (Fig. 4.10A). However, AD3-HPRTPM 
failed to induce mutation at the targeted HPRT and non-targeted TK loci above the 
detection limits of this assay (Fig. 4.10B and C, respectively).  
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Ergo, the initial genotoxicity observed with AD3-HPRTPM was not reproduced with/ 
without MSH2 siRNA pre-treatment using a dose range of oligonucleotide up to 10µM. 
Thus, it was important to validate the initial observation as a true mutagenic event. For this 
reason, a restriction fragment length polymorphism (RFLP) assay was designed. 
Mutant HPRT clones were picked from 96 well plates and expanded in 6-well plates 
for a week. Genomic DNA from clones was extracted and used for PCR amplification of 
exon 3 in the HPRT locus. In particular, a 177bp stretch encompassing the AD3-HPRTPM 
target sequence was amplified. According to TNE, AD3-HPRTPM mediated mutation 
should occur at the site of the mismatched base. AD3-HPRTPM was designed to induce a 
point mutation (G→T transversion) in exon 3 of the HPRT locus such that it causes the 
loss of a 5’-↓GATC-3’ Mbo I restriction enzyme recognition sequence. Thus, subjecting 
177bp PCR fragments to Mbo I restriction digestion should yield resistant fragments if 
AD3-HPRTPM induced site specific mutation. If mutation does not alter the 5’-GATC-3’ 
recognition sequence then PCR fragments will cleave into two fragments (~140bp and 
37bp). 
A typical PCR reaction is shown in Fig. 4.11A yielding a PCR fragment close to 
200bp (177bp). Out of 20 HPRT mutant clones from the control oligonucleotide treatment 
only 14 successfully PCR; Mbo I restriction enzyme digestion of 14 PCR products from 
control clones showed cleavage into two fragments (Fig. 4.11B). Thus, mutation in the 
control samples did not alter the 5’-GATC-3’ sequence within exon 3.  
Similarly, 35 HPRT mutant clones from the AD3-HPRTPM treatment were subject 
to PCR and only 28 were successful. These 28 PCR products were subject to Mbo I 
restriction digestion. Unexpectedly, all 28 PCR clones were cleaved by Mbo I into two 
fragments (Fig. 4.11C). As mentioned above, AD3-HPRTPM induced HPRT mutants ~2 
fold above the control oligonucleotide, but the magnitude of this mutation was similar to the 
spontaneous mutant frequency. Furthermore, this genotoxicity was not reproduced under 
 134 
 
Figure 4.11. Mbo I restriction enzyme digestion of PCR products. Isolated HPRT mutant clones from 
control (1-14) or AD3-HPRTPM (21-48) oligonucleotide treatments from Fig. 4.6B were subject to 
genomic DNA extraction followed by 30 cycles of PCR to yield a 177bp product. PCR reactions (50μl) 
contained 300ng of genomic DNA, 5U Tfi DNA polymerase, 200μM dNTP, 200nM primer pair 2 (Table 
2.4) and 2mM MgCl2. A typical PCR reaction using genomic DNA from control oligonucleotide clones 
is shown in panel A. From 20 control clones 14 successfully PCR and all were cleaved by Mbo I 
restriction enzyme (B). From 35 AD3-HPRTPM induced clones 28 successfully PCR and all cleaved 
by Mbo I restriction enzyme (C). 
B 
C 
A 
the same conditions in subsequent experiments. These data suggest that AD3-HPRTPM 
failed to induce site specific mutation above control oligonucleotide treatment and the 
spontaneous mutant frequency at the HPRT locus, under the conditions investigated so 
far. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A particular concern was that AD3-HPRTPM mediated site specific mutation within 
exon 3 of the HPRT locus would not result in a 6-TG resistant phenotype. To explore this 
further, an oligonucleotide was engineered to contain sequence homology to exon 3 of the 
HPRT locus except a single mismatched base (Val-HPRTPM). Point mutation induced by 
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Val-HPRTPM (C>T transition) has been previously reported to result in a 6-TG resistant 
phenotype (Meng et al., 2002). Mutation at this site is expected to change the codon from 
CTC (Leucine) to TTC (phenylalanine). Treating human TK6 cells with 2μM, 5μM and 
10μM Val-HPRTPM was not cytotoxic but nor was it genotoxic at the HPRT or TK loci (Fig. 
4.12). This supports the observations discussed above. However, it does not directly 
address whether AD3-HPRTPM mediated mutation results in a 6-TG resistant phenotype.  
As knockdown of MSH2 protein expression using RNAi technology failed, a MMR 
deficient cell line was employed to explore the role of MMR in oligonucleotide mediated 
genotoxicity. The HCT116 cells line has a mutation in the MLH-1 gene which renders the 
MMR signalling pathway redundant (Papadopoulos et al., 1994).  
HCT116 cells were treated with 5μM control, AD3-HPRTPM or Val-HPRTPM and 
plated to determine cytotoxicity and genotoxicity. Oligonucleotide treatment was not found 
to be cytotoxic nor was it genotoxic at the HPRT locus (Fig. 4.13). It is noteworthy that 
400μg/mL EMS was used as a positive genotoxin using HCT116 cells as opposed 5μg/mL 
EMS for TK6 cells to elicit a similar mutagenic response. Also, the spontaneous HPRT 
mutant frequency in HCT116 cells was ~200x10-6 as opposed to 5-10x10-6 for TK6 cells, in 
line with previous reports (Meng et al., 2002, Glaab, Kort & Skopek, 2000). This suggests 
a higher mutation rate in HCT116 cells as well as a requirement for greater genotoxin 
concentrations (80 fold) to elicit a mutagenic response. Thus, due to these factors, subtle 
induction of HPRT mutants by AD3-HPRTPM would be less likely to be detected using 
HCT116 cells as it would be masked by the spontaneous mutant frequency.  
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Figure 4.12. Investigating the genotoxic effect of Val-HPRTPM using human TK6 cells. Val-HPRTPM 
was engineered to induce a point mutation within the HPRT locus which has previously been reported 
to result in a 6-TG resistant phenotype. An untreated population of cells was used to measure the 
spontaneous mutant frequency (Background) and 5μg/ml EMS was used as a positive genotoxin. 
Cytotoxicity is not evident following treatment of 3x106 TK6 cells with 2μM, 5μM or 10μM 
oligonucleotide (A). Val-HPRTPM failed to induce mutation at the targeted HPRT locus (B) and the 
non-targeted TK locus (C). Data represent mean ± SD of three independent treatments. 
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Figure 4.13. Investigating the genotoxic effect of AD3-HPRTPM and Val-HPRTPM in a mismatch 
repair deficient cell line. Human colon epithelial HCT116 cells were treated with 5μM oligonucleotide. 
An untreated population of cells was used to measure the spontaneous mutant frequency 
(Background) and 400μg/ml EMS was used as a positive genotoxin. Cytotoxicity following treatment 
was not evident (A). All oligonucleotides failed to induce mutation at the targeted HPRT locus (B). 
Data represent mean ± SD of three independent treatments.  
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4.4.4. The of role of homologous recombination repair in antisense oligonucleotide 
genotoxicity 
The mechanism of mutation for oligonucleotide mediated TNE has been proposed to 
involve the HR repair pathway (Morozov & Wawrousek, 2008, Radecke et al., 2006). To 
investigate this further, human TK6 cells were pre-treated with the genotoxin MMS to 
induce the HR repair pathway. The RAD51 protein, which is involved in strand alignment 
during HR (Gupta et al., 1997, Sung & Robberson, 1995), was used as a marker for 
induction of HR repair activity.  
 The concentration range of MMS used to induce RAD51 protein expression in TK6 
cells was carefully considered, as a genotoxic response in subsequent mutagenicity 
studies may have masked subtle mutation induced by AD3-HPRTPM treatment. On this 
basis, TK6 cells were treated with 0μg/mL, 0.1μg/mL, 0.2μg/mL or 0.5μg/mL MMS for 24h. 
Following treatment, TK6 cells were washed to remove the treatment media and passaged 
for a further 48h. Treated TK6 cells were harvested at 2h, 4h, 8h, 24h, 48h and 72h for 
analysis of RAD51 protein expression by immunoblot (Fig. 4.14A). MMS induced RAD51 
protein expression was corrected for the GAPDH loading control and normalised to the 
control (0μg/mL) at the respective time. MMS treatment of TK6 cells showed a clear 
induction of RAD51 protein expression (Fig. 4.14B). At the lowest dose of MMS 
(0.1μg/mL), RAD51 protein expression was induced ~2.5 fold above control at 48h 
returning to basal level by 72h. The highest RAD51 protein induction occurred with 
0.2μg/mL MMS; RAD51 protein expression was almost 3 fold by 24h peaking up to ~5.5 
fold at 48h. The 0.5μg/mL MMS treatment weakly induced RAD51 protein expression (~2 
fold by 24h returning to basal by 48h). The lack of induction at this dose may be a result of 
the activation of an alternative repair mechanism or perhaps apoptosis due to the extent of 
cellular insult.  
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Figure 4.14. Inducing the homologous recombination repair pathway. TK6 cells were treated with the 
genotoxin MMS for 24h, washed and maintained in exponential growth for the desired time. Aliquots of 
cells were harvested at 2h, 4h, 8h, 24h, 48h and 72h. RAD51 protein expression was determined by 
immunoblot (A). GAPDH was used as a loading control (A). Lanes 1-4 are 0μg/ml, 0.1μg/ml, 0.2μg/ml 
and 0.5μg/ml MMS, respectively. Densitometry was used to quantitate protein expression. RAD51 
protein expression was corrected for the GAPDH loading control and normalised to 0µg/ml solvent 
control at the corresponding time (B).  
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RAD51 protein expression was found to be maximally induced from 24h to 48h with 
0.2μg/mL MMS. Thus, TK6 cells were pre-treated with 0.2μg/mL MMS for 24h, washed 
and treated with oligonucleotide (Fig. 4.15). In this study, Val-HPRTPM was included as an 
oligonucleotide control targeting the HPRT locus where mutation at the site of the 
mismatched bases would result in 6-TG resistance, as previously discussed (section 
4.4.3). Additionally, untreated TK6 cells (Untreated) i.e. without 24h MMS treatment were 
included to investigate the cytotoxic/genotoxic effect of the MMS pre-treatment.  
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 Following oligonucleotide treatment, dose dependent cytotoxicity was observed up 
to 10μM oligonucleotide (Fig. 4.15A). Cytotoxicity was no greater than 65% which is less 
than the maximum accepted 80% for this assay (Clements, 2000, Clive et al., 1995).  
 The HPRT and TK mutant frequency between the untreated and MMS pre-treated 
cultures were not significantly different (Fig. 4.15B and C, comparing untreated and 
background). Thus, the MMS pre-treatment was not found to be significantly genotoxic.  
 Most interestingly, AD3-HPRTPM induced a dose dependent increase in HPRT 
mutants. Treatment of TK6 cells with 5µM AD3-HPRTPM induced the HPRT mutant 
frequency ~1.5 fold above 5µM control oligonucleotide treatment whereas 10µM treatment 
induced the HPRT mutant frequency ~4.4 fold (Fig. 4.15B). Similarly, 10μM Val-HPRTPM 
induced HPRT mutants ~4 fold above 10µM control oligonucleotide treatment (Fig. 4.15B). 
As expected, both AD3-HPRTPM and Val-HPRTPM failed to induce mutation at the non-
targeted TK locus (Fig. 4.15C). Thus, both AD3-HPRTPM and Val-HPRTPM were capable 
of sequence specific and locus specific mutation when RAD51 protein expression was 
induced in human TK6 cells.  
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Figure 4.15. Investigating the genotoxic effect of AD3-HPRTPM in a HR repair induced system. TK6 
cells were pre-treated with 0.2μg/ml MMS for 24h to induce HR repair activity, except the untreated 
treatment which measures the cytotoxic/genotoxic effect of the MMS pre-treatment. The background 
treatment measures the spontaneous mutant frequency following MMS pre-treatment and 5μg/ml 
EMS was used as a positive genotoxin. Viability below the minimum accepted 20% RTG is not evident 
following treatment of 3x106 TK6 cells with 2μM, 5μM or 10μM oligonucleotide (A). AD3-HPRTPM 
induced a dose dependent increase in HPRT mutants up to 4.4 fold (B). Val-HPRTPM (10μM) induced 
HPRT mutants to a similar magnitude as 10μM AD3-HPRTPM (B). Both oligonucleotides failed to 
induce mutation at the non-targeted TK locus (C). Data represent mean ± SD of three independent 
treatments. * p<0.05 using two-way students t-test. 
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According to TNE, mutation within duplex DNA is directed to the site of the mismatched 
base (Bonner & Kmiec, 2009, Olsen et al., 2009, Morozov & Wawrousek, 2008, Aarts et 
al., 2006, Radecke et al., 2006, Olsen et al., 2005, Dekker, Brouwers & te Riele, 2003). 
Thus, to confirm sequence specific mutation by AD3-HPRTPM at the HPRT locus, a RFLP 
assay was designed as discussed in section 4.4.3. In this instance, the target region of 
AD3-HPRTPM, within exon 3 of the HPRT locus, was PCR amplified to yield a 1kb 
fragment. AD3-HPRTPM mediated mutation at the site of the mismatched base would be 
expected to result in a G>T transversion causing the loss of the 5’-GATC-3’ Mbo I 
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restriction enzyme recognition sequence to 5’-TATC-3’. Thus, PCR fragments containing 
the mutant sequence would be rendered resistant to Mbo I digestion. Those which 
retained the wild-type sequence would yield 2 cleavage products of ~550bp and ~450bp. 
HPRT mutant clones from 10µM AD3-HPRTPM or control oligonucleotide treatment 
were isolated, expanded for up to 10 days and harvested for genomic DNA extraction and 
PCR amplification. Interestingly, Mbo I digestion of 14 control and 29 AD3-HPRTPM 
induced HPRT mutant clones all resulted in cleavage of all PCR products into 2 fragments, 
contradicting the expected mechanism of mutagenesis (Fig. 4.16A and B). Those which 
failed to PCR across the 1kb sequence in exon 3, were subject to PCR amplification 
across a 177bp stretch and Mbo I digested (Fig. 4.16C). Those which failed to PCR across 
exon 3 of the HPRT locus using primer pairs 2 and 3 (Table 2.4) were subject to PCR 
amplification across the GAPDH locus to inform the integrity of the genomic DNA (primer 
pair 4, Table 2.4). From the 4 control and 5 AD3-HPRTPM induced clones, all successfully 
PCR across the GAPDH locus (Fig. 4.16D). This suggests there may be a problem across 
or within exon 3 in these samples such that the primer (s) could not bind to PCR amplify 
the region.   
To further investigate the molecular nature of mutation within exon 3 of HPRT 
mutant clones, 1kb PCR products were sent for DNA sequencing. Raw sequence data 
was analysed using EBI multiple sequence alignment tool CLUSTALW. Mutation in each 
spectrum was then manually confirmed using NCBI-BLAST. Sequencing of PCR amplified 
HPRT mutant clones (41 AD3-HPRTPM induced HPRT mutant clones and 29 control) 
supported the retention of the wild-type 5’-GATC-3’ sequence at position 138 (Fig. 4.17). 
However, DNA sequencing revealed a single base deletion (position 171; 34%) adjacent to 
a single G>A transition mutation (position 172; 29%) downstream of the AD3-HPRTPM 
target sequence (underlined; position 134-156). Importantly, these mutations were 
primarily found in AD3-HPRTPM induced HPRT mutant clones and not control. All of the 
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G>A transition mutations (position 172) were found to be adjacent to the single thymidine 
deletion at position 171. The frequency of particular point mutations upstream (G>A 
position 126; 58% control vs. 81% AD3-HPRTPM) and downstream (G>A position 158; 
19% control vs. 51% AD3-HPRTPM) of the AD3-HPRTPM target sequence were also 
found to be effected following AD3-HPRTPM treatment (Fig. 4.17). Also, ~86% of clones 
harbouring the thymidine deletion at position 171 either had a G>A transition at position 
175 or a G>A transition at position 158 (although the frequency of the G>A transition at 
position 175 was greater than mutation at position 158; 57% vs. 43%, respectively).  
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Figure 4.16. Mbo I restriction enzyme digestion of HPRT mutant PCR products. In brief, isolated 6-TG 
resistant clones from 10µM control (1-18) or AD3-HPRTPM (19-53) oligonucleotide treatments were 
subject to DNA extraction followed by 30 cycles of PCR to yield a 1018bp product encompassing the 
AD3-HPRTPM target sequence in exon 3. PCR reactions (50μl) contained 300ng of genomic DNA, 
5U Tfi DNA polymerase, 200μM dNTP, 200nM primer pair 3 (Table 2.4) and 2mM MgCl2. A typical 
PCR reaction is shown for control (A) and AD3-HPRTPM (B) oligonucleotide clones. From 18 control 
HPRT clones, 14 successfully PCR and all cleaved by Mbo I restriction enzyme (A). From 35          
AD3-HPRTPM induced HPRT clones 29 successfully PCR and all cleaved by Mbo I restriction 
enzyme (B). Those which failed to PCR across the 1kb HPRT sequence, were subjected to PCR 
across a 177bp region (C). Only clone 49 successfully PCR but was also cleaved by Mbo I. Those 
which failed to PCR across the HPRT locus were subject to PCR across the GAPDH locus using 
primer pair 4 (Table 2.4) (D). All clones successfully PCR across GAPDH.  
PCR PCR 
GAPDH 
Mbo I Mbo I 
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Figure 4.17. Distribution of AD3-HPRTPM mediated mutation in exon 3 of the HPRT locus. PCR products (1kb) from Fig. 4.16 were sent for DNA 
sequencing to inform the mechanism of AD3-HPRTPM mutation. Sequences are numbered from the first base of exon 3 (1 to 164). The AD3-HPRTPM 
target sequence is underlined from position 134-156. * above guanine (position 138) indicates the site of the mismatched base in AD3-HPRTPM where 
G>T transversion mutation was predicted. Numbers and letters within a circle represent the frequency (%) and type of mutation from 41 AD3-HPRTPM 
induced HPRT mutant clones whereas those in a square are from 29 control induced HPRT mutant clones. + indicates an insertion and ∆ indicates a 
deletion. Mutation common to both control and AD3-HPRTPM with the same frequency have been removed from the figure for clarity.     
 
 145 
 
4.5. Discussion 
Data presented in this study suggest that a biologically active ASO, AD3-HPRTPM, 
was capable of inducing mutation at genomic DNA in human lymphoblastoid cells when 
RAD51 protein expression was induced. Oligonucleotides have been previously reported 
to be capable of inducing mutation within a homologous sequence in duplex DNA, in a 
process known as TNE, where mutation was a result of a mismatched base within the 
oligonucleotide (Bonner & Kmiec, 2009, Olsen et al., 2009, Papaioannou, Disterer & 
Owen, 2009, Morozov & Wawrousek, 2008, Maguire & Kmiec, 2007, Aarts et al., 2006, 
Radecke et al., 2006, Olsen et al., 2005, Dekker, Brouwers & te Riele, 2003, de Wind et 
al., 1995, te Riele, Maandag & Berns, 1992)(Dekker, Brouwers & te Riele, 2003)(Dekker, 
Brouwers & te Riele, 2003). Furthermore, Bonner et al. (Bonner & Kmiec, 2009) reported 
DNA DSBs were a consequence of TNE; however, DNA DSBs were only reported once 
comet tail intensities were normalised to cytotoxicity following electroporation of 
oligonucleotides; a treatment which itself can result in DNA DSBs (Lepik et al., 2003). In 
this study, Dloop27 targeting genomic DNA was not mutagenic or clastogenic using the in 
vitro micronucleus assay conducted to OECD guidelines 
(http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/ OECD-TG487.pdf).  
An important point to consider is that oligonucleotides employed in previous studies 
reporting TNE tend to be greater than 47 nucleotides in length and contain a single 
mismatched base relative to the target sequence. Thus, in this study, AD3-HPRTPM (23 
nucleotides in length) was engineered to reflect the length of an ASO therapeutic and 
chemically modified to contain phosphorothioate linkages, which is the most common 
modification used in ASO therapeutics (Geary, 2009, Buchini & Leumann, 2003). 
Although AD3-HPRTPM was biologically active as an antisense molecule, reducing 
ADAMTS3 expression by 70%, mutation at the targeted HPRT locus in untreated human 
lymphoblastoid TK6 cells was not observed above the detection limit of the assay. 
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However, in a system where RAD51 protein expression was stimulated prior to treatment 
with oligonucleotide, AD3-HPRTPM induced locus and sequence specific mutation ~4.4 
fold (40x10-6) above control (9x10-6). TNE by a micro-injected oligonucleotide was also 
absent in one cell mouse embryos until coinjection of purified RAD51 protein with 
oligonucleotide (Morozov & Wawrousek, 2008). In that instance, mutant frequencies were 
in the order of 9.9% (99,000x10-6) when 313 cells were screened which is significantly 
higher than reported here. A similar observation as this study was made using an E. Coli 
strain which lacked functional RecA protein (a RAD51 homolog) where TNE to correct a 
kanamycin resistance gene was absent until purified RecA was supplied with 
oligonucleotide (Drury & Kmiec, 2003). However, in the study presented here, RAD51 
protein was not exogenously supplied but rather endogenously induced. 
 Using an engineered mutant GFP construct, mutant frequencies by a 74mer 
oligonucleotide were found to be in the order of 2% using the mismatch deficient HCT116 
cell line (Bonner & Kmiec, 2009). In the study presented here, using a genomic DNA 
target, AD3-HPRTPM failed to induce mutation using the HCT116 cell line, possibly a 
result of higher spontaneous mutation in these cells masking subtle genotoxicity. In 
support of this, the spontaneous HPRT mutant frequency was observed to be remarkably 
higher in HCT116 cells (200x10-6) than in TK6 cells (~5x10-6). Additionally, HCT116 cells 
have functional MSH2 protein so it can still exert its anti-recombinogenic activity (de Wind 
et al., 1995, te Riele, Maandag & Berns, 1992); HR repair has been reported to be 
inhibited by MSH2 protein when DNA in homologous pairing has greater than 0.6% 
sequence divergence (de Wind et al., 1995). For example, a 47mer oligonucleotide with a 
single mismatched base would correlate to ~2% sequence divergence, whereas AD3-
HPRTPM would have a sequence divergence of 4.3%. This may explain why AD3-
HPRTPM mediated genotoxicity was not observed until RAD51 protein expression was 
sufficiently induced to overcome the inhibitory effects of MSH2 protein.    
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Sequencing AD3-HPRTPM induced HPRT mutant clones revealed the predicted 
mutation at the site of the mismatched base was absent in all clones. However, amongst 
other mutations, a single base deletion and point mutation adjacent to but downstream of 
the AD3-HPRTPM target sequence was observed in mutant clones primarily treated with 
AD3-HPRTPM. AD3-HPRTPM binding to its target sequence on the sense strand (non-
transcribed) may be facilitated by the strand pairing properties of RAD51 protein perhaps 
during DNA replication. Indeed, the ability of RAD51 to pair single stranded DNA with 
homologous double stranded DNA in an adenosine triphosphate (ATP) dependent process 
has been previously reported (Gupta et al., 1997, Baumann, Benson & West, 1996, Sung 
& Robberson, 1995). Upon strand invasion of AD3-HPRTPM, a D-loop structure is formed 
which results in the displacement of the antisense strand. Following this, the model can be 
extrapolated from Hanawalt (Hanawalt, 1994) and Wang (Wang, Seidman & Glazer, 
1996). The D-loop structure may result in a physical blockade to a progressing replication 
fork causing it to revert back to a natural pause site generating a reiterative repair patch. 
Repeated attempts in progression of a replication fork may result in mutation introduced by 
the natural error frequency of the polymerase. It may be the bound AD3-HPRTPM is 
removed by the helicase activity associated with a replication fork but repeated cycles of 
binding inhibition of replication and re-iterative repair may increase the probability of a 
mutagenic event.  
Alternatively, perhaps through HR repair during S-phase (Johnson & Jasin, 2001, 
Takata et al., 1998), AD3-HPRTPM physically incorporates into the genome (Radecke et 
al., 2006). The influence of cell cycle progression has been reported to affect TNE with 
optimum mutation occurring during early S phase (Olsen et al., 2005). Once incorporated, 
AD3-HPRTPM with the mismatched base and the non-canonical phosphorothioate 
linkages at either end may stimulate the nucleotide excision repair (NER) pathway in 
recognising the sulphur within the phosphodiester backbone as a lesion, ultimately 
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resulting in the excision of an encompassing fragment of 27-29nt in length (Svoboda et al., 
1993, Huang et al., 1992). In support of this, the introduction of phosphorothioate bonds 
into a DNA double helix has been reported to cause structural alterations (Kanaori et al., 
1999), which may stimulate the repair pathway. This latter mechanism may explain why 
the mismatched base from AD3-HPRTPM treatment was not observed in HPRT mutant 
clones but observed in previous studies using oligonucleotides that are far greater in 
length than the NER repair pathway is able to cleave.  
Recent efforts have focused on efficient and site specific delivery methods to 
improve bioavailability/ biological efficacy of ASO therapeutics and reduce susceptibility to 
degradation by nucleases in blood (Morvan et al., 1993, Akhtar, Kole & Juliano, 1991, 
Hoke et al., 1991). However, increasing intracellular concentration of ASO as a result of 
efficient delivery systems may increase the probability of binding to genomic DNA, which 
may in turn result in an increased risk of introducing heritable sequence alterations.    
These data suggest that an ASO could induce mutation if it is involved in strand 
invasion mediated by high RAD51 protein activity.  
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Chapter 5  
Incorporation and genotoxicity of oligonucleotide degradation 
products into the genome 
 
5.1. Introduction 
ASO therapeutics can be used to modulate protein expression in a mechanism known as 
RNAi (Denli & Hannon, 2003, Zamore, 2001). However, ASO therapeutics are chemically 
modified to offer protection from nuclease mediated degradation in order to remain 
biologically active. One of the most common chemical modifications used in ASO design is 
the phosphorothioate linkage (Geary, 2009, Buchini & Leumann, 2003, Pirollo et al., 2003); 
here, a non-bridging oxygen in the 5’ phosphate moiety, that forms the sugar phosphate 
backbone, is replaced with sulphur. This confers resistance of the ASO to nuclease 
degradation (Kenner et al., 2002, Eckstein, 1985). As described in section 3.4.4, a 
phosphorothioate modified oligonucleotide had a half-life in cell culture media over 24h 
whereas the unmodified counterpart (containing a phosphodiester backbone) was 
degraded with a half-life of 3h (Fig. 3.10). Similarly, an unmodified oligonucleotide has 
been reported to degrade in human serum within 30 mins (Akhtar, Kole & Juliano, 1991).  
Although phosphorothioate linkages offer nuclease resistance, they can be 
degraded over time at a much slower rate relative to phosphodiester linkages to release 
monophosphate nucleotide analogues (Spitzer & Eckstein, 1988). The likelihood of 
chemically modified oligonucleotide based therapeutics (e.g. ASO) to degrade and release 
potentially genotoxic nucleotide analogues was a concern highlighted by the EMA 
(European Medicines Agency, 2004); it was proposed that if nucleotide analogues could 
enter endogenous nucleotide pools and become a substrate for DNA polymerase, base-
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pairing in newly synthesised DNA may occur with reduced fidelity increasing the probability 
of mutation.  
It may be that perturbation of intracellular dNTP pools by the presence of nucleotide 
analogues may exert a mutagenic effect. Indeed, the balance of cellular dNTP pools is 
known to be critical to maintain the fidelity of DNA replication and ensure the integrity of 
the genome (Kunz, 1988, Meuth, 1984, Meuth, 1981b, Reichard, 1978). This pre-requisite 
has been demonstrated in several studies, for example, supplementing mammalian cells 
with 1mM or 3mM thymidine inhibited DNA synthesis by 90% (Bjursell & Reichard, 1973) 
and induced GC→AT transition mutations in runs of guanine (Kresnak & Davidson, 1992), 
respectively. Further to this, exogenous supply of 5µM deoxyadenosine was reported to 
increase mutation at the genomic HPRT locus up to 59 fold in human CCRF-CEM 
lymphoblast cells (Mattano, Palella & Mitchell, 1990).  
Nucleoside analogues have also been adapted for use as viral therapeutics (Lee, 
Hanes & Johnson, 2003, Ward & Duchin, 1997). In particular, AZT has been used in the 
United States of America to decrease the rate of perinatal transmission of HIV-1 (Ward & 
Duchin, 1997). However, AZT has been shown to be mutagenic, cause chromosome 
aberrations and induce epithelial neoplasms in rats and mice (Sussman et al., 1999, Ayers 
et al., 1996).  
Nucleoside analogues used in viral therapy are not used in ASO therapeutic design. 
Thus, it was important to inform the potential for nucleotide analogues used in 
oligonucleotide based therapeutics to incorporate into newly synthesised DNA and cause 
mutation.  
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5.2. Experimental outline 
The study presented here reports (i) the potential for nucleotide analogues, used in ASO 
design, to incorporate into newly synthesised DNA and (ii) the genotoxicity of nucleotide 
analogue incorporation in human lymphoblastoid TK6 cells. 
 In brief, the ability of Tfi DNA polymerase to incorporate various nucleotide 
analogues into a primed DNA template, in vitro, was investigated using a method 
extrapolated from Lacenere et al. (Lacenere et al., 2006). In this method, duplex DNA is 
engineered to contain a 5’ fluorophore on the primer strand (25mer) whilst the template 
strand has either one or five 5’ nucleotide overhang (Fig. 5.1). If DNA polymerase was 
capable of extending the primer strand (5’ to 3’) it would be visible as a band of reduced 
migration following electrophoresis through polyacrylamide gel. Under certain conditions, 
Tfi DNA polymerase was capable of utilising nucleotide analogues, but could not fully 
extend the primed template. In these instances, the reaction time was increased until the 
template was fully extended. Comparing the time and dose required to fully extend the 
primed template using nucleotide analogue with the time and dose required to extend the 
primed template using the unmodified nucleotide counterpart informed the incorporation 
efficiency of that particular nucleotide analogue.  
 Once a nucleotide analogue was shown to incorporate into a primed template, the 
genotoxicity of this incorporation relative to the unmodified counterpart was assessed in 
human TK6 cells using the HPRT and TK forward mutation assays. Clastogenic and 
aneugenic activity following nucleotide analogue incorporation was assessed using the in 
vitro micronucleus assay according to OECD guideline 487 (http://iccvam.niehs.nih.gov/ 
SuppDocs /FedDocs/OECD/OECD-TG487.pdf). 
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Figure 5.1. Template used in the in vitro primer extension assay. Primer strand (25nt) was 
conjugated 5’ with 6FAM fluorophore for detection. Either, A1, A5 of C5 template strands were 
annealed to primer strand to produce a single or five 5’ nucleotide overhang. Primed template was 
incubated with nucleotide and Tfi DNA polymerase, denatured and electrophoresed. Extended 
primer strand (green arrow) appeared as a band of reduced migration relative to unextended primer 
strand if DNA polymerase could incorporate nucleotide. Oligonucleotide sequences used in the 
primer extension assay are listed in Table 2.5. 
5.3. Methods 
1. Primer extension assays are described in section 2.1.8. 
2. The HPRT and TK forward mutation assay for nucleotide treatments are described 
in sections 2.3.5 and 2.4. 
3. The in vitro micronucleus assay is described in section 2.4.3. 
4. RNA extraction is described in section 2.2.4. 
5. PCR is described in section 2.5. 
  
Primer strand 
Template strand 
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Figure 5.2. The chemical structure of adenine based nucleotides. Canonical dATP is shown in part A. 
A phosphorothioate nucleotide analogue (dATPαS) where a non-bridging oxygen in the α-phosphate 
group is replaced with sulphur is shown in B. A 2’O-methyl-ribose-ATP nucleotide analogue has an O-
methyl group on the 2’ position of the ribose moiety of ATP is shown in C. The red circle depicts the 
position of the modification in each nucleotide analogue. Images were adapted from the manufacturer 
(Jena Bioscience, Germany). 
5.4. Results 
5.4.1. In vitro incorporation efficiency of nucleotide analogues  
In the first instance, a primed template (Fig. 5.1) with a single thymidine nucleotide 
overhang was used to measure incorporation of dATP up to 5µM (Fig. 5.2A). Single 
nucleotide incorporation would allow determination of the Kd and maximum speed of 
incorporation (Vmax) for each nucleotide analogue (Boosalis, Petruska & Goodman, 
1987). However, gels could not clearly distinguish between unextended and extended 
primed template using dATP, although it appeared to fully extend the primer strand around 
0.5µM (Fig. 5.3). To clearly define incorporation of dATP, the overhang on the template 
strand was extended to five thymidine nucleotides. Using this extended template, Tfi DNA 
polymerase was clearly capable of fully extending the primer strand using 0.5µM dATP in 
a 10 minute reaction (Fig. 5.4). Below 0.5µM, intermediate lengths of primer strand could 
be seen. This concluded that an overhang of five nucleotides was appropriate for detecting 
nucleotide incorporation and was used in subsequent experiments.  
  
B 
A 
C 
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Figure 5.3. Single nucleotide incorporation of dATP. Primer strand (25nt) and A1-template strand 
(26nt) were annealed together to produce a primed template with one 5’ thymidine nucleotide 
overhang (Table 2.5). The ability of Tfi DNA polymerase to extend the primer strand by one nucleotide 
can be observed as a band of reduced migration relative to unextended primer strand (0µM). The 
numbers above each lane are dose of nucleotide (μM). Samples were resolved through 15% urea-
polyacrylamide gel. Tfi DNA polymerase appeared to fully extend primed template by one nucleotide 
using 0.5µM dATP in a 10 minute reaction. However, bands are not clearly resolved.  
Figure 5.4. Incorporation of dATP using an extended template. Primer strand (25nt) and A5-template 
strand (30nt) were annealed together to produce a primed template with five 5’ thymidine nucleotide 
overhang (Table 2.5). The number above each lane is the concentration of nucleotide (μM). The 
ability of Tfi DNA polymerase to extend the primer strand by five nucleotides can be observed as a 
pronounced band of reduced migration relative to unextended primer strand (0µM). Tfi DNA 
polymerase clearly extended the primed template to completion using 0.5µM dATP in a 10 minute 
reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To investigate the capability of Tfi DNA polymerase to incorporate nucleotide 
analogues derived from ASO therapeutics, the above in vitro primer extension assay was 
employed. Using a phosphorothioate nucleotide analogue (dATPαS) where a non-bridging 
oxygen in the alpha phosphate moiety is replaced with sulphur (Fig. 5.2B); the most 
common modification used in ASO therapeutics to increase nuclease resistance and 
bioavailability (Geary, 2009, Buchini & Leumann, 2003), Tfi DNA polymerase was capable 
of incorporating dATPαS to extend the primed template (Fig. 5.5A). Progressive bands of 
reduced migration were evident with increasing dose of dATPαS and fully extended 
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Figure 5.5. Incorporation kinetics of phosphorothioate nucleotide analogue dATPαS. Primer strand 
(25nt) and A5-template strand (30nt) were annealed together to produce a primed template with five 
5’ thymidine nucleotide overhang (Table 2.5). The number above each lane is the concentration of 
nucleotide (μM). Primed template was incubated with dATPαS up to 5µM in a 10 minute (A) and 20 
minute reaction (B). As a positive control in each reaction (lane C), 5µM dATP was used to depict a 
fully extended template. In a 10 minute reaction, Tfi DNA polymerase was capable of using dATPαS 
but could not extend the primed template to completion (A). Using a 20 minute reaction time, Tfi DNA 
polymerase fully extended primed template using 2µM dATPαS (B).  
template can be seen from 1µM. However, Tfi DNA polymerase failed to completely 
extend all the primed templates so the reaction time was increased to 20 mins using the 
same concentrations of dATPαS. Using this extended reaction time, Tfi DNA polymerase 
fully extended primed template using 2μM dATPαS (Fig. 5.5B). This utilisation of dATPαS 
correlates to ~12% incorporation efficiency (8 fold less) compared to the unmodified 
nucleotide counterpart dATP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A common modification used to increase ASO target binding affinity is replacing the 
2’hydroxyl group of the sugar moiety (within a ribonucleotide) with 2’O-methyl (Yoo et al., 
2004). A 2’O-methyl-adenosine triphosphate (2’OMe-ATP) nucleotide analogue was also 
investigated to inform its potential to incorporate into a primed template (Fig. 5.2C). 
B 
A 
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Figure 5.6. Incorporation kinetics of 2’O-methyl ribose modified nucleotide analogue 2’OMe-ATP. 
Primer strand (25nt) and A5-template strand (30nt) were annealed together to produce a primed 
template with five 5’ thymidine nucleotide overhang (Table 2.5). The number above each lane is the 
concentration of nucleotide (μM). Primed template was incubated with 2’OMe-ATP up to 5µM in a 10 
minute (A) and 60 minute reaction (B). As a positive control in each reaction (lane C), 5µM dATP was 
used to depict a fully extended template. Tfi DNA polymerase failed to incorporate 2’OMe-ATP up to 
5μM in a 10 minute (A) and 60 minute reaction (B) whereas the positive control worked suggesting a 
viable experiment.  
Incubating Tfi DNA polymerase with 2’OMe-ATP up to 5µM in a 10 minute reaction failed 
to extend the primed template so the reaction time was increased (Fig. 5.6A). Tfi DNA 
polymerase failed to incorporate 2’OMe-ATP up to 5µM in an extended 60 minute reaction 
(Fig. 5.6B). The positive control (dATP) in each experiment was fully incorporated 
suggesting a viable experiment (Lane C, Fig. 5.6A and B). These data suggest that Tfi 
DNA polymerase cannot use 2’OMe-ATP to extend a primed template in vitro and the 
incorporation efficiency of 2’OMe-ATP relative to dATP is <<1.7%.  
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Figure 5.7. The chemical structure of cytidine based nucleotides. Canonical dCTP is shown in part A. 
5Me-dCTP is shown in part B. The red circle depicts the position of the modification in the nucleotide 
analogue. Images were taken from the nucleotide data sheets supplied by the manufacturer (Jena 
Bioscience, Germany). 
An alternative modification used in pyrimidine motif based TFO and ASO 
therapeutics is 5-methyl cytosine (Fig. 5.7; discussed in sections 1.2.1 and 1.3.1) which is 
used to alleviate the pH dependence of triplex formation and avoid an immune response 
with ASO therapeutics (Krieg, 1999, Xodo et al., 1991, Lee et al., 1984). The incorporation 
efficiency of this nucleotide analogue and its unmodified counterpart was investigated 
using a primed template as described above. In the first instance, the incorporation 
efficiency of canonical dCTP was informed (Fig. 5.7A). Incubation of Tfi DNA polymerase 
with dCTP in a 20 minute reaction fully extended the primed template using 5μM 
nucleotide (Fig. 5.8A). Using 5-methyl dCTP (5Me-dCTP), Tfi DNA polymerase fully 
extended primed template in a 40 minute reaction (Fig. 5.8B). The incorporation efficiency 
of 5Me-dCTP is approximately 50% relative to dCTP.  
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Figure 5.8. Incorporation kinetics of dCTP and 5Me-dCTP. Primer strand (25nt) and C5-template 
strand (30nt) were annealed together to produce a primed template with five 5’ guanine nucleotide 
overhang (Table 2.5). Primed template was incubated with dCTP up to 5µM in a 20 minute reaction 
(A) or with 5Me-dCTP in a 40 minute reaction (B). As a positive control in part B (lane C), 5µM dCTP 
was used to depict a fully extended template. Tfi DNA polymerase fully extended primed template 
using 5μM dCTP in a 20 minute reaction (A) whereas it took a 40 minute reaction using 5μM 5Me-
dCTP (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4.2. Genotoxic fate of canonical nucleotides 
Previous studies have reported that exogenous supply of canonical nucleotides can have 
a genotoxic effect if perturbation of intracellular nucleotide pools occurs (Mattano, Palella 
& Mitchell, 1990, Phear, Nalbantoglu & Meuth, 1987). If an ASO was not chemically 
modified i.e. one that contained canonical bases, sugar moieties and a phosphodiester 
backbone, it would be rapidly degraded by serum nucleases (Akhtar, Kole & Juliano, 
1991); in section 3.4.4, it was shown that an unmodified 27mer oligonucleotide (PO-
TFO27) had a half-life of ~3h in cell culture media, whilst a 15mer was previously reported 
to be completely degraded within 30 mins in human serum (Akhtar, Kole & Juliano, 1991). 
Nuclease mediated degradation of an unmodified ASO therapeutic would release excess 
conical nucleotides (Tanaka & Nyce, 2001) which may perturb endogenous nucleotide 
B 
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pools and cause mutation. In the study presented here, the genotoxic effect of 
deoxyadenosine, deoxyadenosine monophosphate (dAMP) and dATP was investigated 
using the established HPRT and TK forward mutation assay. 
 Human lymphoblastoid TK6 cells (4x106) were treated with nucleotide from 20µM 
up to 1mM for 24h. Viability following treatment with all canonical nucleotides was not 
below the accepted 20% RTG for this assay (Fig. 5.9A). Treatment with deoxyadenosine 
and dAMP resulted in dose dependent cytotoxicity up to 40% cell death (Fig. 5.9A). 
However, dATP failed to induce any cell death following treatment (Fig. 5.9A). 
  Treatment of TK6 cells with deoxyadenosine induced dose dependent mutation at 
the HPRT and TK loci up to 3 and 1.8 fold above control (0mM), respectively, with an 
increase in the proportion of small TK mutant clones from 14% in control up to 26% with 
1mM treatment (Fig. 5.9B-D). An increase in small TK mutant colonies may suggest large 
inter-gene deletions or chromosome aberrations involving the TK gene in these clones 
which may affect the rate of growth due to the extent of genomic insult or perhaps a result 
of mutation within an adjacent growth regulatory gene (Liechty et al., 1998, Applegate et 
al., 1990, Moore et al., 1985, Hozier et al., 1981); although such a gene has never been 
identified (Liechty et al., 1998). 
 Interestingly, treating TK6 cells with dAMP resulted in a dose dependent increase in 
TK mutants up to 1.7 fold above control (Fig. 5.9B). In this case also, an increase in the 
proportion of small clones was evident (Fig. 5.9C). However, dAMP failed to induce HPRT 
mutants above control (Fig. 5.9D). This may suggest the TK locus was more sensitive in 
detecting mutation induced by dAMP or that dAMP mediated mutation within the HPRT 
locus was lethal to the cell or did not result in a 6-TG resistant phenotype. Certain types of 
mutation within the HPRT locus are known to be lethal to a cell; for example inter-gene 
deletions, whilst the TK locus is a more robust reporter capable of detecting point 
mutations, deletions, chromosome aberrations and even recombination events (Doak et 
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al., 2007, Liechty et al., 1998, McGregor et al., 1996, Applegate et al., 1990, Yandell, Dryja 
& Little, 1986).  
 Most peculiar was the treatment of TK6 cells with dATP up to 1mM did not induce 
TK mutants (Fig. 5.9B) but induced dose dependent mutation at the HPRT locus up to 2.7 
fold (Fig. 5.9D). However, the increase in mutant frequency was not statistically significant 
(p>0.05). Perhaps dATP mediated mutation at the TK locus did not result in a TFT 
resistant phenotype. 
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Figure 5.9. Genotoxicity of canonical nucleotides. TK6 cells (4x106) were treated with nucleotide up to 1mM for 24h. Cytotoxicity following treatment with 
nucleotides was not below the accepted 20% RTG for this assay (A). Deoxyadenosine and dAMP induced dose dependent mutation at the TK locus up 
to 1.8 fold whilst treatment with dATP did not (B). Deoxyadenosine and dAMP treatment resulted in an increase in the proportion of small TK mutant 
clones (C). Deoxyadenosine and dATP treatment resulted in dose dependent mutation at the HPRT locus up to 3 fold and 2.7 fold, respectively, whilst 
treatment with dAMP failed to induce mutation at the HPRT locus (D). Data represent mean ± SD of three independent treatments. Data is compared to 
negative control (0mM) for each nucleotide using one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test. * p<0.05. 
B A 
C D 
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5.4.3. Genotoxic fate of a phosphorothioate nucleotide analogue 
Having shown a phosphorothioate nucleotide analogue could be used by Tfi DNA 
polymerase to extend a primed template in vitro (section 5.4.1); the potential for utilisation 
in vivo was investigated using human TK6 cells. Mutation caused by nucleotide analogue 
utilisation/ incorporation into genomic DNA was informed using the HPRT and TK forward 
mutation assay whilst aneugenic/ clastogenic activity was informed using the micronucleus 
assay conducted to OECD guidelines (OECD guideline 487; http://iccvam.niehs.nih.gov/ 
SuppDocs /FedDocs/OECD/OECD-TG487.pdf). 
 Of important consideration was that degradation of an oligonucleotide would not 
yield nucleotides as a triphosphate but rather as monophosphates. Thus, to reflect a true 
biologically relevant event, taking into account the prerequisite for phosphorylation of 
monophosphate nucleotides into triphosphates before utilisation by DNA polymerase, 
human TK6 cells were treated with monophosphate phosphorothioate nucleotide dAMPαS.  
 Human lymphoblastoid TK6 cells (4x106) were treated with dAMPαS up to 1mM for 
24h. As a nucleotide control, TK6 cells were also treated with 1mM of the unmodified 
nucleotide counterpart, dAMP. This would inform the genotoxicity caused by the single 
substitution of oxygen for sulphur in the 5’ phosphate group in dAMPαS (Fig. 5.2B).  
 Treating TK6 cells with dAMPαS up to 0.5mM was not cytotoxic above the 
maximum recommended 80% for this assay (30% RTG; Fig. 5.10A). However, 1mM 
dAMPαS was significantly cytotoxic (10% RTG) which prompted caution when interpreting 
genotoxicity data. Interestingly, the magnitude of cytotoxicity following 1mM dAMP 
treatment (54% RTG) was much less than treatment with 1mM dAMPαS suggesting the 
nucleotide analogue was more cytotoxic (Fig. 5.10A). 
Phenomenally, treating TK6 cells with 0.5mM and 1mM dAMPαS resulted in TK 
mutant frequencies of 317x10-6 and 1540x10-6, which is equivalent to an increase of ~20 
fold and ~96 fold above control, respectively (Fig. 5.10A). Noteworthy was that treatment 
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with 1mM dAMPαS induced TK mutant clones in every well of three 96 well microtitre 
plates for each independent treatment at that dose. To allow calculation of mutant 
frequency, one empty well was assumed from each treatment. This infers that the 
frequency of mutation at the TK locus was a minimum of 96 fold greater than control with 
1mM dAMPαS treatment.  
To support mutation at the TK locus following 0.5mM dAMPαS treatment, randomly 
selected clones were expanded in TFT media for 7-10 days. All clones tested grew 
successfully informing mutation at the TK locus. 
dAMPαS treatment did not increase the proportion of small TK mutant clones (Fig. 
5.10C). In fact, treatment with 1mM dAMPαS produced entirely large TK colonies. 
Interestingly, 1mM dAMP treatment only induced the TK mutant frequency ~1.7 fold above 
control (Fig. 5.10B), similar to the initial observation (Fig. 5.9B). This correlates the 
genotoxicity of 1mM dAMPαS to be at least 56 fold more potent than the unmodified 
counterpart. Most interesting was that dAMP and dAMPαS treatment, even up to 1mM, 
failed to induce mutation at the HPRT locus (Fig. 5.10D). This infers a cytotoxicity based 
mechanism of mutation at the TK locus could be excluded with 1mM dAMPαS treatment.  
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Figure 5.10. Genotoxicity of a non-canonical phosphorothioate nucleotide analogue. TK6 cells (4x106) were treated with dAMPαS up to 1mM for 24h. As 
a negative nucleotide control, TK6 cells were also treated with 1mM of the unmodified counterpart dAMP. EMS (5µg/ml) was used as a positive 
genotoxic control. Treatment with dAMPαS resulted in dose dependent cytotoxicity up to 10% RTG (A). Treatment with dAMP was not cytotoxic (A). 
Phenomenally, treatment with 0.5mM and 1mM dAMPαS resulted in significant mutation above control at the TK locus ~20 fold and ~96 fold, 
respectively (B). dAMP treatment induced the TK mutant frequency ~1.7 fold (B). There was no shift in the proportion of small TK mutant clones 
following dAMPαS treatment (C). All nucleotide treatments failed to induce mutation at the HPRT locus (D). Data represent mean ± SD of three 
independent treatments. Data is compared to negative control (0mM) using one-way ANOVA with Dunnett’s post-hoc test. * p<0.05; 
**p<0.01;***p<0.001. EMS and 1mM dAMPαS are excluded from statistical analysis. 
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Following 48h of treatment with nucleotide, TK6 cells were harvested to inform the 
frequency of micronuclei as a marker of clastogenic/ aneugenic activity. Surprisingly, 
treatment with either dAMPαS up to 1mM or 1mM dAMP failed to induce the frequency of 
micronuclei in mononucleate cells despite significant mutation at the TK locus (Fig. 5.11A). 
The positive control, 5µg/mL EMS, induced the frequency of micronuclei in mononucleate 
cells over 2 fold suggesting a viable experiment (Fig. 5.11A). Cytotoxicity in the 
micronucleus assay was not evident following nucleotide treatment of TK6, assessed 
using the RPD according to OECD guideline 487 (Fig. 5.11B) 
(http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/OECD-TG487.pdf). The RPD is 
important to ascertain whether cells have undergone mitosis to facilitate expression of 
micronuclei. Cells which fail to undergo mitosis do not express micronuclei and can be a 
factor for false negative results. According to OECD guideline 487, cytotoxicity should not 
be greater than 55% to avoid false positive results which is in concert with the results 
obtained here (Fig. 5.11B) (http://iccvam.niehs.nih.gov/SuppDocs /FedDocs/OECD/OECD-
TG487.pdf). 
Interestingly, treatment with 1mM dAMP and 0.2mM, 0.5mM and 1mM dAMPαS 
produced a dose dependent increase in the frequency of binucleate cells and 
micronucleated binucleate cells (Fig. 5.11C and D, respectively). The frequency of 
binucleate cells with 1mM dAMP treatment was almost twice that observed with 1mM 
dAMPαS treatment (Fig. 5.11C).  
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Figure 5.11. Clastogenic/ aneugenic activity of dAMPαS in human TK6 cells. Human TK6 cells (4x106) were treated with 1mM dAMP and dAMPαS up to 
1mM for 24h. After 48h from treatment, TK6 cells were sampled to score the incidence of micronuclei in mononucleate cells (A), cytotoxicity following 
treatment measured as the relative population doubling (B), binucleate cells (C) and binucleate cells containing micronuclei (D). Treatment with 
nucleotides failed to induce micronuclei in 2000 mononucleate cells scored per treatment (A) and cytotoxicity was no greater than the recommended 
55% for this assay (B). Treatment with nucleotide caused a dose dependent increase in binucleate cells and micronucleated binucleate cells (C and D, 
respectively). Data represent mean ± SD of three independent treatments. Data is compared to negative control (0mM) using one-way ANOVA with 
Dunnett’s post-hoc test. * p<0.05; **p<0.01;***p<0.001. EMS is excluded from statistical analysis. 
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Figure 5.12. PCR amplification of cDNA from isolated dAMPαS induced TK mutants. Control (0mM) 
and 0.5mM dAMPαS TK mutant clones were isolated and expanded for total RNA extraction. RNA 
extracts were reverse transcribed and used to PCR amplify 837bp of the TK mRNA using primer pair 
5 (Table 2.4). To inform possible RNA contamination during reverse transcription, RNA was omitted 
from a mixture including the reverse transcriptase enzyme (RT+). To inform the potential for genomic 
DNA contamination and PCR amplification using primer pair 5, reverse transcriptase was omitted from 
a reaction mixture containing RNA (RT-). To inform the potential of cDNA contamination and 
amplification during PCR reactions, cDNA was replaced with water (W). Only 4 out of 6 control TK 
mutants successfully PCR (A). From 15 dAMPαS induced TK mutants only 2 clones efficiently PCR to 
yield products capable of sequencing (B).  
To inform the mechanism of dAMPαS mediated mutation, TK mutant clones were 
expanded for RNA extraction. Following reverse transcription of RNA into cDNA, extracts 
were subject to PCR across the TK mRNA (837bp). PCR primers (Table 2.4) were 
designed to include the entire coding region of the TK gene. Following successful PCR, 
products would be sent for DNA sequencing. However, following PCR of 6 control (0mM) 
TK mutant clones, only 4 successfully PCR amplified (Fig. 5.12A). Nevertheless, 15 TK 
clones from 0.5mM dAMPαS treatment were also amplified. Although almost all clones 
produced a visible band ~850bp only 2 PCR reactions efficiently permitted DNA 
sequencing (Fig. 5.12B). This posed a problem for molecular analysis as an accurate 
mechanism of action could not be elucidated from the sequence of 2 mutant clones. Due 
to time restraints, this work could not be pursued any further and so DNA sequence 
analysis of clones could not be completed. 
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5.5. Discussion 
In a reflection paper by the EMA, concern was raised regarding the fate of degradation 
products from chemically modified oligonucleotide based pharmaceuticals (European 
Medicines Agency, 2004). It was proposed that nucleotide analogues released from 
degradation of ASO therapeutics may enter endogenous nucleotide pools and become 
substrates for DNA polymerase. If base-pairing with nucleotide analogues in newly 
synthesised DNA occurred with reduced fidelity, mutation would be likely. Indeed, the 
genotoxicity associated with non-canonical nucleotides used in treatment of HIV has been 
well documented and supports the concern presented by the EMA (Lee, Hanes & 
Johnson, 2003, Sussman et al., 1999, Ward & Duchin, 1997, Ayers et al., 1996). The 
objective of this study was to inform (i) the capability of putative nucleotide analogues, 
released from ASO degradation, to be utilised by DNA polymerase to extend a DNA 
template and (ii) the genotoxicity associated with this incorporation in vivo.  
Data presented here suggest that Tfi DNA polymerase can utilise some of the 
nucleotide analogues commonly found in ASO therapeutics. Tfi DNA polymerase was 
capable of incorporating dATPαS and 5Me-dCTP into a primed DNA template, albeit with 
reduced affinity (8 and 2 fold compared to the unmodified nucleotide control, respectively). 
However, Tfi DNA polymerase failed to use 2’OMe-ATP even in extended reactions. It may 
be plausible to suggest that nucleotide analogue incorporation entirely depends on the 
nature of the chemical modification.  
Although 5-methyl cytosine is not a non-canonical base per se (cytosine can be 
methylated in vivo on the 5’ position to epigenetically alter gene expression) unexpected 
incorporation of 5Me-dCTP released from oligonucleotide degradation, may change the 
methylation profile of highly regulated genes and may be deleterious to the cell (Esteller, 
2008, Weber et al., 2007, Herman & Baylin, 2003, Greger et al., 1989).  
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To inform genotoxicity following nucleotide incorporation into genomic DNA in vivo, 
TK6 cells were treated for 24h. In the first instance, cells were treated with canonical 
adenine based nucleotides. Here, genotoxicity was no greater than 3 fold at either the TK 
or HPRT loci. Treating TK6 cells with 0.5mM and 1mM phosphorothioate nucleotide 
analogue dAMPαS, derived from the most common chemical modification used in ASO 
therapeutics (Geary, 2009, Buchini & Leumann, 2003, Pirollo et al., 2003), was 
phenomenally genotoxic (>96 fold) at the genomic TK locus. Surprisingly, mutation at the 
HPRT locus was not observed. This phenomenon can be explained from previous studies 
suggesting a large proportion of mutations at the HPRT locus can be deleterious to the cell 
whilst the TK locus is a more robust reporter capable of detecting point mutations, large 
inter-gene deletions, chromosome aberrations and even recombination events (Doak et 
al., 2007, Liechty et al., 1998, McGregor et al., 1996, Applegate et al., 1990, Yandell, Dryja 
& Little, 1986). Perhaps the extent of genomic insult at the HPRT locus following 
nucleotide analogue treatment was lethal to the cell, or, if phosphorothioate analogue 
mutation was the result of a delayed mechanism, then perhaps there was not sufficient 
phenotypic expression of HPRT mutants. Premature selection in 6-TG media would result 
in lethality to cells that contained residual wild type HPRT activity. For example, 
phenotypic expression of TK mutants is recommended to be 1-2 days whereas HPRT is 6-
7 days. In this study, TK and HPRT mutants are selected on Day 3 and 7, respectively. If 
mutation by dAMPαS was 48h from treatment, this would still provide TK6 cells sufficient 
phenotypic expression of TK mutants but not HPRT. To confirm this speculation, the 
genotoxicity experiments could be repeated with a longer phenotypic expression period for 
HPRT. However, one would still expect some recovery of HPRT mutants during selection, 
even those prematurely selected by 1 day, especially when mutation at the TK locus is 
~100 fold above control.  
 170 
 
  Although TK mutant clones were not sequenced, having considered the threshold 
effect observed at the TK locus, we suggest the mechanism of mutation by dAMPαS 
treatment may be in accordance with the next nucleotide effect model (Phear, Nalbantoglu 
& Meuth, 1987). The speed at which DNA polymerase extends an elongating strand (5’ to 
3’) is governed by the availability of the next (3’) nucleotide in sequence. Thus, if a 
misinserted nucleotide is followed 3’ by a highly abundant nucleotide, polymerisation of 
this next nucleotide is favoured rather than the excision of the incorrect one by the 3’ to 5’ 
exonuclease activity associated to DNA polymerase (Fersht, 1979). However, in this case, 
the insertion of the phosphorothioate analogue would render the bond nuclease resistant 
sealing the error. This mechanism of mutation would also explain why micronuclei (as a 
marker of DNA double strand breaks) were not observed following nucleotide treatment 
despite significant mutation at the TK locus.   
Further to this is that dATPαS incorporation into newly synthesised genomic DNA 
may still occur below 0.5mM without mutation, as the critical balance of nucleotide pools 
dictates the fidelity of DNA polymerase and concentrations of dAMPαS ≥ 0.5mM may 
perturb these pools such that mutation results from misincorporation of canonical 
nucleotides by DNA polymerase which becomes sealed by dATPαS. It is also noteworthy 
that the human TK6 cells were treated with the monophosphate analogue (dAMPαS) and 
so for incorporation into genomic DNA, not only must the concentration of dATPαS exceed 
beyond a threshold for insertion of analogue rather than canonical dATP, but importantly, 
dAMPαS must first become a substrate for various kinases (possibly Adenylate Kinase 
(EC 2.7.4.3) and nucleoside-diphosphate kinase (EC 2.7.4.6) (Stadtman & et al., 1973)) to 
convert the monophosphate into a triphosphate for utilisation by DNA polymerase. In 
essence, these limitations would contribute to a genotoxic threshold as observed in the 
data presented here. 
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One cannot dismiss the possibility of an epigenetic mechanism of mutation by 
dAMPαS. It is reported that AZT can epigenetically silence TK gene expression by 
inducing promoter hypermethylation (Hoever et al., 2003, Wu et al., 1995, Nyce et al., 
1993). This is thought to be the cause of AZT drug resistance. DNA hypermethylation is 
thought to be one of the cellular responses to drugs that inhibit DNA synthesis (Nyce et al., 
1989, Nyce, 1989). This hypermethylation silences expression of genes that may be 
involved in activation/phosphorylation of the drug. Thus, TK gene silencing increases 
resistance to AZT treatment because AZT is not monophosohorylated by TK. Similarly, 
dAMPαS may be inducing global hypermethylation similar to that reported following AZT 
treatment (Nyce et al. 1993). Furthermore, once dAMPαS is phosphorylated to dATPαS, it 
may become oxidised to ATPαS which can then be utilised for S-adenosylmethionine 
biosynthesis, which is the methyl donor for methylation of 5’-CpG dinucleotide motifs by 
DNA methyltransferase (Mato et al., 1997). If this confers increased 5’-CpG methylation 
potential by DNA methyltransferase this would also explain an epigenetic mechanism of 
gene silencing.  
Most surprising was that dAMPαS treatment was not clastogenic in the in vitro 
micronucleus assay despite the mutagenic response observed at the TK locus. However, 
this would support the above hypothesis of a mechanism of mutation through perturbation 
of intracellular nucleotides pools resulting in excess nucleotide misincorporation and 
subsequent point mutation or epigenetic silencing of TK gene expression. Despite this, a 
dose dependent increase in binucleate cells with and without micronuclei was observed 
following nucleotide treatments. It seems likely that the presence of excess nucleotide 
analogue results in perturbation of intracellular nucleotide pools. In an E. Coli system, 
treatment of cells with adenine caused a two fold increase in ATP levels with a three to 
four fold decrease in GTP levels (Levine & Taylor, 1982). In a lymphoblastoid cell line, 
treating cells with 20µM deoxyadenosine increased the dATP/dGTP ratio almost 28 fold 
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(Mattano, Palella & Mitchell, 1990). It is possible that perturbation of nucleotide pools and 
subsequent reduction in GTP levels following dAMPαS treatment affects the 
efficiency/kinetics of cytokinesis which is a GTP dependent process (reviewed by Lacroix 
and Maddox (Lacroix & Maddox, 2011)).  
With increasing focus to produce more efficient delivery systems and chemical 
modifications for oligonucleotide based pharmaceuticals to enhance in vivo bioavailability/ 
function (Morvan et al., 1993, Akhtar, Kole & Juliano, 1991, Hoke et al., 1991), the risk of 
intracellular accumulation of ASO degradation products may also become a factor that 
needs considering. Data presented here suggest that some ASO degradation products 
can be used by DNA polymerase and, if the concentration of nucleotide analogue is 
sufficient, mutation at genomic DNA can occur. 
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Chapter 6  
General discussion and conclusions 
 
ASO therapeutics are powerful therapeutic tools theoretically capable of modulating 
protein expression of any gene (Davidson & McCray, 2011, Pirollo et al., 2003, Agrawal, 
1999). Currently, there are several ASO in clinical trials for treatment of various diseases, 
predominantly cancer (Cunningham et al., 2001, Chen et al., 2000, Cunningham et al., 
2000). The current genotoxicity test battery is deemed inappropriate for safety assessment 
of biotechnology derived pharmaceuticals, which includes oligonucleotide based 
therapeutics, according to the ICH S6 guidelines 
(www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S
6_R1_Guideline.pdf). Previous studies have presented data demonstrating oligonucleotide 
mediated mutagenesis through triplex and D-loop formation (sections 1.3.1.1 and 1.3.2.1). 
These studies have raised concern from the EMA regarding the capability of 
oligonucleotide based therapeutics, such as ASO, to form such structures at genomic DNA 
and cause mutation (European Medicines Agency, 2004). However, an important point to 
consider is that previous studies have employed plasmid based reporter systems to 
evaluate genotoxicity of oligonucleotides and do not take into account ASO design (length 
and chemical modification). Of further consideration when using engineered reporter 
systems is the number of copies of plasmid/ vector in each cell; those with more copies 
are more likely to undergo oligonucleotide mediated mutation due to the increased number 
of available target sites and, thus, does not necessarily reflect mutagenesis at a genomic 
target where a single target sequence is likely to exist within one or two alleles complexed 
with histone proteins.  
Additionally, the EMA questioned the fate of degradative products (nucleotide 
analogues) from chemically modified ASO therapeutics as chromosomal damage following 
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antiretroviral nucleoside analogue incorporation into genomic DNA has been previously 
established (Carter et al., 2007, Meng et al., 2002, Wutzler & Thust, 2001, Thust et al., 
2000a, Thust et al., 2000b, Sussman et al., 1999, Thust, Schacke & Wutzler, 1996). 
Importantly, antiretroviral nucleoside analogues are not used in ASO design and so the 
genotoxicity associated with antiviral nucleoside analogue therapy cannot be extrapolated 
to putative ASO degradation products.  
This study has addressed these concerns by testing the genotoxic potential of 
oligonucleotides designed to form triplex and D-loop structures as well as assessing the 
mutagenic potential of a phosphorothioate nucleotide analogue at genomic DNA.  
 Data presented in this study shows a TFO targeting genomic DNA could not induce 
mutation above the detection limit of the assay despite high affinity binding to the target 
motif (chapter 3). It is likely that the complexity of the chromatin structure hinders 
accessibility of TFO27 to its binding site within the HPRT locus or that the triplex structure 
is unwound by a progressing replication/transcription fork. This study has also shown that 
previous reports of triplex mediated mutagenesis using the supF based reporter system 
should be interpreted with caution as the target sequence is also capable of DNA 
quadruplex formation in the presence of targeting oligonucleotide (Kalish et al., 2005, 
Datta et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Wang, 
Seidman & Glazer, 1996). Indeed, DNA quadruplex structures are known to be sources of 
genomic instability and it may have been DNA quadruplex and not triplex formation that 
contributed to mutagenesis in supF based systems previously employed (Broxson, Beckett 
& Tornaletti, 2011, Basundra et al., 2010).  
This study has also shown a biologically active ASO molecule to be capable of 
inducing sequence specific mutation at genomic DNA by forming a D-loop structure 
(chapter 4). D-loop formation is more likely to be a concern/ consideration for future 
oligonucleotide pharmaceutical design as triplex formation is dictated by divalent cations 
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and more importantly a purine stretch (Duca et al., 2008, Kalish et al., 2005, Hoogsteen, 
1959, Felsenfeld, Davies & Rich, 1957) whereas D-loop formation is not governed by such 
stringent conditions. Treating TK6 cells with AD3-hprtPM, in a system where RAD51 
protein expression was induced, led to mutation downstream of the target sequence, 
contrary to the expected mechanism of TNE where mutation was predicted to be at the 
site of the mismatched base. This observation may be particularly important as a 
mismatched base may not be a pre-requisite for mutation following D-loop formation by 
oligonucleotides. Thus, an ASO molecule perfectly complimentary to a genomic sequence 
may also result in mutation; however, this will need to be experimentally confirmed.  
 An important limitation to the data set is that genotoxicity of a single TFO and ASO 
molecule has been investigated. This presents with several questions: (1) Can a TFO 
targeting a different genomic sequence induce mutation? (2) Can ASO molecules 
homologous to difference coding regions of genomic DNA induce mutation similar to that 
observed at the HPRT locus and does mutagenicity depend on RAD51 protein 
expression? These limitations were acknowledged during the early stages of the study and 
an attempt was made to resolve them. An effort was made to design a TFO to target the 
TK and other regions of the HPRT locus but as triplex formation is limited to purine 
stretches, a TFO could not successfully be engineered. Similarly, two other ASO 
molecules containing homology to a protein target and a selectable locus such as HPRT 
and TK were designed; both ASO were tested in a preliminary mutation study with 
negative results but upon ASO sequence examination, both were found to be capable of 
forming stable hair-pin structures rendering the oligonucleotides biologically inactive for 
target binding and so abandoned for further testing.   
Despite these limitations, these data still suggest an ASO molecule may present 
mutation potential, providing RAD51 protein expression is sufficient to mediate strand 
invasion. Although ASO mediated mutagenesis appeared to depend on RAD51 protein 
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induction, the possibility of mutagenesis occurring below the detection limit of the assay 
cannot be excluded in the absence of RAD51 induction.  
The dependence of AD3-hprtPM mediated mutagenesis on RAD51 protein 
induction is clinically relevant to patients with p53 mutant tumours that are often found to 
have elevated RAD51 protein expression; it has been proposed that RAD51 
overexpression may contribute to drug resistance and genomic instability (Klein, 2008). 
Furthermore, the majority of ASO currently in clinical trials are for cancer therapy and 
reportedly p53 is inactivated in half of human cancers (Soussi & Lozano, 2005). Since p53 
negatively regulates RAD51 gene expression these patients may also present with 
elevated RAD51 protein expression (Hannay et al., 2007, Arias-Lopez et al., 2006). For 
example, the extent of RAD51 protein expression in invasive ductal breast cancer 
correlated with the histological grading of tumours and RAD51 is reportedly induced 2-7 
fold in several cancer cell lines derived from prostate cancer, colon cancer and breast 
cancer, similar to that reported here (Raderschall et al., 2002, Maacke et al., 2000). 
However, how these in vitro genotoxicity data translate to an in vivo system is unknown 
and warrants further investigation. 
Noteworthy is that in this study, human TK6 cells were transfected with 
oligonucleotide for 4h and then removed from treatment. It seems plausible to suggest that 
exposure of cells to oligonucleotide for longer periods of time may increase the probability 
for ASO hybridisation to genomic DNA and mutation. For example, in a Phase I/II clinical 
trial using a 2’OMe/phosphorothioate ASO (PRO051, Prosensa Therapetucis), plasma 
half-life of oligonucleotide was between 19 and 56 days (Goemans et al., 2011). 
Additionally, subcutaneous injection of a phosphorothioate ASO has been shown to rapidly 
distribute to the liver in mice and remain there with a half-life up to 19 days (Yu et al., 
2001). In fact, ASO elimination from the liver was reduced with increasing ASO dose. ASO 
distribution is not found to be isolated to the liver; administration of a single dose of a 
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phosphorothioate ASO (30mg/kg) has also been shown to accumulate ASO in the spleen 
(8µg/g of tissue), heart (4µg/g of tissue), small and large intestines (~10µg/g of tissue), 
lung (1µg/g of tissue) and testes (7µg/g of tissue) (Agrawal, Temsamani & Tang, 1991). 
Analysis of extracted tissues informed the concentration of oligonucleotide remained 
consistent in the tissues listed above from 1h to 48h. The concentrations of oligonucleotide 
found in these tissues are a fraction of those used in the study presented here, but daily 
treatment of mice (intraperitoneal injection) for 21 days with 20mg/kg ISIS 3521 reached 
intra-tumoural concentrations of 2µM which are very similar to the concentrations used 
here (Yazaki et al., 1996). Thus, accumulation and constant exposure of cells to ASO may 
increase the probability of ASO hybridisation to genomic DNA and subsequent mutation; 
repeated cycles of ASO binding may further increase the likelihood of mutation.  
This hypothesis is supported from a study by Leonetti et al. (Leonetti et al., 1991) 
and Chin et al. (Chin et al., 1990) where micro-injected oligonucleotides were shown to 
rapidly accumulate in the cell nucleus and not the cytoplasm. Thus, ASO binding to 
genomic DNA is even more likely if ASO reside in the cell nucleus.  
 The bioavailability of ASO for gene silencing is a major limitation to their use as 
therapeutic tools, to address this, focus has been drawn to optimise biological efficacy 
through effective design and efficient delivery of ASO to target tissue (Dias & Stein, 2002). 
However, as discussed above, increasing intracellular concentrations of ASO through 
efficient delivery methods may further facilitate intracellular accumulation of ASO 
increasing the likelihood of an ASO molecule binding to a complimentary sequence in 
genomic DNA.  
 It seems premature to suggest novel safety assessment techniques are required for 
ASO therapeutics, especially when the genotoxicity data presented here is based on 
mutagenesis by a single ASO. However, the data cannot be entirely dismissed as the 
possibility for heritable sequence alterations is now evident. If novel pre-clinical safety 
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assessment techniques were to be developed to screen sequence specific off-target 
mutagenesis by oligonucleotide pharmaceuticals, it is most likely that a fluorescent 
activated cell sorting (FACS) based method will be employed. Sequence specific mutation 
by oligonucleotides at genomic DNA would render gene products non-functional and 
mutant cells could be detected/ isolated as those without a fluorescent signal. DNA 
sequencing of mutant clones could be used to confirm sequence specific mutation.   
Using new chemical modifications for ASO design may increase biological efficacy, 
but may also present with new concerns; ASO degradation, mainly from the 3’ end (Shaw 
et al., 1991, Tidd & Warenius, 1989, Wickstrom, 1986), may release monophosphate 
nucleotide analogues which may be substrates for DNA polymerase and incorporate into 
newly synthesised genomic DNA. Degradation of unmodified phosphodiester 
oligonucleotides has previously been shown to release monophosphate nucleotides 
(Vaerman et al., 1997). In this study, data is presented illustrating the use of 
phosphorothioate and 5-methyl-cytosine modified nucleotide analogues by DNA 
polymerase, albeit with reduced efficiency (chapter 5). However, DNA polymerase could 
not use a 2’O-methyl-ribose modified nucleotide most likely because it resembles an RNA 
molecule and not DNA. Treatment of TK6 cells with 1mM phosphorothioate nucleotide 
analogue resulted in mutation ~100 fold above control. A limitation that should be 
acknowledged is that the genotoxicity of an adenine based phosphorothioate nucleotide 
was investigated without evaluating potential differences in genotoxicity for those 
containing cytosine, guanine or thymidine as the nucleobase. Although the concentration 
of dAMPαS found to be genotoxic (≥0.5mM) is greater than the physiological dNTP 
concentration in mammalian cells (24µM dATP; 5.2µM dGTP; 29µM dCTP; 37µM dTTP 
according to Traut (Traut, 1994)), intracellular accumulation of ASO is also likely to be 
paralleled to the level of nucleotide analogues available for entry into endogenous dNTP 
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pools. Similar to ASO described above, prolonged exposure to nucleotide analogues may 
increase the risk of utilisation/ incorporation and mutation. 
 Although the genotoxicity of 5-Me-dCTP was not investigated in this study DNA 
polymerase was shown to be capable of incorporating 5-Me-dCTP into a primed DNA 
template. Methylation of cytosine at CpG dinucleotide motifs in genomic DNA is a method 
of epigenetically altering gene expression and so 5-Me-dCTP may not necessarily be 
considered a non-canonical nucleotide (Esteller, 2008, Weber et al., 2007, Herman & 
Baylin, 2003, Greger et al., 1989). ASO such as Vitravene, G3139 and ISIS 3521 are 
commonly modified to contain 5-methyl-cytosine residues at CpG dinucleotide motifs to 
prevent immune stimulation, as described in section 1.2.1 (Agrawal & Kandimalla, 2004, 
Krieg et al., 1995). If these chemically modified ASO are degraded by endogenous 
nucleases they are likely to release 5-methyl-cytosine monophosphate nucleotides. 
Incorporation of 5-methyl-cytosine into genomic DNA, thus, has the potential to alter the 
epigenome and this may lead to altered gene expression and changes to certain 
biochemical processes such as cell proliferation.   
 The data generated in this study shows that an ASO was capable of off-target 
genotoxicity by directly interacting with genomic DNA or through utilisation of it’s 
degradative product during DNA synthesis. The concentration of oligonucleotide coupled 
to the conditions used during treatments (i.e. MMS pre-treatment to induce RAD51 protein 
expression) that elicited a genotoxic response suggest ASO entities are not likely to result 
in genomic insult at physiological concentrations that are employed for therapeutic 
application. However, the data informs the potential for mutation providing favourable 
conditions are met. It is likely that further testing of ASO and putative degradation products 
is required to draw final conclusions.  
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6.1. Future work 
To bolster the data presented in this study and the mechanism of mutation by ASO and 
putative degradation products, several experiments can be suggested: 
 
The mutagenicity data for triplex formation that has been presented in this study is 
based on a single TFO targeting a selectable genomic locus due to the limitations for 
triplex formation, as discussed in section 1.3. However, to confirm the results for TFO27 
targeting the HPRT locus, the genotoxicity of TFO targeting distinct gene loci can also be 
investigated using a FACS based method that can be optimised for each target by 
monitoring a decrease in cellular fluorescence.  
Furthermore, developing the method outlined in section 3.4.6. to detect and quantify 
triplex formation at genomic DNA will allow a correlation between the binding capacity and 
mutagenicity of TFO.  
Data presented in this study also implicates the SupF gene target sequence as a 
site for DNA quadruplex formation and triplex formation in the presence of targeting 
oligonucleotide. Mutation of key guanine residues in the engineered triplex target 
sequence of the SupF gene was shown to reduce DNA quadruplex formation (chapter 3). 
By employing this engineered system as a reporter for mutation, DNA quadruplex and not 
triplex formation may be implicated in the mutagenicity of oligonucleotides, that contain a 
high guanine content, previously used by Wang and co-workers  (Kalish et al., 2005, Datta 
et al., 2001, Vasquez et al., 2001, Faruqi et al., 2000, Vasquez et al., 1999, Wang, 
Seidman & Glazer, 1996).  
  The study presented here also assessed the genotoxicity of a single ASO targeting 
a genomic locus. To design an ASO that contained homology to a selectable and a 
functional protein target was limited to sites of homology. However, by employing a FACS 
based method the genotoxicity of ASO can also be investigated at several distinct genomic 
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loci. Additionally, AD3-HPRTPM was only mutagenic in a RAD51 induced system. 
Reproducing this observation for ASO targeting different genomic loci will be important.  
Additionally, although RAD51 induction appeared to be vital for AD3-HPRTPM 
mediated mutation, the effect of silencing KU70 protein expression using RNAi should also 
be investigated to further confirm the putative mechanism of mutation. KU70 protein 
expression has been reported to negatively modulate HR repair (Morozov & Wawrousek, 
2008, Pierce et al., 2001), thus, silencing KU70 protein expression may increase the 
mutagenicity of AD3-HPRTPM. This would imply physical incorporation of oligonucleotide 
into genomic DNA through HR repair. If silencing did not alter the potency this would imply 
ASO incorporation by serving as an Okazaki fragment following strand annealing by 
RAD51. 
Mutation by AD3-HPRTPM at the HPRT locus did not appear to be dependent on 
the mismatched base as described for TNE. Reproducing this result with AD3-HPRTPM 
without a mismatched will be important to confirm the mechanism of action suggested in 
chapter 4, as well as investigating the extent of mismatched bases, positional effects and 
different chemical modifications. 
Data presented in this study also highlighted the genotoxicity of an adenine based 
phosphorothioate monophosphate nucleotide analogue. It would be interesting to 
investigate the genotoxicity of phosphorothioate nucleotide analogues containing different 
nucleobases i.e. thymidine, guanine and cytosine. Due to time restrictions, the genotoxicity 
of 5-methyl-dCTP could not be investigated although its incorporation was shown using a 
primer extension assay. Ideally, epigenetic effects could be assessed using a 
transformation assay with BALB/c 3T3 cells. 
 A primer extension assay was employed to assess the incorporation efficiency of 
nucleotide analogues using Tfi DNA polymerase. Ideally, the method should have used a 
recombinant human DNA polymerase. The primer extension assay can also be used to 
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investigate the fidelity of base pairing with nucleotide analogues. For example, can a 
thymidine based analogue base pair with guanine. A more relevant method to assess 
incorporation of nucleotide analogues would be to use a radiolabeled counterpart and 
quantitate the radioactivity in genomic DNA following DNA extraction. These methods 
could then be used to correlate the incorporation efficiency and mutagenicity of nucleotide 
analogues using the HPRT and TK forward mutation assay and the in vitro micronucleus 
assay. 
 Recently, improved efficacy and toxicity with ASO containing phosphorothioate and 
2’O-methyl ribose has been described (section 1.2.1). The incorporation efficiency and 
mutagenicity of such second generation nucleotide analogues can also be investigated 
using the methods described above.   
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Appendix 1. Buffers and reagents 
 
Annealing buffer 1 50mM sodium chloride 
Annealing buffer 2 75mM Tris pH 7.2 and 75mM NaCl 
Biotin binding buffer 
20mM Tris (pH 7.8), 1M NaCl, 1mM EDTA, 0.02%v/v Triton 
X-100 
Blocking buffer 
PBS-T wash buffer plus 5%w/v semi-skimmed milk powder. 
Prepared fresh on the day 
Gel loading buffer (6x) 
0.25%w/v bromophenol blue and 40% w/v sucrose. 
Stored at 4°C 
Master lysis buffer 
10μL Halt protease inhibitor + 990μL lysis buffer [150mM 
NaCl, 0.1%v/v igepal, 1mM Tris (pH 7.4) and 1mM EDTA] 
PBS 
10 mM phosphate buffer (pH 7.4), 2.7mM potassium 
chloride and 137mM sodium chloride. 
PBS-T wash buffer 
1x PBS plus 0.1%v/v Tween-20. 
Prepared fresh on the day. 
Quadruplex buffer 10mM Tris pH 7.2, 0.1mM MgCl2 and 140mM KCl 
SDS loading buffer (5x) 
66mM Tris (pH) 6.8, 26%w/v glycerol, 2.1% SDS, 0.01%w/v 
bromophenol blue. 
SDS resolving gel buffer 
(2.5x) 
1.5M Tris (pH 8.8, 0.4%w/v SDS.  
Autoclaved and stored at 4°C 
SDS running buffer (10x) 
25mM Tris (pH 8.3), 250mM glycine and 0.1%w/v SDS. 
Stored at 4°C  
SDS stacking gel buffer (4x) 
0.5M Tris (pH 6.8) and 0.4%w/v SDS. 
Autoclaved and stored at 4°C 
TBE buffer (1x) 89 mM Tris (pH 8.3), 89mM boric acid and 2 mM EDTA. 
Tfi PCR buffer (5x) 
200 mM Hepes-KOH (pH 8.1), 75 mM KCl, 75 mM 
(NH4)2S04, 10% Glycerol and proprietary stabilizers 
Transfer buffer (10x) 
250mM Tris and 1.86M glycine. 
Stored at 4°C 
Transfer buffer (1x) 
100mL transfer buffer (10x), 200mL 100% methanol and 
700mL water. 
Prepared on the day of use. 
Triplex binding buffer 10mM Tris (pH 7.2) and 10mM MgCl2 
Triplex Running buffer 17.8mM Tris (pH 7.2), 17.8mM boric acid and 10mM MgCl2 
Urea gel loading buffer 
1.5M sucrose, 7M urea, 10mM EDTA, 0.1% bromophenol 
blue 
Urea-TBE loading buffer 1xTBE, 7M urea and 0.1%w/v bromophenol blue 
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